US20090198144A1 - Systems and Methods for Anxiety Treatment Using Neuro-EEG Synchronization Therapy - Google Patents

Systems and Methods for Anxiety Treatment Using Neuro-EEG Synchronization Therapy Download PDF

Info

Publication number
US20090198144A1
US20090198144A1 US12/237,304 US23730408A US2009198144A1 US 20090198144 A1 US20090198144 A1 US 20090198144A1 US 23730408 A US23730408 A US 23730408A US 2009198144 A1 US2009198144 A1 US 2009198144A1
Authority
US
United States
Prior art keywords
subject
eeg
frequency
magnetic field
magnet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/237,304
Other languages
English (en)
Inventor
James William Phillips
Yi Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEOSYNC Inc
Original Assignee
NEOSYNC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40472478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20090198144(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NEOSYNC Inc filed Critical NEOSYNC Inc
Priority to US12/237,304 priority Critical patent/US20090198144A1/en
Publication of US20090198144A1 publication Critical patent/US20090198144A1/en
Assigned to NEOSYNC, INC. reassignment NEOSYNC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JIN, YI, PHILLIPS, JAMES WILLIAM
Priority to US15/891,721 priority patent/US11311741B2/en
Priority to US17/014,663 priority patent/US11938336B2/en
Priority to US17/650,207 priority patent/US20220161044A1/en
Priority to US17/650,203 priority patent/US20220161043A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/12—Magnetotherapy using variable magnetic fields obtained by mechanical movement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/372—Analysis of electroencephalograms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/06—Magnetotherapy using magnetic fields produced by permanent magnets
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Social work or social welfare, e.g. community support activities or counselling services
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4094—Diagnosing or monitoring seizure diseases, e.g. epilepsy
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training

Definitions

  • rTMS Repetitive Transcranial Magnetic Stimulation
  • rTMS uses an electromagnet placed on the scalp that generates a series of magnetic field pulses roughly the strength of an MRI scan.
  • methods of treating a subject comprising: (a) adjusting output of a magnetic field for influencing an intrinsic frequency of a specified EEG band of the subject toward a pre-selected or target intrinsic frequency of the specified EEG band; and (b) applying said magnetic field close to a head of the subject.
  • methods of altering an intrinsic frequency of a brain of a subject within a specified EEG band comprising: (a) determining the intrinsic frequency of the subject within the specified EEG band; (b) comparing the intrinsic frequency from step (a) to an average intrinsic frequency of a healthy population database; (c) if the intrinsic frequency from step (a) is higher than the average intrinsic frequency of the healthy population database, shifting down the intrinsic frequency of the subject by applying a specific magnetic field close to a head of the subject, wherein said specific magnetic field has a frequency lower than the intrinsic frequency of the subject; and (d) if the intrinsic frequency from step (a) is lower than the average intrinsic frequency of the healthy population database, shifting up the intrinsic frequency of the subject by applying a specific magnetic field close to a head of the subject, wherein said specific magnetic field has a frequency higher than the intrinsic frequency of the subject.
  • methods of treating a subject comprising: (a) adjusting output of a magnetic field for influencing a Q-factor, a measure of frequency selectivity of a specified EEG band, of the subject toward a pre-selected or target Q-factor of the band; and (b) applying said magnetic field close to a head of the subject.
  • methods of treating a subject comprising: determining the Q-factor of the intrinsic frequency within the specified EEG band of the subject; comparing the Q-factor of the intrinsic frequency from step (a) to an average Q-factor of the intrinsic frequency of a healthy population database; if the Q-factor of the intrinsic frequency from step (a) is higher than the average Q-factor of the intrinsic frequency of the healthy population database, tuning down the Q-factor of the intrinsic frequency of the subject by applying a magnetic field with a plurality of frequencies or with a single pre-selected frequency close to a head of the subject; and if the Q-factor of the intrinsic frequency from step (a) is lower than the average Q-factor of the intrinsic frequency of the healthy population database, tuning up the Q-factor of the intrinsic frequency of the subject by applying a magnetic field with a pre-selected frequency to a head of the subject.
  • methods of treating a subject comprising: (a) adjusting output of a magnetic field for influencing a coherence of intrinsic frequencies among multiple sites in a brain of the subject within a specified EEG band toward a pre-selected or target coherence value; and (b) applying said magnetic field close to a head of the subject
  • methods adjusting output of a magnetic field for influencing a coherence of intrinsic frequencies among multiple sites in a brain of the subject within a specified EEG band toward a pre-selected or target coherence value comprising: determining the coherence value of the intrinsic frequencies among multiple locations throughout a scalp of the subject; comparing the coherence value from step (a) to an average coherence value of a healthy population database; if the coherence value from step (a) is higher than the average coherence value of the healthy population database, lowering the coherence value of the subject by applying at least two asynchronous magnetic fields close to a head of the subject; if the coherence value from step (a) is lower than the average coherence value of the healthy population database, raising the coherence value of the subject by applying at least one synchronized magnetic field close to a head of the subject.
  • TMS Transcranial Magnetic Stimulation
  • any of the devices described herein may be used to treat anxiety.
  • a method of treating depression in a subject comprising tuning down the Q-factor of an intrinsic frequency of the subject by applying a magnetic field close to a head of the subject, wherein the magnetic field comprises at least one of (a) a single frequency; (b) a plurality of frequencies within a specified EEG band; and (c) an intrinsic frequency of a brain of the subject within a specified EEG band.
  • any of the devices described herein may be used to treat depression.
  • methods for treating a subject comprising: (a) adjusting output of a magnetic field for influencing an EEG phase between two sites in the brain of a subject of a specified EEG frequency toward a pre-selected EEG phase of the specified EEG frequency; and (b) applying said magnetic field close to a head of the subject.
  • the pre-selected EEG phase is lower than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is any EEG phase lower than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is higher than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is any EEG phase higher than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is an EEG phase of a population of people. The population of people may be a set of people having a particular trait, characteristic, ability, or feature. The population may be a healthy population of people.
  • the population of people may be a set of people not having a particular disorder, such as anxiety, depression, or other disorders mentioned herein.
  • the methods comprise measuring EEG data of two sites in the brain of the subject, and calculating the EEG phase between the two sites in the brain of a subject.
  • the specified EEG frequency may be an intrinsic frequency as described herein.
  • the specified EEG frequency may be a pre-selected frequency as described herein.
  • the pre-selected frequency may be an average intrinsic frequency of a healthy population database within a specified EEG band.
  • methods for influencing an EEG phase of a specified EEG frequency between multiple locations of a brain of a subject comprising: (a) determining the EEG phase the between at least two locations measured on the head of the subject; (b) comparing the EEG phase from step (a) to an average EEG phase of a healthy population; and (c) applying a magnetic field close to a head of the subject wherein applying the magnetic field influences the determined EEG phase toward the average EEG phase of a healthy population.
  • TMS Transcranial Magnetic Stimulation
  • the magnetic field results from a first magnetic source and a second magnetic source.
  • the first magnetic source and the second magnetic source are out of phase relative to each other.
  • the amount that the first magnetic source and the second magnetic source are out of phase relative to each other is called the magnetic phase.
  • the methods described are with the proviso that the methods are not used to treat schizophrenia.
  • the step of applying the magnetic field is for a pre-determined cumulative treatment time.
  • the pre-selected or target intrinsic frequency with the specified EEG band is from about 0.5 Hz to about 100 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is from about 1 Hz to about 100 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is not greater than about 50 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is not greater than about 30 Hz.
  • the pre-selected or target intrinsic frequency with the specified EEG band is not greater than about 20 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is not greater than about 10 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is greater than about 3 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is greater than about 1 Hz. In some embodiments, of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is up to about 25 Hz.
  • applying of the magnetic field is to the motor cortex of the subject.
  • the pre-selected and/or target intrinsic frequency is chosen from a plurality of intrinsic frequencies in the specified EEG band. In some embodiments the pre-selected and/or target intrinsic frequency is chosen from a plurality of intrinsic frequencies across a plurality of EEG bands. In some embodiments the specified EEG band is the Alpha band. In some embodiments the specified EEG band is the Beta band.
  • the methods further comprise the step of measuring EEG data of the subject before the applying step.
  • said higher frequency is not greater than about 50 Hz. In some embodiments of at least one aspect described above, said higher frequency is not greater than about 30 Hz.
  • the varying frequencies are moving average frequencies based on a pre-determined frequency around an intrinsic frequency within a predetermined frequency range. In some embodiments, the varying frequencies are randomly selected within a predetermined frequency range. In some embodiments of at least one aspect described above, the varying frequencies are moving average frequencies within a specified EEG band of a healthy population database. Those moving average frequencies can change from an initial frequency to a target frequency within a specific amount of time. In some embodiments of at least one aspect described above, the varying frequencies are frequencies hopping around within a pre-determined frequency range.
  • the varying frequencies are frequencies hopping around an intrinsic frequency within a specified EEG band of a healthy population database.
  • the pre-selected or target frequency is an average intrinsic frequency of a healthy population database within a specified EEG band.
  • the pre-selected or target frequency is an intrinsic frequency of a brain of the subject within a specified EEG band.
  • the methods further comprise the step of measuring EEG data of the subject after the applying step. In some embodiments, further comprising the steps of:
  • the applying of the magnetic field is continuous, in that it does not consist of discrete pulses separated by significant sections in which no magnetic field is applied.
  • the magnetic field is continuously applied.
  • a magnetic field that is continuously applied may alternate between a positive and negative field and include one or more neutral field(s), or alternate between a positive field and a neutral field, or alternate between a negative field and a neutral field, or some other combination of magnetic fields. It is continuous in the sense that it has a repetitive pattern (waveform) of charged fields (whether positive, negative, or a combination thereof) and uncharged fields.
  • the applying of the magnetic field applies the magnetic field to a diffused area in a brain of the subject.
  • the magnetic field is generated by movement of at least one permanent magnet.
  • said movement comprises rotation of at least one said permanent magnet.
  • said movement comprises linear motion of at least one said permanent magnet.
  • said movement comprises curvilinear motion of at least one said permanent magnet.
  • said movement comprises at least one of rotational motion, linear motion, and swing motion.
  • the strength of the at least one permanent magnetic is from about 10 Gauss to about 4 Tesla.
  • the distance between the at least one permanent magnet and the subject is from about 0 inches to about 12 inches, from about 1/32 inches to about 12 inches, from about 1/16 inches to about 5 inches, or from about 1 inch to about 5 inches.
  • the term “about” when referring to distance between the at least one permanent magnet and the subject can mean variations of 1/64 inch, 1/32 inch, 1/16 inch, 1 ⁇ 8 inch, 1 ⁇ 4 inch, 1 ⁇ 3 inch, 1 ⁇ 2 inch, or 1 inch.
  • said pre-determined cumulative treatment time is at least 5 min. In some embodiments where the step of applying the magnetic field is for a pre-determined cumulative treatment time, said pre-determined cumulative treatment time is from about 5 min to about two hours.
  • the methods further comprise repeating the applying step after an interval of treatment.
  • the interval of treatment is from about 6 hours to about 14 days.
  • the method improves an indication selected from the group consisting of replacement for meditation, quick nap, stress release, attention span, comprehension, memory, lowered blood pressure, increased libido, sports performance, academic performance, and any combination thereof.
  • the method improves a mental disorder selected from the group consisting of depression, bipolar, anxiety, obsessive-compulsive, seizure, Parkinson's disease, ADHD, autism, substance abuse, head injury, Alzheimer's disease, eating disorder, sleep disorder, tinnitus, and any combination thereof.
  • the method improves symptoms of fibromyalgia.
  • the method halts the onset of a seizure. In some embodiments of at least one aspect described above, the method prevents the onset of a seizure. In some embodiments of at least one aspect described above, the method improves a characteristic selected from the group consisting of peripheral visual response, attention span, immediate reaction time (IRT), movement time (MT), simple perceptual reaction time (SPR), conflict perceptual reaction time (CPR), and any combination thereof. In some embodiments of at least one aspect described above, the method provides an improvement as measured using a rating scale selected from the group consisting of HAMA, HAMD, PANSS, MADRS, BARS, SAS, and any combination thereof.
  • the method provides an improvement as measured using the Unified Parkinson's Rating Scale. In some embodiments of at least one aspect described above, the method provides an improvement as measured using a modified Unified Parkinson's Rating Scale. In some embodiments of at least one aspect described above, the method uses a Permanent Magneto-EEG Resonant Therapy (pMERT) device (alternatively called a Neuro-EEG Synchronization Therapy (NEST) device). In some embodiments of at least one aspect described above, the method uses a device as described in any of claims 44 - 88 , and/or as described herein. In some embodiments of at least one aspect described above, the method does not use a Transcranial Magnetic Stimulation (TMS) device.
  • TMS Transcranial Magnetic Stimulation
  • devices comprising,
  • devices comprising,
  • devices comprising a means for applying a magnetic field to a head of a subject; whereby the means for applying the magnetic field is capable of influencing an intrinsic frequency of a brain of the subject within a specified EEG band.
  • devices comprising a means for applying a magnetic field to a head of a subject; whereby the means for applying the magnetic field is capable of influencing a Q-factor of an intrinsic frequency of a brain of the subject within a specified EEG band.
  • devices comprising a means for applying a magnetic field to a head of a subject; whereby the means for applying the magnetic field is capable of influencing a coherence of intrinsic frequencies among multiple sites in a brain of the subject within a specified EEG band.
  • the subunit comprises a rotating mechanism.
  • said rotating mechanism comprises:
  • said device comprises at least one permanent magnet.
  • the strength of the at least one permanent magnet is from about 10 Gauss to about 4 Tesla.
  • the magnetic field is an alternating magnetic field.
  • the magnetic field is generated by movement of at least one permanent magnet.
  • the movement of the at least one said magnet is at a frequency between about 0.5 Hz and about 100 Hz. In some embodiments, the movement of the at least one said magnet is at a frequency between about 2 Hz and about 20 Hz.
  • said movement comprises rotation of at least one said permanent magnet. In some embodiments of at least one aspect described above, said movement comprises linear motion of at least one said permanent magnet. In some embodiments of at least one aspect described above, said movement comprises swing motion of at least one said permanent magnet. In some embodiments, said movement comprises at least one of rotational motion, linear motion, and swing motion.
  • said movement generates an alternating magnetic field.
  • the magnetic field is continuously applied.
  • the magnetic field covers a diffused area in a brain of a subject.
  • the device is a Permanent Magneto-EEG Resonant Therapy (pMERT) device.
  • the device is a Neuro-EEG Synchronization Therapy (NEST) device.
  • NEST Neuro-EEG Synchronization Therapy
  • NEST Permanent Magneto-EEG Resonant Therapy
  • the devices further comprise logic that controls the frequency to be any frequency between about 2 and about 20 Hz in increments of about 0.1 Hz. In some embodiments of at least one aspect described above, the devices further comprise logic that controls the frequency to be any frequency between about 2 and about 50 Hz in increments of about 0.1 Hz. In some embodiments of at least one aspect described above, the devices further comprise logic that automatically changes the frequency in response to EEG readings of a subject before and/or during treatment. In some embodiments of at least one aspect described above, the devices further comprise logic that allows a user to set duration of a treatment before said treatment.
  • the user may be, for non-limiting example, a patient, a therapist, a psychiatrist, a psychologist, a neurologist, a family doctor, a general practitioner, a another medical professional, or a person treating a patient. In some embodiments, the user is not a patient.
  • the devices comprise a white noise generator.
  • the devices further comprise a coupling to at least one of an internet line and a phone line. In some embodiments, at least a portion of the coupling to the internet line or to the phone line is wireless.
  • the device may further comprise a smart card for storing and transferring information.
  • the devices further comprise logic that calculates information from EEG data collected from the subject within a specified EEG band,
  • said information comprises at least one of items listed below:
  • the devices further comprise logic that uploads said information through at least one of an internet line and a telephone line to an EEG data analysis service capable of storing said information.
  • said EEG data analysis service is capable of associating the said information with an identification associated with the subject.
  • the devices further comprise logic that uploads EEG data collected from the subject to an EEG data analysis service, wherein the EEG data analysis service is capable of validating information uploaded from the device, wherein said information comprises at least one of items listed below:
  • said information comprises at least two of the listed items.
  • the treatment dosage quota is chosen by a user treating the subject based on a diagnosis of the subject.
  • the treatment dosage quota is chosen by a user who is charged for requesting a download of a cumulative treatment time based on a diagnosis of the subject.
  • the user is charged by a billing service before, during, or after the download of the dosage quota.
  • the devices further comprise logic that uploads a subject's EEG data through at least one of an internet line and a phone line to an EEG data analysis service. In some embodiments of at least one aspect described above, the devices further comprise logic that records usage information for using the device. In some embodiments, the device further comprises logic that ceases to deliver treatment after a treatment dosage quota is depleted. In some embodiments, the billing service is a vendor of the device. In some embodiments of at least one aspect described above, the devices further comprise logic that allows a user to establish a user account.
  • the device comprises at least two permanent magnets. In some embodiments, the device comprises a helmet to be used for a subject's head. In some embodiments of at least one aspect described above, the device comprises a communication subunit for coupling to an internet line. In some embodiments of at least one aspect described above, the device comprises a communication subunit for coupling to a phone line. In some embodiments, the device comprises a memory subunit for storing information during a treatment.
  • the user may be allowed, in some embodiments, to download the therapeutic dosage quota.
  • the methods further comprise the step of establishing a user account based on a request from a user for ordering a therapeutic dosage quota.
  • allowing the user to upload may include allowing the user to move data from a device as described herein to a database.
  • the method may comprise receiving a request from the user to access the user account through at least one of an internet line or a phone line for access to said database.
  • the method may comprise allowing the user to upload at least one of an intrinsic frequency within a specified EEG band, Q-factor of the intrinsic frequency, an EEG phase, and a coherence value of intrinsic frequencies.
  • the data may include at least one of the EEG data, an intrinsic frequency within a specified EEG band, Q-factor of the intrinsic frequency, a coherence value of intrinsic frequencies, or any combination thereof.
  • the device is any device of claims 44 - 88 .
  • the user account comprises
  • the user information excludes identifying information (e.g. user names).
  • the methods further comprise the step of charging at least one of the user, the subject, and an insurance company associated with the subject a fee for use of the device based on the dosage quota ordered in at least one of the user account and the device.
  • said data of said individual subject comprises at least one of EEG data of the subject, at least one intrinsic frequency within a specified EEG band of the subject, Q-factor of the intrinsic frequency of the subject, a coherence value of intrinsic frequencies of the subject, an EEG phase of a specified EEG frequency of the subject, treatment information of the subject, and device usage information for the subject.
  • the retrieving and updating steps occur upon the subject's visit to a psychiatrist, a therapist, a treatment provider, and/or another type of medical professional. In some embodiments, the retrieving and updating steps occur prior to a subject's visit to a psychiatrist, a therapist, a treatment provider, and/or another type of medical professional. In some embodiments, the retrieving and updating steps occur following a subject's visit to a psychiatrist, a therapist, a treatment provider, and/or another type of medical professional.
  • the methods or devices use a Transcranial Magnetic Stimulation (TMS) device.
  • TMS Transcranial Magnetic Stimulation
  • a method comprising adjusting an output current of an electric alternating current source for influencing an intrinsic frequency of an EEG band of a subject toward a target frequency of the EEG band; and applying said output current across a head of the subject.
  • the step of adjusting the output current comprises setting the output current to a frequency that is lower than the intrinsic frequency of the subject.
  • the step of adjusting the output current comprises setting the output current to a frequency that is higher than the intrinsic frequency of the subject.
  • the step of adjusting the output current comprises setting the output current to the target frequency.
  • a method comprising determining the intrinsic frequency of the EEG band of the subject; and comparing the intrinsic frequency to the target frequency of the EEG band, wherein the target frequency is an average intrinsic frequency of the EEG band of a healthy population of people, wherein if the intrinsic frequency is higher than the target frequency, the step of adjusting the output current comprises setting the output current to a frequency that is lower than the intrinsic frequency of the subject, and if the intrinsic frequency is lower than the target frequency, the step of adjusting the output current comprises setting the output current to a frequency that is higher than the intrinsic frequency of the subject.
  • a method comprising adjusting an output current of an electric alternating current source for influencing a Q-factor of an intrinsic frequency of an EEG band of a subject toward a target Q-factor; and applying said output current across a head of the subject.
  • the step of adjusting the output current comprises varying a frequency of the output current.
  • the step of adjusting the output current comprises setting the output current to a frequency that is higher than the intrinsic frequency of the subject.
  • the step of adjusting the output current comprises setting the output current to a frequency that is lower than the intrinsic frequency of the subject.
  • the step of adjusting the output current comprises setting the output current to the target frequency.
  • the method further comprises determining the Q-factor of the intrinsic frequency of the EEG band of the subject; and comparing the Q-factor to the target Q-factor, wherein the target Q-factor is an average Q-factor of the intrinsic frequencies of the EEG band of a healthy population of people, wherein if the Q-factor of the intrinsic frequency is higher than the target Q-factor, the step of adjusting the output current comprises varying a frequency of the output current, and if the Q-factor of the intrinsic frequency is lower than the target Q-factor, the step of adjusting the output current comprises setting the output current to a frequency that is the intrinsic frequency of the subject.
  • influencing an intrinsic frequency may include influencing harmonics of the pre-selected intrinsic frequency of the specified EEG band.
  • the pre-selected intrinsic frequency is a harmonic of the peak intrinsic frequency of a specified EEG band.
  • influencing the pre-selected intrinsic frequency includes applying harmonic frequencies of the pre-selected intrinsic frequency.
  • the varying frequencies comprise harmonic frequencies of a single frequency. The single frequency may comprise the pre-selected intrinsic frequency.
  • a device as described herein is operable to influence an intrinsic frequency of the brain of a subject within a specified EEG band.
  • a device as described herein may be operable to influence a Q-factor of an intrinsic frequency of the brain of a subject within a specified EEG band.
  • a device as described herein may be operable to influence a coherence of intrinsic frequencies among multiple sites in the brain of a subject within a specified EEG band.
  • a device as described herein further comprises a first electrode operable to detect electrical brain activity; and a second electrode operable to detect a reference signal, wherein the first electrode is located on the subject in at least one of: an area of low electrical resistivity on a subject, and an area with substantially no electrical impulse interference on a subject, and wherein the second electrode is located on the subject.
  • a device as described herein further comprises a first electrode operable to detect electrical brain activity; and a second electrode operable to detect a reference signal, wherein the first electrode is located on the subject in at least a portion of the ear canal of the subject, and wherein the second electrode is located on the subject.
  • the method or methods may comprise locating a first electrode operable to detect electrical brain activity on the subject in at least one of an area of low electrical resistivity on a subject and an area with substantially no electrical impulse interference on a subject.
  • the method or methods may further comprise locating a second electrode operable to detect a reference signal on the subject.
  • the method or methods may further comprise determining the intrinsic frequency from the electrical brain activity detected by the first electrode and the reference signal detected by the second electrode. In some embodiments, determining the intrinsic frequency may comprise removing the reference signal detected by the second electrode from the electrical brain activity detected by the first electrode.
  • the method or methods may further comprise determining the Q-factor of an intrinsic frequency of the specified EEG band from the electrical brain activity detected by the first electrode and the reference signal detected by the second electrode.
  • determining the Q-factor of an intrinsic frequency of the specified EEG band comprises ascertaining the Q-factor from the electrical brain activity detected by the first electrode and the reference signal detected by the second electrode.
  • the method or methods may comprise locating a first electrode operable to detect electrical brain activity on the subject in at least a portion of the ear canal of the subject.
  • the method or methods may further comprise locating a second electrode operable to detect a reference signal on the subject.
  • the method or methods may further comprise determining the intrinsic frequency from the electrical brain activity detected by the first electrode and the reference signal detected by the second electrode.
  • a device as described herein is operable to influence an EEG phase between two sites in the brain of a subject of a specified EEG frequency.
  • the device may comprise a second permanent magnet, wherein the subunit is coupled to the second magnet, and wherein the subunit enables movement of the second magnet at a frequency between about 0.5 Hz and about 100 Hz.
  • the subunit may enable movement of the second magnet at a frequency between about 2 Hz and about 20 Hz.
  • the first permanent magnet may have a first rotational orientation relative to a treatment surface of the device and the second permanent magnet may have a second rotational orientation relative to the treatment surface of the device.
  • the device may be operable to move the first permanent magnet at the same frequency as the second permanent magnet.
  • the first rotational orientation relative to a first portion of a treatment surface of the device may be between at least about 0 degrees and about 360 degrees different from the second rotational orientation relative to a second portion of the treatment surface of the device.
  • the first rotational orientation relative to a first portion of a treatment surface of the device may be at least one of: between at least about 0 degrees and about 180 degrees, between at least about 0 degrees and about 90 degrees, between at least about 0 degrees and about 45 degrees, between at least about 0 degrees and about 30 degrees, between at least about 0 degrees and about 15 degrees, between at least about 0 degrees and about 10 degrees, at least about 5 degrees, at least about 10 degrees, at least about 15 degrees, at least about 30 degrees, at least about 45 degrees, at least about 60 degrees, at least about 90 degrees, at least about 120 degrees, at least about 180 degrees, at least about 240 degrees, and at least about 270 degrees different from the second rotational orientation relative to a second portion of the treatment surface of the device.
  • the specified EEG frequency may be an intrinsic frequency
  • a magnetic field results from a first magnetic source and a second magnetic source.
  • the first magnetic source and the second magnetic source are out of phase relative to each other.
  • the amount that the first magnetic source and the second magnetic source are out of phase relative to each other is called the magnetic phase.
  • the first portion of the treatment surface is the portion of the treatment surface approximately closest to the first permanent magnet
  • the second portion of the treatment surface is the portion of the treatment surface approximately closest to the second permanent magnet.
  • the first portion of the treatment surface is the portion of the treatment surface closest to the first permanent magnet that is intended to be approximately tangential to the head of the subject nearest that treatment surface
  • the second portion of the treatment surface is the portion of the treatment surface approximately closest to the second permanent magnet that is intended to be approximately tangential to the head of the subject nearest that treatment surface.
  • the difference between the first rotational orientation and the second rotational orientation results in a magnetic phase when the first permanent magnet is moved at the same frequency as the second permanent magnet.
  • the magnetic phase of the device may be operable to influence an EEG phase between a first site and a second site in the brain of a subject within a specified EEG band.
  • the first site generally aligns with the first permanent magnet
  • the second site generally aligns with the second permanent magnet of the device.
  • a device comprising,
  • the means for applying the first magnetic field and the means for applying the second magnetic field are capable of influencing an EEG phase between at least two sites in a brain of the subject of a specified EEG frequency.
  • the magnetic fields may be of the same frequency, but out of phase with each other. Additional magnetic fields may be provided by additional means for applying such magnetic fields. These too may be out of phase with each other, or with any of the magnetic fields. Nevertheless, the magnetic fields in some embodiments may have the same frequencies.
  • the devices may be a Permanent Magneto-EEG Resonant Therapy (pMERT) (i.e. a Neuro-EEG Synchronization Therapy NEST device) as described herein.
  • pMERT Permanent Magneto-EEG Resonant Therapy
  • the specified EEG frequency may be an intrinsic frequency as described herein.
  • the specified EEG frequency may be a pre-selected frequency as described herein.
  • the pre-selected frequency may be an average intrinsic frequency of a healthy population database within a specified EEG band.
  • a device for use in treating a subject comprising: a Transcranial Magnetic Stimulation (TMS) device; whereby the means for applying the magnetic field is capable of influencing (a) an intrinsic frequency of a brain of the subject within a specified EEG band; (b) a Q-factor of an intrinsic frequency of a brain of the subject within a specified EEG band; (c) a coherence of intrinsic frequencies among multiple sites in a brain of the subject within a specified EEG band; or (d) a combination thereof.
  • TMS Transcranial Magnetic Stimulation
  • FIG. 1 shows an exemplary device in which the magnet rotates so that the plane of rotation is perpendicular to the surface of the scalp.
  • FIG. 2 shows an exemplary device in which a horseshoe magnet is positioned such that the plane of rotation is parallel to the surface of the scalp.
  • FIG. 3 shows an exemplary device which two bar magnets are rotated synchronously to provide a more uniform phase for the magnetic field in the brain.
  • FIG. 4 shows an exemplary device in which the magnet rotates so that the plane of rotation is perpendicular to the surface of the scalp and a pair of electrodes is used to record the EEG of the patient.
  • FIG. 5 shows a sample EEG segment for a subject before therapy is delivered.
  • the block on the left shows a time series EEG while the subject is sitting at rest with eyes closed.
  • the block in the center shows the energy across the frequency spectrum for the sampled EEG.
  • the vertical line drawn through the peaks is at 9.1 Hz, the subject's intrinsic alpha frequency.
  • the circle at the right shows the distribution of EEG energy at the intrinsic alpha frequency throughout the scalp, looking down on the top of the subject's head. In the circle representation, the majority of the EEG energy at the alpha frequency is concentrated at the back of the brain.
  • FIG. 6 is similar to FIG. 5 , except the EEG was sampled immediately following therapy. In this, it can be seen that the energy associated with the intrinsic alpha frequency has increased significantly. From the circle representation on the right, it can be seen that the distribution of energy at the intrinsic alpha frequency throughout the head is more uniform, though the majority of energy is still concentrated at the back of the brain.
  • FIG. 7 shows an exemplary embodiment of the pMERT or NEST device.
  • a button EEG electrode is located on the concave surface of the device and a second reference electrode extends via a wire from the side of the device.
  • the display and control buttons are located on top of the device to provide information and allow the user to adjust parameters and enter patient data.
  • a USB port is located at the top rear of the device, to allow it to be connected via a USB cable to a PC, allowing uploading of data and downloading of a dosage quota.
  • FIG. 8 shows the pMERT or NEST device from FIG. 7 in which a subject is lying with the head against the concave surface. At least one moving magnet is unseen inside the pMERT or NEST device in order to deliver therapy to the subject. The subject's head is pressed against the button EEG electrode, with the second electrode attached to the subject's right ear.
  • FIG. 9 shows an alternate angle of the subject receiving therapy from the pMERT or NEST device as described in FIG. 8 .
  • FIG. 10 shows some exemplary embodiments for various movements of at least one permanent magnet.
  • FIGS. 11A through 11K 11 L show additional exemplary embodiments for various movements of at least one permanent magnet.
  • FIG. 12 shows an example of the Q-factor as used in this invention.
  • the figure shows a sample graph of the frequency distribution of the energy of an EEG signal. It can be seen that a frequency range, ⁇ f can be defined as the frequency bandwidth for which the energy is above one-half the peak energy.
  • the frequency f 0 is defined as the intrinsic frequency in the specified band.
  • the Q-factor is defined as the ratio of f 0 / ⁇ f. As can be seen, when ⁇ F decreases for a given f 0 , the Q-factor will increase. This can occur when the peak energy E max of the signal increases or when the bandwidth of the EEG signal decreases.
  • FIG. 13 shows an example embodiment of a diametrically magnetized cylindrical magnet for use in a NEST device.
  • FIG. 14 shows an example embodiment of a NEST device having a diametrically magnetized cylindrical magnet rotating about its cylinder axis and applied to a subject.
  • FIG. 15 shows an example embodiment of a NEST device having two diametrically magnetized cylindrical magnets rotating about their cylinder axes and applied to a subject.
  • FIG. 16 shows an example embodiment of a NEST device having three diametrically magnetized cylindrical magnets rotating about their cylinder axes and applied to a subject.
  • FIG. 17 shows an example embodiment of a NEST device having three diametrically magnetized cylindrical magnets configured to rotate about their cylinder axes.
  • FIG. 18 shows an exploded view of the example embodiment of the NEST device of FIG. 17 having three diametrically magnetized cylindrical magnets configured to rotate about their cylinder axes.
  • FIG. 19 shows the example NEST device embodiment of FIG. 17 having three diametrically magnetized cylindrical magnets configured to rotate about their cylinder axes and including a frame and base for mounting the NEST device.
  • FIG. 20 shows an example embodiment of a NEST device having eight diametrically magnetized cylindrical magnets configured to rotate about their cylinder axes.
  • FIG. 21 shows the magnet rotation of the example NEST device embodiment of FIG. 20 having eight diametrically magnetized cylindrical magnets configured to rotate about their cylinder axes.
  • FIG. 22 shows an example embodiment of a NEST device having two axially polarized half-disc magnets that rotate about a common rotation axis.
  • FIG. 23 shows an exploded view of an alternate embodiment of an example NEST device embodiment similar to that of FIG. 22 having two rectangular magnets that rotate about a common rotation axis.
  • FIG. 24 shows an example embodiment of a NEST device similar to the embodiments depicted in FIGS. 22 and/or 23 having two magnets rotating about a common rotation axis applied to a subject and showing the controller subunit.
  • FIG. 25 shows block diagram of an example embodiment of a NEST showing the elements of the NEST device and its controller subunit.
  • FIG. 26 shows an example embodiment of a NEST device having a single bar magnet that moves linearly along its north-south axis once each time the supporting ring is rotated, providing a pulse-type alternating magnetic field at the frequency of rotation.
  • FIG. 27 shows an example embodiment of a NEST device having an EEG electrode located in the subject's ear canal, and a reference EEG electrode located on an earlobe of the subject.
  • FIG. 28 shows an example embodiment of a NEST device applied to a subject, wherein the NEST device has three diametrically magnetized cylindrical magnets rotating about their cylinder axes having a magnetic phase between at least two of the magnets that is not zero.
  • FIG. 29 shows the magnetic field strengths of two magnets moving at the same frequency at the same time, but having a magnetic phase relative to one another (out of phase relative to each other).
  • FIG. 30 shows a theoretical EEG electrode readings measured at two locations on a subject's head within a single EEG band when the two locations are exhibiting similar (or the same) frequency, but are out of phase relative to each other, i.e. displaying an EEG phase.
  • FIG. 31 is a comparison of change in the HAMD score of Responders versus Non-Responders.
  • FIG. 32 is a comparison of the change in HAMD scores Subjects receiving NEST therapy versus Subjects receiving SHAM (i.e. control) therapy.
  • FIG. 33 shows the change in HAMA score of two patients over a period of three weeks.
  • methods of treating a subject comprising: (a) adjusting output of a magnetic field for influencing an intrinsic frequency of a specified EEG band of the subject toward a pre-selected or target intrinsic frequency of the specified EEG band; and (b) applying said magnetic field close to a head of the subject.
  • methods of altering an intrinsic frequency of a brain of a subject within a specified EEG band comprising: (a) determining the intrinsic frequency of the subject within the specified EEG band; (b) comparing the intrinsic frequency from step (a) to an average intrinsic frequency of a healthy population database; (c) if the intrinsic frequency from step (a) is higher than the average intrinsic frequency of the healthy population database, shifting down the intrinsic frequency of the subject by applying a specific magnetic field close to a head of the subject, wherein said specific magnetic field has a frequency lower than the intrinsic frequency of the subject; and (d) if the intrinsic frequency from step (a) is lower than the average intrinsic frequency of the healthy population database, shifting up the intrinsic frequency of the subject by applying a specific magnetic field close to a head of the subject, wherein said specific magnetic field has a frequency higher than the intrinsic frequency of the subject.
  • methods of treating a subject comprising: (a) adjusting output of a magnetic field for influencing a Q-factor, a measure of frequency selectivity of a specified EEG band, of the subject toward a pre-selected or target Q-factor of the band; and (b) applying said magnetic field close to a head of the subject.
  • methods of treating a subject comprising: determining the Q-factor of the intrinsic frequency within the specified EEG band of the subject; comparing the Q-factor of the intrinsic frequency from step (a) to an average Q-factor of the intrinsic frequency of a healthy population database; if the Q-factor of the intrinsic frequency from step (a) is higher than the average Q-factor of the intrinsic frequency of the healthy population database, tuning down the Q-factor of the intrinsic frequency of the subject by applying a magnetic field with a plurality of frequencies or with a single pre-selected frequency close to a head of the subject; and if the Q-factor of the intrinsic frequency from step (a) is lower than the average Q-factor of the intrinsic frequency of the healthy population database, tuning up the Q-factor of the intrinsic frequency of the subject by applying a magnetic field with a pre-selected frequency to a head of the subject.
  • methods of treating a subject comprising: (a) adjusting output of a magnetic field for influencing a coherence of intrinsic frequencies among multiple sites in a brain of the subject within a specified EEG band toward a pre-selected or target coherence value; and (b) applying said magnetic field close to a head of the subject
  • methods adjusting output of a magnetic field for influencing a coherence of intrinsic frequencies among multiple sites in a brain of the subject within a specified EEG band toward a pre-selected or target coherence value comprising: determining the coherence value of the intrinsic frequencies among multiple locations throughout a scalp of the subject; comparing the coherence value from step (a) to an average coherence value of a healthy population database; if the coherence value from step (a) is higher than the average coherence value of the healthy population database, lowering the coherence value of the subject by applying at least two asynchronous magnetic fields close to a head of the subject; if the coherence value from step (a) is lower than the average coherence value of the healthy population database, raising the coherence value of the subject by applying at least one synchronized magnetic field close to a head of the subject.
  • TMS Transcranial Magnetic Stimulation
  • methods for treating a subject comprising: (a) adjusting output of a magnetic field for influencing an EEG phase between two sites in the brain of a subject of a specified EEG frequency toward a pre-selected EEG phase of the specified EEG frequency; and (b) applying said magnetic field close to a head of the subject.
  • any of the devices described herein may be used to treat anxiety.
  • a method of treating depression in a subject comprising tuning down the Q-factor of an intrinsic frequency of the subject by applying a magnetic field close to a head of the subject, wherein the magnetic field comprises at least one of (a) a single frequency; (b) a plurality of frequencies within a specified EEG band; and (c) an intrinsic frequency of a brain of the subject within a specified EEG band.
  • any of the devices described herein may be used to treat depression.
  • the pre-selected EEG phase is lower than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is any EEG phase lower than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is higher than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is any EEG phase higher than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is an EEG phase of a population of people. The population of people may be a set of people having a particular trait, characteristic, ability, or feature. The population may be a healthy population of people.
  • the population of people may be a set of people not having a particular disorder, such as anxiety, depression, or other disorders mentioned herein.
  • the methods comprise measuring EEG data of two sites in the brain of the subject, and calculating the EEG phase between the two sites in the brain of a subject.
  • the specified EEG frequency may be an intrinsic frequency as described herein.
  • the specified EEG frequency may be a pre-selected frequency as described herein.
  • the pre-selected frequency may be an average intrinsic frequency of a healthy population database within a specified EEG band.
  • methods for influencing an EEG phase of a specified EEG frequency between multiple locations of a brain of a subject comprising: (a) determining the EEG phase the between at least two locations measured on the head of the subject; (b) comparing the EEG phase from step (a) to an average EEG phase of a healthy population; and (c) applying a magnetic field close to a head of the subject wherein applying the magnetic field influences the determined EEG phase toward the average EEG phase of a healthy population.
  • TMS Transcranial Magnetic Stimulation
  • FIG. 1 shows an exemplary device having a magnet 2 coupled to and rotated by a motor 72 in which the magnet 2 rotates so that the plane of rotation is generally perpendicular to the surface of the scalp of the subject 6 , and the rotation axis 36 is generally parallel to at least a portion of the surface of the scalp of the subject 6 .
  • the motor 72 is coupled to the magnet 2 by a drive shaft 4 , and the magnet rotation is controlled by a controller 58 (i.e. controller subunit) that can at least monitor and/or control the rotation of the magnet 2 .
  • Control of the rotation may include, for non-limiting example, the speed of rotation, and the acceleration and/or deceleration of rotation, the time of rotation, and the direction of rotation (e.g. clockwise, counter-clockwise).
  • FIG. 2 shows an exemplary device in which a magnet 2 in the shape of a horseshoe is coupled to and rotated by a motor 72 , and the magnet 2 is positioned such that the plane of rotation is generally parallel to at least a portion of the surface of the scalp of the subject 6 , and the rotation axis 36 is generally perpendicular to at least a portion of the surface of the scalp of the subject 6 .
  • the motor 72 is coupled to the magnet 2 by a drive shaft 4
  • the magnet rotation is controlled by a controller 58 (i.e. controller subunit) that can at least monitor and/or control the rotation of the magnet 2 .
  • Control of the rotation may include, for non-limiting example, the speed of rotation, and the acceleration and/or deceleration of rotation, the time of rotation, and the direction of rotation (e.g. clockwise, counter-clockwise).
  • FIG. 3 shows an exemplary device which two bar magnets 2 a , 2 b are coupled to and rotated by motors 72 a , 72 b , and the magnets 2 a , 2 b are rotated synchronously to provide a more uniform phase for the magnetic field in the brain of a subject 6 .
  • the motors 72 a , 72 b are coupled to the magnets 2 a , 2 b , respectively, by a drive shafts 4 a , 4 b , and the rotation of the magnets 2 a and 2 b about rotation axes 36 a , 36 b , respectively, is controlled by a controller 58 (i.e.
  • controller subunit that can at least monitor and/or control the rotation of the magnet 2 a , 2 b .
  • Control of the rotation of the magnets may include, for non-limiting example, the speed of rotation, and the acceleration and/or deceleration of rotation, the time of rotation, and the direction of rotation (e.g. clockwise, counter-clockwise).
  • the rotation of a single magnet (magnet 2 a , for example), may be controlled independently from and/or simultaneously with the rotation of a second magnet (magnet 2 b , for example) by the controller 58 . Additional magnets may be similarly added to the device.
  • a single motor is coupled to a plurality of magnets, and each of the magnets may be controlled by the controller, independently or simultaneously.
  • the magnetic field used by the methods or devices are not capable of exciting brain cells. In some embodiments, the magnetic field used by the methods or devices are below thresholds of exciting brain cells.
  • the devices described can have one or more permanent magnets mounted onto one or more rotating shafts in such a way that it creates an alternating magnetic field when the shaft or shafts are spun. In some embodiments, the speed of rotation can be set by the user or controlled using neurological feedback to provide optimal therapy.
  • methods and devices described herein can be used to treat at least two mental disorders listed above. In some embodiments, methods and devices described herein can be used to treat at least three mental disorders listed above. In some embodiments, methods and devices described herein can be used to treat at least four mental disorders listed above. In some embodiments, methods and devices described herein can be used to treat at least five mental disorders listed above. In some embodiments, methods and devices described herein can be used to treat at least six mental disorders listed above. In some embodiments, methods and devices described herein are not used to treat schizophrenia.
  • any of the devices described herein may be used to treat anxiety.
  • a method of treating depression in a subject comprising tuning down the Q-factor of an intrinsic frequency of the subject by applying a magnetic field close to a head of the subject, wherein the magnetic field comprises at least one of (a) a single frequency; (b) a plurality of frequencies within a specified EEG band; and (c) an intrinsic frequency of a brain of the subject within a specified EEG band.
  • any of the devices described herein may be used to treat depression.
  • methods and/or devices as described herein can be used to treat symptoms of fibromyalgia. In some embodiments, methods and/or devices as described herein can be used to improve symptoms of fibromyalgia.
  • some symptoms that may be improved include widespread pain, tenderness to touch, nausea dizziness, temporomandibular joint dysfunction, skin problems, depression, myofascial pain, morning stiffness, sleep issues, headaches, chemical sensitivity, dysmenorrhea, muscle twitches and weakness, fatigue, urinary and pelvic problems, fibro-fog cognitive and/or memory impairment, anxiety, memory loss, breathing problems, and vision problems.
  • methods and/or devices as described herein can be used to halt the onset of a seizure. In some embodiments, methods and/or devices as described herein can be used to prevent the onset of a seizure. In some embodiments, methods and/or devices as described herein can be used to reduce or eliminate seizures by detuning the brain near the frequency of the seizures. In some embodiments, methods and/or devices as described herein can be used to reduce or eliminate seizures by tuning up an area of the brain (i.e., an intrinsic frequency in a band, such as alpha) different than the seizure area of the brain, thereby reducing the energy in the frequency associated with the seizure. The seizure may be caused by various conditions, diseases, injuries, and/or other factors.
  • the conditions may include abnormalities in the blood vessels of the brain, atherosclerosis, or hardening of the arteries supplying the brain, bleeding into the brain, such as a subarachnoid hemorrhage, brain tumors, chromosomal abnormalities, congenital diseases or conditions, high blood pressure, pregnancy and problems associated with pregnancy, stroke, transient ischemic attack (mini-stroke).
  • the diseases may include liver disease, Alzheimer's disease, dementia diseases, epilepsy, nervous system diseases, hereditary diseases, infections involving the brain, encephalitis, brain abscess, bacterial meningitis, kidney failure, and chronic renal failure.
  • the injuries may include choking, head injuries, electrical injuries, birth injuries, poisonous bites or stings.
  • Methods and devices described herein can be used to improve at least one indication selected from the group consisting of replacement for meditation, quick nap, stress release, attention span, comprehension, memory, lowered blood pressure, increased libido, sports performance, academic performance, and any combination thereof.
  • methods and devices described herein can be used to improve at least two indications from the group presented above.
  • methods and devices described herein can be used to improve at least three indications from the group presented above.
  • methods and devices described herein can be used to improve at least four indications from the group presented above.
  • methods and devices described herein can be used to improve at least five indications from the group presented above.
  • methods and devices described herein can be used to improve at least six indications from the group presented above.
  • methods and devices described herein can be used to improve at least one indication from the group presented above, and at least one mental disorder listed above. In some embodiments, methods and devices described herein can be used to improve at least one indication from the group presented above, and at least two mental disorders listed above. In some embodiments, methods and devices described herein can be used to improve at least two indications from the group presented above, and at least one mental disorder listed above. In some embodiments, methods and devices described herein can be used to improve at least two indications from the group presented above, and at least two mental disorders listed above. In some embodiments, methods and devices described herein can be used to improve at least one indication from the group presented above, and at least three mental disorders listed above.
  • methods and devices described herein can be used to improve at least two indications from the group presented above, and at least three mental disorders listed above. In some embodiments, methods and devices described herein can be used to improve at least three indications from the group presented above, and at least three mental disorders listed above. In some embodiments, methods and devices described herein can be used to improve at least three indications from the group presented above, and at least two one mental disorders listed above.
  • Methods and devices described herein can be used to improve at least one characteristic selected from the group consisting of peripheral visual response, attention span, immediate reaction time (IRT), movement time (MT), simple perceptual reaction time (SPR), conflict perceptual reaction time (CPR), and any combination thereof.
  • methods and devices described herein can be used to improve at least two indications from the group presented above.
  • methods and devices described herein can be used to improve at least three indications from the group presented above.
  • methods and devices described herein can be used to improve at least four indications from the group presented above.
  • methods and devices described herein can be used to improve at least five indications from the group presented above.
  • methods and devices described herein can be used to improve at least six indications from the group presented above.
  • methods and devices described herein can be used to improve at least one characteristic from the group presented above, and at least one mental disorder listed above. In some embodiments, methods and devices described herein can be used to improve at least one characteristic from the group presented above, and at least two mental disorders listed above. In some embodiments, methods and devices described herein can be used to improve at least two characteristics from the group presented above, and at least one mental disorder listed above. In some embodiments, methods and devices described herein can be used to improve at least two characteristics from the group presented above, and at least two mental disorders listed above. In some embodiments, methods and devices described herein can be used to improve at least one characteristic from the group presented above, and at least three mental disorders listed above.
  • methods and devices described herein can be used to improve at least two characteristics from the group presented above, and at least three mental disorders listed above. In some embodiments, methods and devices described herein can be used to improve at least three characteristics from the group presented above, and at least three mental disorders listed above. In some embodiments, methods and devices described herein can be used to improve at least three characteristics from the group presented above, and at least two one mental disorders listed above.
  • methods and devices described herein can be used to improve at least one characteristic from the group presented above, and at least one indication presented above. In some embodiments, methods and devices described herein can be used to improve at least one characteristic from the group presented above, and at least two indications presented above. In some embodiments, methods and devices described herein can be used to improve at least two characteristics from the group presented above, and at least one indication presented above. In some embodiments, methods and devices described herein can be used to improve at least two characteristics from the group presented above, and at least two indications presented above. In some embodiments, methods and devices described herein can be used to improve at least one characteristic from the group presented above, and at least three indications presented above.
  • methods and devices described herein can be used to improve at least two characteristics from the group presented above, and at least three indications presented above. In some embodiments, methods and devices described herein can be used to improve at least three characteristics from the group presented above, and at least three indications presented above. In some embodiments, methods and devices described herein can be used to improve at least three characteristics from the group presented above, and at least two one indications presented above.
  • Methods and devices described herein can be used to provide an improvement to a mental disorder as measured using a rating scale selected from the group consisting of HAMA, HAMD, PANSS, MADRS, BARS, SAS, and any combination thereof.
  • the method provides an improvement as measured using the Unified Parkinson's Rating Scale.
  • the method provides an improvement as measured using a modified Unified Parkinson's Rating Scale.
  • the modified Unified Parkinson's Rating Scale may include, for non-limiting example, measuring muscle tone and knee/arm flexibility.
  • the pMERT (permanent Magneto-EEG Resonant Therapy) device i.e. the NEST device
  • the pMERT device comprises one or more powerful magnets (>5000 G each) that rotate at a specific frequency or frequencies to bring about the desired therapy.
  • a single, dual, or multi-channel EEG is incorporated in the device to acquire a sample EEG segment and determine the alpha frequency distribution. From this information, the device controls the frequency of rotation of the magnet or magnets to deliver therapy.
  • FIG. 4 shows an exemplary device in which the magnet 2 rotates so that the plane of rotation is generally perpendicular to the surface of the scalp of a subject 6 and a bio-feedback sensor and/or EEG electrode 82 a is used to control the speed of rotation about the rotation axis 36 .
  • the rotation of the magnet 2 is driven by a motor 72 which is coupled to a drive shaft 4 , and the drive shaft 4 is coupled to the magnet 2 .
  • at least two EEG electrodes, 82 a , 82 b are used to control the speed of rotation, wherein at least one EEG electrode, for example EEG electrode 82 b , is used as a reference electrode (and/or a ground electrode).
  • the electrodes, 82 a , 82 b may be connected to an amplifier 80 which can amplify the signal received from the electrodes, 82 a , 82 b .
  • the magnet rotation may be controlled and/or monitored by a controller subunit (controller), 58 , which may also receive, record, and/or display the signal or signals received from the EEG electrodes 82 a , 82 b .
  • the reading from a reference EEG electrode for example EEG electrode 82 b
  • the bio-feedback sensor/EEG electrode is used, at least in part, to determine the subsequent treatment regimen for the subject.
  • the EEG electrodes are used to measure the brain waves of the subject at various times, for non-limiting example, prior to applying a method of treatment as provided herein using a device described herein, during application of a method of treatment as provided herein using a device described herein, and/or after applying a method of treatment as provided herein using a device described herein.
  • the EEG electrodes are used to measure the brain waves of the subject at various times, for non-limiting example, prior to using a device described herein, during use of a device described herein, and/or after using a device described herein.
  • the EEG electrodes are used to measure the brain waves of the subject continuously for a specified period of time.
  • the specified period of time is for non-limiting example, at least about one hour, at least about 45 minutes, at least about 40 minutes, at least about 30 minutes, at least about 20 minutes, at least about 15 minutes, at least about 10 minutes, at least about 5 minutes, at least about 1 minute, at least 30 seconds, at least about 10 seconds, at least about 5 seconds, and at least about 1 second.
  • the term “about” when referring to the specified period of time of use of the EEG electrodes to measure brain waves can mean variation of, for example, 1 minute to 5 minutes, 30 seconds to 1 minute, 15 seconds to 30 seconds, 5 seconds to 15 seconds, 1 second to 10 seconds, 1 second to 5 seconds, 0.5 seconds to 1 second, and 0.1 seconds to 0.5 second.
  • the intrinsic frequency of the subject is an alpha frequency of a brain of the subject.
  • alpha EEG of a brain of a subject can be critical in normal cognitive processes and the desynchronization of alpha activity can play a pathophysiological role in the mental disorders listed above.
  • the therapy using methods or systems described lasts for about 20 minutes, is very gentle, and unnoticeable to the subject.
  • the quantifiable change in alpha frequency can be seen clearly following the therapy session, and the patient may have an immediate reduction in symptoms.
  • the therapy using methods or systems described can be mild enough to be used every day or as needed. The therapy using methods or systems described does not have to involve any medication whatsoever.
  • Patient and “subject” are synonyms, and are used interchangeably. As used herein, they mean any animal (e.g. a mammal) on which the inventions described herein may be practiced. Neither the term “subject” nor the term “patient” is limited to an animal under the care of a physician.
  • FIG. 5 shows a sample EEG segment for a subject before therapy is delivered.
  • the block on the left shows a time series EEG while the subject is sitting at rest with eyes closed.
  • the block in the center shows the energy across the frequency spectrum for the sampled EEG.
  • the vertical line drawn through the peaks is at 9.1 Hz, the subject's intrinsic alpha frequency.
  • the circle at the right shows the distribution of EEG energy at the intrinsic alpha frequency throughout the head, looking down on the top of the subject's head. In the circle representation, the majority of the EEG energy at the alpha frequency is concentrated at the back of the brain.
  • FIG. 6 is similar to FIG. 5 , except the EEG was sampled immediately following therapy. In this, it can be seen that the energy associated with the intrinsic alpha frequency has increased significantly. From the circle representation on the right, it can be seen that the distribution of energy at the intrinsic alpha frequency throughout the head is more uniform, though the majority of energy is still concentrated at the back of the brain.
  • the pMERT Device (NEST Device)
  • Devices described may contain a plurality of magnets, and a plurality of magnets may be used to form an array to produce a desired magnetic field.
  • Such magnetic field can be a pulsing or temporally variable unipolar magnetic field where treatments are performed with a magnetic field having a specific pole.
  • the device is operable to influence an intrinsic frequency of the brain of a subject within a specified EEG band.
  • a device as described herein may be operable to influence a Q-factor of an intrinsic frequency of the brain of a subject within a specified EEG band.
  • a device as described herein may be operable to influence a coherence of intrinsic frequencies among multiple sites in the brain of a subject within a specified EEG band.
  • a device as described herein may be operable to influence a EEG phase of intrinsic frequencies among multiple sites in the brain of a subject within a specified EEG band.
  • a method of treating a subject comprises: (a) adjusting output of a magnetic field for influencing a Q-factor, a measure of frequency selectivity of a specified EEG band, of the subject toward a pre-selected or target Q-factor of the band; and (c) applying said magnetic field close to a head of the subject.
  • devices described can comprise a substantially planar member upon which are affixed a plurality of magnets.
  • the magnets may be oriented so as to permit application of a magnetic field having a substantially uniform polarity to a user.
  • the magnets may also be positioned on the array so that adjacent magnets have opposite polarities.
  • the devices described may be configured so as to restrict, in one or more directions, the movement of the magnet within the devices, thereby enabling selection of the polarity of the magnetic field to which the user is subjected.
  • magnets may be placed within the devices described so that one face of the magnet is always pointing toward a head of a subject. Accordingly, the subject is subjected to a dynamic magnetic field having a specific polarity.
  • the devices described comprise at least one rotating mechanism.
  • mechanical subunits including cams, gears and/or linkages may be utilized to move at least one magnet. These mechanical subunits may be powered through motorized means or may be connected to other devices moving in the surrounding environment which will cause the mechanical device to move the magnet.
  • An external exciter magnet may be positioned near the devices described, where the external exciter magnet generating a sufficiently strong magnetic field to cause movement of at least one magnet contained within the devices described.
  • magnets of the devices described can be rotated by a rotating mechanism other than a motor.
  • the devices comprise at least one orifice so that a stream of fluid such as a gas or liquid may be forced into the devices, wherein the stream of fluid being sufficiently strong so as to move at least one magnet, thus creating relative movement between the at least one magnet and a head of a subject.
  • While permanent magnets of any strength may be utilized for the methods and devices described herein, generally magnets having strengths within the range of about 10 Gauss to about 4 Tesla can be used. In some embodiments, the strength of at least one permanent magnet is from about 100 Gauss to about 2 Tesla. In some embodiments, the strength of at least one permanent magnet is from about 300 Gauss to about 1 Tesla.
  • the permanent magnets for the methods and devices described comprise rare earth magnets such as neodymium, iron, boron or samarium cobalt magnets. In some embodiments, the permanent magnets for the methods and devices described are neodymium iron boron magnets. In some embodiments, ceramic magnets, electromagnets or other more powerful magnets may be utilized as they become available. In some embodiments, electromagnets may be utilized for the methods and devices described. Current can be supplied to the electromagnet by wires penetrating through the devices described and connecting to an external power source.
  • the treatment area is exposed to a half waveform of magnetic flux.
  • the treatment area is exposed to a full waveform of magnetic flux.
  • Still other embodiments may permit treatment area to be exposed to either a half or full waveform.
  • the magnetic source may be rotated, oscillated, moved through a particular pattern, or otherwise moved relative to a head of a subject.
  • the application area of the subject can be positioned relative to the magnetic source so that the magnetic field extends around and/or through the application area.
  • the devices described comprise at least one magnet having a north and south magnetic pole and a pole width equal to the width of the magnet at the poles.
  • the application area is subject to a “full waveform” according to the devices and methods described. For example, when a permanent magnet rotates relative to an application area, the application area may initially be subjected to a “full north pole field” where the north pole of the magnet is closest to the application area. As the north pole rotates away from the application area and the south pole rotates toward the application area, the strength of the north pole field decreases until a “neutral field” is encountered, approximately at the midpoint of the magnet.
  • a south pole may also be referred to as “negative,” ( ⁇ ), or S, and a north pole may also be referred to as “positive,” (+), or N.
  • FIG. 10A through FIG. 10G show some exemplary embodiments for various movements of at least one permanent magnet.
  • FIG. 10A shows a graph of the magnetic field over time. That is, it shows a graph 92 a expressing an example magnetic field experienced by a subject 6 a as a magnet 2 a rotation about an axis between the north pole (+) and south pole ( ⁇ ) of the magnet 2 a .
  • the position of the magnet relative to the subject 6 a and the field strength (+ or ⁇ , amplitude can vary, depending on for example, the application, method, magnet and therapy being delivered) is shown in FIG. 10A .
  • the subject 6 a may experience no magnetic field (i.e.
  • a neutral field when the magnet's north pole is equally as far from the subject 6 a as the magnet's south pole (assuming the north pole and south pole have equal strengths yet opposite polarities).
  • the magnet 2 a spins such that the south pole of the magnet 2 a is closest to the subject 6 a , the subject 6 a experiences a negative magnetic field, as shown in FIG. 10 a , and as the magnet 2 a spins further, the subject 6 a is exposed to a changing magnetic field from, for example, a neutral field, to a negative field, to a neutral field, to a positive field, and so on.
  • an array of magnets i.e.
  • FIG. 10A shows a subject 6 a 1 exposed to an array of nine rotating magnets, as well as a subject 6 a 2 exposed to an array of five rotating magnets. In some embodiments, any number of rotating magnets may be used to provide a more uniform field to the subject's brain.
  • FIG. 10B shows a full waveform in the form of a step function where a magnetic field cycles through a sequence wherein the magnetic field is positive (+) then neutral, then negative ( ⁇ ), then neutral, and repeats.
  • FIG. 10C shows a half waveform in the form of a step function where a magnetic field cycles through a sequence wherein the magnetic field is positive (+) then neutral, and repeating this sequence.
  • FIG. 10B shows a full waveform in the form of a step function where a magnetic field cycles through a sequence wherein the magnetic field is positive (+) then neutral, then negative ( ⁇ ), then neutral, and repeats.
  • FIG. 10C shows a half waveform in the form of a step function where a magnetic field cycles through a sequence wherein the magnetic field is positive (+) then neutral, and repeating this sequence.
  • FIGS. 10E , 10 F and 10 G each show example full wave forms resulting from embodiments of a NEST device having at least one magnet wherein the magnet's, or magnets' north pole and south pole alternatively change distances from the subject in a regular pattern.
  • half waveforms may be created using the same array of magnets, for example shielding as shown in FIG. 11C and/or FIG. 11D , discussed further below.
  • the application area is subject to a “half waveform” according to the devices and methods described.
  • a “half waveform” where the magnet rotates relative to the application area from a full north pole field to a neutral field or from full south pole field to a neutral filed.
  • the “half waveform” treatment can be achieved by limiting rotation or movement of the magnets.
  • the “half waveform” treatment can be achieved by shielding the north pole or south pole of the magnet, leaving only the other pole exposed for the treatment of the application area.
  • the magnetic source may be rotated, oscillated, moved through a particular pattern, or otherwise moved relative to the treatment area.
  • the magnetic source is rotated about an axis.
  • the magnetic source is oscillated with respect to the application area.
  • the magnetic source has a linear movement with respect to the application area. Such linear movement can be like a piston movement.
  • the magnetic source has a swing motion with respect to the application area. Such swing motion can be like a swinging pendulum movement.
  • the magnetic source has a combination of rotation, linear, oscillated, and swing movements.
  • the magnetic source has any combination of rotation, linear, oscillated, and swing movements.
  • said movement comprises at least one of rotational motion, linear motion, and swing motion.
  • a plurality of magnets are fixedly mounted on a supporting plate, the magnets being spaced apart from each other so that the each magnet is spaced apart from the next nearest magnets by at least one pole width.
  • Each magnet may be positioned so that the upwardly facing pole of each magnet is the same.
  • the north pole face of each magnet is mounted to a supporting plate.
  • the south pole face of each magnet is mounted to a supporting plate.
  • a plurality of elongated magnetic sources are placed adjacent to each other so that a repeating pattern of alternating magnetic poles are formed, the poles being spaced apart by a predetermined distance.
  • the oscillation of the magnetic sources by a distance equal to or greater than the predetermined distance subjects an application area to a complete reversal of magnetic flux, i.e., a full waveform.
  • FIGS. 11A through 11K 11 L show additional exemplary embodiments for various movements of at least one permanent magnet.
  • FIG. 11A shows two magnets 102 a 1 , 102 a 2 coupled to each other and spun about a rotation axis 138 a .
  • the subject (not shown) could be positioned, for example, such that the rotation axis 138 is generally perpendicular with the scalp of the subject, or wherein the rotation axis 138 is generally parallel to the scalp of the subject, depending on the desired waveform and/or magnetic flux for the particular subject.
  • FIG. 11B is similar to FIG. 11A but with the magnets 102 b 1 , 102 b 2 having opposite polarity to the magnets 102 a 1 , 102 a 2 of FIG. 11A .
  • FIG. 11C depicts another embodiment device having a single magnet 102 c having a shield 194 covering the north pole of the magnet 102 c .
  • the magnet 102 c spins about a rotation axis 138 along the neutral plane of the magnet (i.e. between the north and south poles of the magnet 102 c ).
  • the subject (not shown) could be positioned, for example, such that the rotation axis 138 is generally perpendicular with the scalp of the subject, or wherein the rotation axis 138 is generally parallel to the scalp of the subject, depending on the desired waveform and/or magnetic flux for the particular subject.
  • FIG. 11D is similar to FIG. 11C but with the magnet 102 d having opposite polarity to the magnet 102 c of FIG. 11C .
  • FIG. 11D shows single magnet 102 d having a shield 194 covering the south pole of the magnet 102 d.
  • FIG. 11E shows another embodiment device having a single magnet 102 e that swings with pendulum-like motion along a pendulum path 198 , the pendulum path 198 at least in part defined by the distance between magnet 102 e and the pendulum pivot 96 .
  • the south pole (S) of the magnet 102 e is farther from the pendulum pivot 96 than the north pole (N) of the magnet 102 e .
  • N north pole
  • FIG. 11E the subject (not shown) could be positioned, for example, such that the pendulum path 198 is generally perpendicular with the scalp of the subject, or wherein the pendulum path 198 is generally parallel to the scalp of the subject, depending on the desired waveform and/or magnetic flux for the particular subject.
  • FIG. 11F has similar characteristics to FIG. 11E , but with the magnet 102 f of FIG. 11F having opposite polarity to magnet 102 e of FIG. 11E .
  • FIG. 11G depicts another embodiment device having a single magnet 102 g that is configured to spin about a rotation axis 138 positioned in the north pole region of the magnet 102 g (i.e. somewhere between the neutral plane of the magnet and the north pole (N) end of the magnet 102 g ).
  • the rotation axis 138 is generally parallel to the neutral plane (not shown) of the magnet 102 g .
  • the subject could be positioned, for example, such that the rotation axis 138 is generally perpendicular with the scalp of the subject, or wherein the rotation axis 138 is generally parallel to the scalp of the subject, depending on the desired waveform and/or magnetic flux for the particular subject.
  • FIG. 11G depicts another embodiment device having a single magnet 102 g that is configured to spin about a rotation axis 138 positioned in the north pole region of the magnet 102 g (i.e. somewhere between the neutral plane of the magnet and the north pole (N) end of the magnet 102 g ).
  • FIG. 11H is similar to FIG. 11G but with the magnet 102 h having opposite polarity to the magnet 102 g of FIG. 11G , and wherein the rotation axis 138 positioned in the south pole region of the magnet 102 h (i.e. somewhere between the neutral plane of the magnet and the south pole (S) end of the magnet 102 h ).
  • FIG. 11I 11 J shows another embodiment device having a single magnet 102 j mounted a distance away from the rotation axis 138 of the device, and having the north pole (N) of the magnet 102 j closer to the rotation axis 138 than the south pole (S) of the magnet 102 j .
  • the subject (not shown) could be positioned, for example, such that the rotation axis 138 is generally perpendicular with the scalp of the subject, or wherein the rotation axis 138 is generally parallel to the scalp of the subject, depending on the desired waveform and/or magnetic flux for the particular subject.
  • FIG. 11J 11 K is similar to FIG. 11I 11 J but with the magnet 102 k having opposite polarity to the magnet 102 j of FIG. 11I 11 J.
  • FIG. 11K 11 L depicts an alternate embodiment device having a single arc-like magnet 102 l (which may be, for example, a horseshoe magnet), that is coupled to a drive shaft 104 aligned with the rotation axis 138 .
  • the magnet 102 l As the drive shaft 104 spins about the rotation axis 138 , the magnet 102 l likewise rotates about the rotation axis 138 .
  • the subject (not shown) could be positioned, for example, such that the rotation axis 138 is generally perpendicular with the scalp of the subject, or wherein the rotation axis 138 is generally parallel to the scalp of the subject, depending on the desired waveform and/or magnetic flux for the particular subject.
  • continuous applied or “continuous application” refer to treatments where an application area is subject to at least one magnetic field with a full waveform or a half waveform for a period of time typically longer than 2 minutes. Such phrases are distinguished from short pulse application (typically microseconds) of a magnetic field.
  • the devices described can be powered with a rechargeable battery.
  • One battery charge can be enough for one or more therapy sessions.
  • a display can indicate battery life remaining and signal when the device should be recharged.
  • the devices described use at least one connection to a computer to allow for upload of therapy information, download of software upgrades, and to order more sessions to be allowed for the device.
  • the connection may be a USB type of connection, or another type of connection known or contemplated.
  • the speed of rotation can be critical to the specific therapy that is delivered. Therefore, in some embodiments, the speed of rotation is tightly controlled.
  • the speed setting may be set by the user or may be set by a controller that uses a biological sensor as feedback to optimize the magnetic field frequency.
  • the methods and devices described use at least one bio-feedback sensor
  • the sensor can be an EEG lead placed on the scalp, along with a reference electrode that can be placed in an area of little sensed brain activity.
  • a reference electrode that can be placed in an area of little sensed brain activity.
  • correlation information can be gained among separate areas of the brain.
  • the EEG and reference leads can be connected through a differential amplifier to a controller module that regulates the speed of at least one motor to rotate at least one magnet above the scalp.
  • Sensing EEG with a magnet rotating in the vicinity can be difficult, since the magnet can affect the electrode.
  • a technique may be used to subtract the pure sine wave from the sensed EEG.
  • the magnet rotation can be stopped temporarily in order to take an EEG measurement that does not include the effect of the rotating magnet.
  • the device may comprise at least two permanent magnets 2802 a , 2802 b , wherein the subunit (not shown in FIG. 28 , but shown in other figures, for example, FIGS. 1-4 , 24 , 25 , 27 ) of the device is coupled to both the first and the second magnet, and wherein the subunit enables movement of the second magnet at a frequency between about 0.5 Hz and about 100 Hz.
  • the subunit may enable movement of the second magnet at a frequency between about 2 Hz and about 20 Hz.
  • the subunit may enable movement of the first and second magnet at the same frequencies.
  • FIG. 28 shows an example embodiment of a NEST device applied to a subject 2806 , wherein the NEST device has three diametrically magnetized cylindrical magnets 2802 a , 2802 b , 2802 c , rotating about their cylinder axes having a magnetic phase between at least two of the magnets that is not zero.
  • a first permanent magnet 2802 a of a device operable to influence an EEG phase may have a first rotational orientation relative to a treatment surface 2899 of the device and the second permanent magnet 2802 b may have a second rotational orientation relative to the treatment surface 2899 of the device.
  • the device may be operable to move the first permanent magnet 2802 a at the same frequency as the second permanent magnet 2802 b.
  • a magnetic field results from a first magnetic source and a second magnetic source.
  • FIG. 29 shows the magnetic field strengths 2997 a , 2997 b of two magnets moving at the same frequency at the same time 2992 , but having a magnetic phase 2991 relative to one another (out of phase relative to each other).
  • the magnetic field strengths in this graph are plotted with time on the x axis, and magnetic field strength on the y axis (with two x axis, to show the relative field strengths of each magnet simultaneously).
  • a first magnetic source and a second magnetic source may be out of phase relative to each other in order to influence the EEG phase of the subject.
  • the amount that the first magnetic source and the second magnetic source are out of phase relative to each other is called the magnetic phase 2991 .
  • the magnetic phase may be measured peak to peak (i.e. peak of the first magnet's field strength to peak of the second magnet's field strength-as shown in FIG. 29 , at 2991 ), or trough to trough, or inflection to inflection, or any similar plot characteristic on both of the magnets' field strength graphs.
  • the first portion of the treatment surface is the portion of the treatment surface approximately closest to the first permanent magnet
  • the second portion of the treatment surface is the portion of the treatment surface approximately closest to the second permanent magnet.
  • the treatment surface 2899 extends between the magnets 2802 a , 2802 b , 2802 c and the head of the subject 2806 .
  • the first portion of the treatment surface is that portion of the treatment surface 2899 between the first magnet 2802 a and the nearest portion of the head of the subject 2806
  • the second portion of the treatment surface is that portion of the treatment surface 2899 between the second magnet 2802 b and the nearest portion of the head of the subject 2806 .
  • the first portion of the treatment surface is the portion of the treatment surface closest to the first permanent magnet that is intended to be approximately tangential to the head of the subject nearest that treatment surface.
  • the second portion of the treatment surface is the portion of the treatment surface approximately closest to the second permanent magnet that is intended to be approximately tangential to the head of the subject nearest that treatment surface.
  • the difference between the first rotational orientation and the second rotational orientation results in a magnetic phase when the first permanent magnet is moved at the same frequency as the second permanent magnet.
  • the first magnet 2802 a has a rotational orientation relative to the treatment surface 2899 that is different than the rotational orientation of second magnet 2802 b .
  • the first magnet 2802 a has a rotational orientation wherein its neutral axis nearly parallel (or tangential, where the treatment surface is curved) to the treatment surface 2899 nearest it, with its north pole closest to the treatment surface 2899 .
  • the second magnet 2802 b has a rotational orientation wherein its neutral axis that is nearly perpendicular to the treatment surface 2899 nearest it, with its north pole only slightly closer to the treatment surface 2899 than its south pole. Relative to the treatment surface nearest each magnet, thus, the first magnet 2802 a has a rotational orientation that is offset from the rotational axis of the second magnet 2802 b by around 90 degrees.
  • the first rotational orientation relative to a first portion of a treatment surface of the device may be between at least about 0 degrees and about 360 degrees different from the second rotational orientation relative to a second portion of the treatment surface of the device.
  • the first rotational orientation relative to a first portion of a treatment surface of the device may be at least one of: between at least about 0 degrees and about 180 degrees, between at least about 0 degrees and about 90 degrees, between at least about 0 degrees and about 45 degrees, between at least about 0 degrees and about 30 degrees, between at least about 0 degrees and about 15 degrees, between at least about 0 degrees and about 10 degrees, at least about 5 degrees, at least about 10 degrees, at least about 15 degrees, at least about 30 degrees, at least about 45 degrees, at least about 60 degrees, at least about 90 degrees, at least about 120 degrees, at least about 180 degrees, at least about 240 degrees, and at least about 270 degrees different from the second rotational orientation relative to a second portion of the treatment surface of the device.
  • the specified EEG frequency may be an intrinsic frequency as described herein.
  • the specified EEG frequency may be a pre-selected frequency as described herein.
  • the pre-selected frequency may be an average intrinsic frequency of a healthy population database within a specified EEG band.
  • the magnetic phase of the device may be operable to influence an EEG phase between a first site and a second site in the brain of a subject of a specified EEG frequency.
  • FIG. 30 shows theoretical EEG electrode readings 3095 a , 3095 b measured at two locations on a subject's head within a single EEG band when the two locations are exhibiting similar (or the same) frequency, but are out of phase relative to each other, i.e. displaying an EEG phase 3089 .
  • the EEG readings over time in this graph are plotted with time on the x axis, and EEG readings on the y axis (with two x axis, to show two EEG electrode readings taken simultaneously at different locations on the head of the subject). As depicted in FIG.
  • a first EEG reading 3095 a , and a second EEG reading 3095 b may be out of phase relative to each other.
  • the amount that the first EEG reading and the second EEG reading are out of phase relative to each other is called the EEG phase 3089 .
  • the EEG phase 3089 may be measured peak to peak (i.e. peak of the first EEG reading to peak of the second EEG reading—as shown in FIG. 30 , at 3089 ), or trough to trough, or inflection to inflection, or any similar plot characteristic on both of the EEG reading graphs.
  • the first site in the brain of a subject may generally align with a first permanent magnet
  • the second site in the brain of a subject may generally align with a second permanent magnet of the device to influence the EEG phase between those two sites. Additional sites also be measured, and additional magnets may additionally be used to influence the EEG phase between given sites toward a pre-selected EEG phase.
  • a device comprising, a means for applying a first magnetic field to a head of a subject; and a means for applying a second magnetic field to a head of a subject whereby the means for applying the first magnetic field and the means for applying the second magnetic field are capable of influencing an EEG phase between at least two sites in a brain of the subject of a specified EEG frequency.
  • the magnetic fields may be of the same frequency, but out of phase with each other.
  • the devices may be a Permanent Magneto-EEG Resonant Therapy (pMERT) (i.e. a Neuro-EEG Synchronization Therapy NEST device) as described herein.
  • pMERT Permanent Magneto-EEG Resonant Therapy
  • a device having a magnetic phase of 0, where the magnets spin at the same frequencies, and in-phase relative to the treatment surface of the device (and/or relative to the head of the subject), may influence the EEG phase between two locations measured on the subject's head. For example, if prior to treatment, two EEG electrodes take EEG readings within an EEG band, and the frequencies are the same (or substantially so), however, the EEG readings have peaks for each electrode at different times (i.e. a non-zero EEG phase), a device as described herein may influence the EEG phase by applying a magnetic field having a magnetic phase (i.e. where the magnets move at the same frequency and in-phase with each other).
  • a device comprises a first electrode operable to detect electrical brain activity; and a second electrode operable to detect a reference signal, wherein the first electrode is located on the subject in at least one of: an area of low electrical resistivity on a subject, and an area with substantially no electrical impulse interference on a subject, and wherein the second electrode is located on the subject.
  • a device comprises a first electrode operable to detect electrical brain activity; and a second electrode operable to detect a reference signal, wherein the first electrode is located on the subject in at least a portion of the ear canal of the subject, and wherein the second electrode is located on the subject.
  • Such electrode placements and configurations may be part of any NEST device described herein.
  • these electrode configurations may be part of any device wherein a clearer EEG signal is desired, since these configurations result in reductions in noise and reduced resistivity from other signals (such as muscle twitches, etc) as compared to electrodes placed on, for example, the head of a subject.
  • FIG. 27 shows an example embodiment of a NEST device having a first EEG electrode 2782 a located in the subject's ear canal 2707 , and a reference EEG electrode 2782 b (i.e. a second electrode) located on an earlobe of the subject 2706 .
  • Conductive gel 2783 may also be used with the first electrode 2782 b .
  • the electrodes 2782 a , 2782 b couple by wires to a controller subunit 2758 .
  • the controller subunit 2758 also couples to at least one magnet 2702 operable to apply a magnetic field to the subject's 2706 brain by spinning the magnet 2702 about its axis (not shown).
  • the first electrode may be shaped to fit the area having substantially no electrical impulse interference, for non-limiting example, a portion of the ear canal or a portion of the nasal cavity.
  • the electrode may be shaped like a hearing aid, including, for non-limiting example, completely in the canal shaped, canal shaped, half-shell shaped, full shell shaped, behind the ear shaped, and open ear shaped.
  • the first electrode may be conformable to the area having substantially no electrical impulse interference.
  • the first electrode may be compliant such that it fits the specific anatomy of the subject.
  • the first electrode may come in multiple sizes to accommodate a range of subjects' anatomy.
  • the first electrode may be configured such that the subject may place the electrode in the area having substantially no electrical impulse interference without assistance from, for non-limiting example, a second person, a trained EEG technician, or a medical professional.
  • the area having substantially no electrical impulse interference may be a location having substantially no muscle activity.
  • the area having substantially no muscle activity may naturally have substantially no muscle activity.
  • the area having substantially no muscle activity may be relaxed by a muscle relaxation means such as, for non-limiting example, an injection with a substance that relaxes (and/or paralyzes) the muscles in the area, a topical application of a substance that relaxes (and/or paralyzes) the muscles in the area, and/or by an ingested muscle relaxation substance.
  • the first electrode may alternatively be placed on the scalp (either directly, and/or with hair between the scalp and the electrode).
  • a single or a plurality of electrodes may be placed on the scalp for coherence measurement, phase measurement, intrinsic frequency measurement, and/or Q-factor measurement.
  • Noise from scalp movement and/or resistivity from the skull may be filtered from the signal (or signals) received from the EEG electrodes, however, such filtering may not be necessary.
  • Curve smoothing may be applied to the signal (or signals) received from the EEG electrodes, however, such curve smoothing may not be necessary.
  • multiple signal recordings may be taken and combined to determine, for non-limiting example, a coherence measurement, an intrinsic frequency measurement, and/or a Q-factor measurement.
  • An EEG electrode cap may be used, and signals from one or more electrodes of the cap may be used as described herein to determine an intrinsic frequency, a Q-factor, or coherence.
  • the area of the scalp upon which the first EEG electrode (or the plurality of electrodes) is/are placed may be induced to have less muscle activity, or it may naturally have less muscle activity than other areas on the scalp. Inducing less muscle activity in the area of the scalp may be achieved in various ways.
  • the area may be relaxed by a muscle relaxation means such as an injection with a substance that relaxes (and/or paralyzes) the muscles in the area, a topical application of a substance that relaxes (and/or paralyzes) the muscles in the area, and/or by an ingested muscle relaxation substance.
  • the second electrode operable to detect a reference signal is a ground reference.
  • the second electrode may be an ear clip attached to, for non-limiting example, a subject's earlobe.
  • the second electrode may be attached to a location showing substantially no EEG activity.
  • the second electrode may be an ear clip.
  • the device as described herein may be operable to measure the EEG signal from the subject's brain prior to and/or after the application of the magnetic field to the subject.
  • the device as described herein may comprise logic (in a computer readable format-for non-limiting example, hardware, software) that receives and records the EEG signal prior to and/or following application of the magnetic field to the subject's brain (or a portion thereof).
  • the device as described herein may comprise logic (in a computer readable format) that determines the intrinsic frequency of a specified EEG band of the subject using the EEG signal prior to and/or following application of the magnetic field to the subject's brain (or a portion thereof).
  • the device as described herein may comprise logic (in a computer readable format) that determines the Q-factor of an intrinsic frequency of a specified EEG band of the subject using the EEG signal prior to and/or following application of the magnetic field to the subject's brain (or a portion thereof).
  • the device as described herein may comprise logic (in a computer readable format) that determines the coherence of the intrinsic frequencies of a specified EEG band of the subject measured at multiple brain locations.
  • the device as described herein may comprise logic (in a computer readable format) that determines the phase of the intrinsic frequencies of a specified EEG band of the subject measured at multiple brain locations.
  • a method of treating a subject comprising adjusting output of a magnetic field for influencing an intrinsic frequency of a specified EEG band of the subject toward a pre-selected intrinsic frequency of the specified EEG band; and applying said magnetic field close to a head of the subject.
  • a NEST device such as one of the NEST devices (pMERT devices) described herein is used to create the magnetic field of the method.
  • influencing an intrinsic frequency may include influencing harmonics of the pre-selected intrinsic frequency of the specified EEG band.
  • the pre-selected intrinsic frequency is a harmonic of the peak intrinsic frequency of a specified EEG band.
  • influencing an intrinsic frequency may include providing a magnetic field having a target frequency that can be represented in the frequency domain by an impulse function. In some embodiments, influencing an intrinsic frequency may include providing a magnetic field having a target frequency having no variation (standard of deviation around the target frequency is 0). In some embodiments, influencing an intrinsic frequency may include providing a magnetic field having a target frequency plus or minus at most 1% of the target frequency. In some embodiments, influencing an intrinsic frequency may include providing a magnetic field having a target frequency plus or minus at most 5% of the target frequency. In some embodiments, influencing an intrinsic frequency may include providing a magnetic field having a target frequency plus or minus at most 10% of the target frequency.
  • influencing an intrinsic frequency may include providing a magnetic field having a target frequency plus or minus at most 10% of the target frequency. In some embodiments, influencing an intrinsic frequency may include providing a magnetic field having a target frequency plus or minus at most 15% of the target frequency. In some embodiments, influencing an intrinsic frequency may include providing a magnetic field having a target frequency plus or minus at most 20% of the target frequency.
  • a method of treating a subject comprising adjusting output of a magnetic field for influencing a Q-factor a measure of frequency selectivity of a specified EEG band of the subject toward a pre-selected Q-factor of the band; and applying said magnetic field close to a head of the subject.
  • a NEST device such as one of the NEST devices (pMERT devices) described herein is used to create the magnetic field of the method.
  • a method of treating a subject comprising adjusting output of a magnetic field for influencing a coherence of intrinsic frequencies among multiple sites in a brain of the subject within a specified EEG band toward a pre-selected coherence value; and applying said magnetic field close to a head of the subject.
  • a NEST device such as one of the NEST devices (pMERT devices) described herein is used to create the magnetic field of the method.
  • a method of altering an intrinsic frequency of a brain of a subject within a specified EEG band comprising determining the intrinsic frequency of the subject within the specified EEG band; comparing the intrinsic frequency from step (a) to an average intrinsic frequency of a healthy population database; if the intrinsic frequency from step (a) is higher than the average intrinsic frequency of the healthy population database, shifting down the intrinsic frequency of the subject by applying a specific magnetic field close to a head of the subject, wherein said specific magnetic field has a frequency lower than the intrinsic frequency of the subject; and if the intrinsic frequency from step (a) is lower than the average intrinsic frequency of the healthy population database, shifting up the intrinsic frequency of the subject by applying a specific magnetic field close to a head of the subject, wherein said specific magnetic field has a frequency higher than the intrinsic frequency of the subject.
  • a NEST device such as one of the NEST devices (pMERT devices) described herein is used to create the magnetic field of the method.
  • a method of altering a Q-factor of an intrinsic frequency within a specified EEG band of a subject comprising determining the Q-factor of the intrinsic frequency within the specified EEG band of the subject; comparing the Q-factor of the intrinsic frequency from step (a) to an average Q-factor of the intrinsic frequency of a healthy population database; if the Q-factor of the intrinsic frequency from step (a) is higher than the average Q-factor of the intrinsic frequency of the healthy population database, tuning down the Q-factor of the intrinsic frequency of the subject by applying a magnetic field with varying frequencies close to a head of the subject; and if the Q-factor of the intrinsic frequency from step (a) is lower than the average Q-factor of the intrinsic frequency of the healthy population database, tuning up the Q-factor of the intrinsic frequency of the subject by applying a specific magnetic field with a pre-selected frequency close to a head of the subject.
  • a NEST device such as one of the NEST devices (pMERT devices) described herein is used to create the
  • a method of improving coherence of intrinsic frequencies within a specified EEG band among multiple locations of a brain of a subject comprising determining the coherence value of the intrinsic frequencies among multiple locations throughout a scalp of the subject; comparing the coherence value from step (a) to an average coherence value of a healthy population database; if the coherence value from step (a) is higher than the average coherence value of the healthy population database, lowering the coherence value of the subject by applying at least two asynchronous magnetic fields close to a head of the subject; if the coherence value from step (a) is lower than the average coherence value of the healthy population database, raising the coherence value of the subject by applying at least one synchronized magnetic field close to a head of the subject.
  • a NEST device such as one of the NEST devices (pMERT devices) described herein is used to create the magnetic field of the method.
  • a method comprising adjusting an output current of an electric alternating current source for influencing a Q-factor of an intrinsic frequency of an EEG band of a subject toward a target Q-factor; and applying said output current across a head of the subject.
  • a method comprising adjusting output of a magnetic field for influencing an EEG phase between two sites in the brain of a subject of a specified EEG frequency toward a pre-selected EEG phase of the specified EEG frequency; and applying said magnetic field close to a head of the subject.
  • the pre-selected EEG phase is lower than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is any EEG phase lower than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is higher than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is any EEG phase higher than the EEG phase between the two sites in the brain of the subject. In some embodiments, the pre-selected EEG phase is an EEG phase of a population of people. The population of people may be a set of people having a particular trait, characteristic, ability, or feature. The population may be a healthy population of people.
  • the population of people may be a set of people not having a particular disorder, such as anxiety, depression, or other disorders mentioned herein.
  • the methods comprise measuring EEG data of two sites in the brain of the subject, and calculating the EEG phase between the two sites in the brain of a subject.
  • the method comprises adjusting output of a magnetic field for influencing an EEG phase between two sites in the brain of a subject within a specified EEG band; and applying said magnetic field close to a head of the subject.
  • the EEG phase may be influenced to be lower, or higher.
  • determining the EEG phase the between at least two locations measured on the head of the subject comprising determining the EEG phase the between at least two locations measured on the head of the subject; comparing the EEG phase to an average EEG phase of a healthy population; and applying a magnetic field close to a head of the subject. Applying the magnetic field may influences the determined EEG phase toward the average EEG phase of a healthy population.
  • the specified EEG frequency may be an intrinsic frequency as described herein.
  • the specified EEG frequency may be a pre-selected frequency as described herein.
  • the pre-selected frequency may be an average intrinsic frequency of a healthy population database within a specified EEG band.
  • TMS Transcranial Magnetic Stimulation
  • the magnetic field results from a first magnetic source and a second magnetic source.
  • the first magnetic source and the second magnetic source are out of phase relative to each other.
  • the amount that the first magnetic source and the second magnetic source are out of phase relative to each other is called the magnetic phase.
  • the step of applying the magnetic field is for a pre-determined cumulative treatment time.
  • the pre-selected or target intrinsic frequency with the specified EEG band is from about 0.5 Hz to about 100 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is from about 1 Hz to about 100 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is not greater than about 50 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is not greater than about 30 Hz.
  • the pre-selected or target intrinsic frequency with the specified EEG band is not greater than about 20 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is not greater than about 10 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is greater than about 3 Hz. In some embodiments of at least one aspect described above, the pre-selected or target intrinsic frequency with the specified EEG band is greater than about 1 Hz.
  • the pre-selected or target intrinsic frequency with the specified EEG band is up to about 25 Hz.
  • the term “about” when referring to a frequency can mean variations of 1 Hz-0.2 Hz, 0.1 Hz to 0.5 Hz, 0.5 Hz to 1 Hz, or 1 Hz to 5 Hz.
  • the pre-selected and/or target intrinsic frequency is chosen from a plurality of intrinsic frequencies in the specified EEG band. In some embodiments the pre-selected and/or target intrinsic frequency is chosen from a plurality of intrinsic frequencies across a plurality of EEG bands. In some embodiments the specified EEG band is the Alpha band. In some embodiments the specified EEG band is the Beta band.
  • the method or methods may comprise locating a first electrode operable to detect electrical brain activity on the subject in an area of low electrical resistivity on a subject. In some embodiments of the methods described herein, the method or methods may comprise locating a first electrode operable to detect electrical brain activity on the subject in an area with substantially no electrical impulse interference on a subject. In some embodiments of the methods described herein, the method or methods may comprise locating a first electrode operable to detect electrical brain activity on the subject in an area having substantially no electrical impulse interference. In some embodiments of the methods described herein, the method or methods may comprise locating a first electrode operable to detect electrical brain activity on the subject in a location having substantially no muscle activity. The method or methods may further comprise locating a second electrode operable to detect a reference signal on the subject. The method or methods may further comprise determining the intrinsic frequency from: the electrical brain activity detected by the first electrode, and the reference signal detected by the second electrode.
  • the method or methods may comprise locating a first electrode operable to detect electrical brain activity on the subject in at least a portion of the ear canal of the subject.
  • the method or methods may further comprise locating a second electrode operable to detect a reference signal on the subject.
  • the method or methods may further comprise determining the intrinsic frequency from the electrical brain activity detected by the first electrode and the reference signal detected by the second electrode.
  • the method or methods described herein may comprise applying conductive gel to the area of low electrical resistivity on a subject (i.e. the location at which the first electrode is placed).
  • the method or methods described herein may comprise applying conductive gel to the area having substantially no electrical impulse interference on a subject (i.e. the location at which the first electrode is placed).
  • the method or methods described herein may comprise applying conductive gel to the area having substantially no muscle activity (i.e. the location at which the first electrode is placed).
  • the method may comprise shaping the first electrode to fit the area at which the first electrode is placed, for non-limiting example, the portion of the ear canal or the portion of the nasal cavity in which the first electrode is placed.
  • the electrode may be pre-shaped to generally fit the intended anatomical location of electrode placement, or the electrode may be shaped in-situ to fit the specific subject's anatomical location of electrode placement.
  • the method may comprise shaping the electrode to fit an anatomical location (for example, the area at which the first electrode is to be placed).
  • the method may comprise providing an electrode that fits an anatomical location (for example, the area at which the first electrode is to be placed).
  • the first electrode may come in multiple sizes to accommodate a range of subjects' anatomy.
  • the first electrode may be configured such that the subject may place the electrode in the area having substantially no electrical impulse interference without assistance from, for non-limiting example, a second person, a trained EEG technician, or a medical professional.
  • the method or methods described herein may comprise placing the first electrode in a location having substantially no electrical impulse interference may be a location having substantially no muscle activity.
  • the area having substantially no muscle activity may naturally have substantially no muscle activity.
  • the method or methods described herein may comprise relaxing the area of the subject at which the first electrode is placed by a muscle relaxation means such as by, for non-limiting example, injecting with a substance that relaxes the muscles in the area, applying a topical substance that relaxes the muscles in the area, and/or by providing an ingestible muscle relaxation substance to the subject that relaxes the muscles in the area.
  • the method or methods described herein may comprise paralyzing the area of the subject at which the first electrode is placed by a muscle paralysis means such as by, for non-limiting example, and/or injecting with a substance that substantially paralyzes the muscles in the area, applying a topical substance that substantially paralyzes the muscles in the area.
  • the methods provided herein may comprise placing the first electrode on the scalp (either directly, and/or with hair between the scalp and the electrode).
  • the methods provided herein may comprise placing a plurality of electrodes on the scalp for coherence measurement, intrinsic frequency measurement, and/or Q-factor measurement.
  • the methods provided herein may comprise filtering from the signal (or signals) received from the EEG electrodes noise from scalp movement and/or resistivity from the skull.
  • the methods provided herein may comprise smoothing the signal curve received and/or determined from the EEG electrodes.
  • the methods provided herein may comprise determining from multiple signal recordings: a coherence measurement, an intrinsic frequency measurement, and/or a Q-factor measurement using any of the EEG recording means noted herein.
  • An EEG electrode cap may be used, and signals from one or more electrodes of the cap may be used as described herein to determine an intrinsic frequency, a Q-factor, or coherence.
  • the area of the scalp upon which the first EEG electrode (or the plurality of electrodes) is/are placed may be induced to have less muscle activity, or it may naturally have less muscle activity than other areas on the scalp. Inducing less muscle activity in the area of the scalp may be achieved in various ways.
  • the methods may comprise relaxing the area where the first electrode is placed, for non-limiting example, by injecting the area with a substance that relaxes (and/or paralyzes) the muscles in the area, applying a topical substance that relaxes (and/or paralyzes) the muscles in the area, and/or by providing an ingestible muscle relaxation substance that relaxes the muscles in the area.
  • the method comprises placing a second electrode operable to detect a reference signal, wherein the second electrode is a ground reference.
  • the method may comprise attaching an ear clip electrode to, for non-limiting example, a subject's earlobe.
  • the ear clip may be removable.
  • the method may comprise attaching the second electrode to a location showing substantially no EEG activity.
  • Measuring the EEG signal from the subject's brain may be done prior to and/or after the application of the magnetic field to the subject.
  • the method may comprise receiving the EEG signals (i.e. receiving the reference signal from the reference electrode and receiving the brain activity from the first electrode) prior to application of the magnetic field to the subject's brain (or a portion thereof).
  • the method may comprise recording the EEG signals prior to application of the magnetic field to the subject's brain (or a portion thereof).
  • the EEG signals i.e.
  • receiving the reference signal from the reference electrode and receiving the brain activity from the first electrode) received and/or recorded prior to application of the magnetic field to the subject's brain (or a portion thereof) may be used in determining at least one of the intrinsic frequency of a specified EEG band of the subject, the Q-factor of an intrinsic frequency of a specified EEG band of the subject, the phase of the intrinsic frequencies of a specified EEG band of the subject, and the coherence of the intrinsic frequencies of a specified EEG band of the subject measured at multiple brain locations.
  • the method may comprise receiving the EEG signals (i.e. receiving the reference signal from the reference electrode and receiving the brain activity from the first electrode) following (or after) application of the magnetic field to the subject's brain (or a portion thereof).
  • the method may comprise recording the EEG signals (i.e. the reference signal from the reference electrode and the brain activity from the first electrode) following or after application of the magnetic field to the subject's brain (or a portion thereof).
  • the EEG signals received and/or recorded i.e.
  • Determining the Q-factor of an intrinsic frequency of the specified EEG band comprises ascertaining the Q-factor from the electrical brain activity detected by the first electrode and the reference signal detected by the second electrode by removing the reference signal detected by the second electrode from the electrical brain activity detected by the first electrode and calculating the Q-factor from the intrinsic frequency f 0 and the ⁇ f as shown in FIG. 12 .
  • Repetitive Transcranial Magnetic Stimulation refers to uses of a magnetic field administered in very short grouped pulses (microseconds in length) to a patient's head to achieve a constant train of activation over brief periods of a treatment session. These brief magnetic fields can stimulate small areas of the brain non-invasively. During a single session, about 3,000 magnetic pulses can be given over an interval of about 30 minutes.
  • the short pulses of magnetic energy generated by rTMS devices can stimulate nerve cells of the brain, often at frequencies close to thresholds of exciting brain cells. Magnetic fields generated by rTMS devices can pass through the skull and into the cortex without being distorted. The result is a very focal type of stimulation, minimizing stimulation of brain tissue not intended to be stimulated.
  • the magnetic pulses generated by rTMS devices are generally believed to induce electrical charges to flow.
  • the amount of electricity created in the brain is very small, and can not be felt by the patient. These flowing electric charges can cause the neurons to fire or become active under certain circumstances.
  • an objective of rTMS Therapy is to stimulate (or activate) brain cells.
  • alphaTMS alpha frequency transcranial magnetic stimulation
  • Frequency Higher frequencies (>10 Hz) are believed to increase cortical excitability
  • Intensity As a percentage of the threshold at which motor activity can be elicited ( ⁇ 1-2 Tesla);
  • Duration Pulse trains are brief (1-2 seconds), and intertrain intervals can be 30-60 seconds; and
  • Site of Stimulation Depending on patient population or specific brain functions.
  • severity of psychosis, depression, and movement disorders can be assessed with PANSS, Montgomery-Asberg Depression Rating Scale (MADRS), Barnes Akathisia Rating Scale (BARS), and Simpson-Angus Scale (SAS), as described by Jin Y et al. above.
  • severity of psychosis, depression, and movement disorders can be assessed with the Hamilton Anxiety Scale (HAMA), the Hamilton Depression Scale (HAMD), or any methods known in the art.
  • efficacy in clinical ratings can be evaluated by using analyses of variance (ANOVA) as described by Jin Y et al. above.
  • raw EEG data can be edited offline by an experienced technician who is blind to the treatment conditions to eliminate any significant or apparent artifact as described in Jin Y et al. above.
  • multivariate analysis of variance (MANOVA) with repeated measures can be used to determine the main effect interactions as described in Jin Y et al. above.
  • EEG changes can be direct consequences of treatments using the methods or devices described herein, those EEG changes can be used to clinically correlate improvement in symptoms of mental disorders. Improvement in symptoms can include positive symptoms and negative symptoms. In some embodiments, the EEG changes after using the methods or devices described correlated to both positive symptoms and negative symptoms. In some embodiments, the EEG changes after using the methods or devices described correlated to only positive symptoms. In some embodiments, the EEG changes after using the methods or devices described correlated to only negative symptoms. In some embodiments, correlations between EEG changes and improvement in negative symptoms are only significant in the absence of positive symptoms. In some embodiments, correlations between EEG changes and improvement in positive symptoms are only significant in the absence of negative symptoms.
  • negative symptoms include, but not limited to, loss of motivation, anhedonia, emotional flattening, and psychomotor retardation. These negative symptoms can be associated with patient's cognitive deficits and poorer clinical prognosis, and often resistant to antipsychotic medications. See Gasquet et al., Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol. 20: 199-205 (2005), which is incorporated by reference in its entirety.
  • Cranial Electrotherapy Stimulation is a method of applying microcurrent levels of electrical stimulation across the head via transcutaneous electrodes.
  • method including applying an electric alternating current (AC) across a head of a subject, and adjusting and/or varying the frequency of the AC current to effect at least one of a characteristic, mental disorder, and an indication presented herein.
  • the AC current is a micro current.
  • a method comprising adjusting an output of an electric alternating current source for influencing an intrinsic frequency of a EEG band of a subject toward a target frequency of the EEG band; and applying said electric alternating current across a head of the subject.
  • a CES therapy is used to influence the intrinsic frequency of a patient's brain toward a target frequency as measured by EEG.
  • a method comprising adjusting an output current of an electric alternating current source for influencing an intrinsic frequency of an EEG band of a subject toward a target frequency of the EEG band; and applying said output current across a head of the subject.
  • the step of adjusting the output current comprises setting the output current to a frequency that is lower than the intrinsic frequency of the subject.
  • the step of adjusting the output current comprises setting the output current to a frequency that is higher than the intrinsic frequency of the subject.
  • the step of adjusting the output current comprises setting the output current to the target frequency.
  • the method further comprises determining the intrinsic frequency of the EEG band of the subject; and comparing the intrinsic frequency to the target frequency of the EEG band, wherein the target frequency is an average intrinsic frequency of the EEG bands of a healthy population of people, wherein if the intrinsic frequency is higher than the target frequency, the step of adjusting the output current comprises setting the output current to a frequency that is lower than the intrinsic frequency of the subject, and if the intrinsic frequency is lower than the target frequency, the step of adjusting the output current comprises setting the output current to a frequency that is higher than the intrinsic frequency of the subject.
  • a controlled waveform CES therapy is used to influence a Q-factor of an intrinsic frequency of a patient's brain.
  • FIG. 12 shows an example of the Q-factor as used in this invention. The figure shows a sample graph of the frequency distribution of the energy of an EEG signal. It can be seen that a frequency range, ⁇ f can be defined as the frequency bandwidth for which the energy is above one-half the peak energy.
  • the frequency f 0 is defined as the intrinsic frequency in the specified band.
  • the Q-factor is defined as the ratio of f 0 / ⁇ f. As can be seen, when AF decreases for a given f 0 , the Q-factor will increase. This can occur when the peak energy E max of the signal increases or when the bandwidth of the EEG signal decreases.
  • a method comprising adjusting an output current of an electric alternating current source for influencing a Q-factor of an intrinsic frequency of an EEG band of a subject toward a target Q-factor; and applying said output current across a head of the subject.
  • the step of adjusting the output current comprises varying a frequency of the output current.
  • the step of adjusting the output current comprises setting the output current to a frequency that is higher than the intrinsic frequency of the subject.
  • the step of adjusting the output current comprises setting the output current to a frequency that is lower than the intrinsic frequency of the subject.
  • the step of adjusting the output current comprises setting the output current to the target frequency.
  • the method further comprises determining the Q-factor of the intrinsic frequency of the EEG band of the subject; and comparing the Q-factor to the target Q-factor, wherein the target Q-factor is an average Q-factor of the intrinsic frequencies of the EEG bands of a healthy population of people, wherein if the intrinsic frequency is higher than the target frequency, the step of adjusting the output current comprises varying a frequency of the output current, and if the intrinsic frequency is lower than the target frequency, the step of adjusting the output current comprises setting the output current to a frequency that is higher than the intrinsic frequency of the subject.
  • the frequency of the output current has a waveform.
  • the waveform is a sinusoidal or near-sinusoidal AC microcurrent waveform (i.e. a controlled waveform).
  • the waveform is any waveform described herein, including but not limited to a half waveform and/or a full waveform.
  • the EEG band is the alpha band measured by EEG.
  • the intrinsic frequency is the alpha frequency of the patient's brain measured by EEG.
  • the target frequency is a target frequency of the alpha band as measure by EEG. In some embodiments the target frequency is an average frequency of a group of at least two people of the specified EEG band.
  • the healthy population of people comprises at least two healthy people. In some embodiments, the healthy population of people comprises at least two people, each of whom do not have at least one of the mental disorders listed above. In some embodiments, the healthy population of people comprises at least two people without any of the mental disorders listed above.
  • the direction of rotation relative to the subject can vary depending on the specific therapy desired.
  • the speed of rotation can be adjusted to provide the optimal therapeutic benefit.
  • the speed adjustment itself can come from the user of the device or from a controller that uses feedback from a bio-sensor to determine the optimal speed.
  • a bar magnet can be mounted at the end of the shaft with the line through the poles perpendicular to the axis of the shaft.
  • the shaft can be rotated by an adjustable motor.
  • the magnet can rotate so that the plane of rotation is perpendicular to the surface of the scalp. Accordingly, the positive and negative poles of the magnet can be alternately brought in close proximity to the scalp. This can create a near-sinusoidal magnetic field in the brain in which the location where the field is strongest is that which is closest to the magnet.
  • a horseshoe magnet can be mounted at the end of the shaft with the poles positioned at the far end from the shaft.
  • the shaft can be rotated by an adjustable motor, as in the previous example.
  • the magnet can be positioned above the subject's scalp such that the plane of rotation is parallel to the surface of the scalp. Accordingly, the positive and negative poles can rotate in a circle around the scalp. This can create a sinusoidal magnetic field in the brain in which the phase of the magnetic field is dependent on where the magnetic poles are in their rotation. In general, the magnetic field under one pole will be of opposite polarity to the magnetic field under the opposite pole.
  • two bar magnets can be used, each mounted at the end of a shaft.
  • the shafts can be rotated by adjustable motors.
  • the magnets can be positioned on opposite sides of the subject's head, and they are rotated synchronously to provide a more uniform phase for the magnetic field in the brain. When the north Pole of one bar magnet is next to the subject's scalp, the south Pole of the other magnet will be next to the subject's scalp on the opposite side of the subject's head.
  • the NEST (pMERT) device is a small, generally cube-shaped device with one side that is curved to allow contact with the top of the subject's head.
  • FIGS. 7-9 show the NEST (pMERT) device in such embodiments, and also show the NEST (pMERT) device with a subject lying on his/her back with his/her head resting in the device to receive therapy.
  • FIGS. 7 , 8 , and 9 show an exemplary embodiment of the pMERT (NEST) device 88 .
  • a button EEG electrode 82 a is located on the concave surface of the device 88 and a second reference electrode 82 b extends via a wire from the side of the device 88 .
  • the display 64 and control buttons 86 are located on top of the device 88 to provide information and allow the user to adjust parameters and enter patient data.
  • a USB port 84 (which may also and/or alternatively be at least one of an internet connection port, a power supply, a modem connection, and another type of communications means) is located at the top rear of the device 88 , to allow it to be connected via a USB cable to a PC, allowing uploading of data and downloading of a dosage quota.
  • FIG. 8 shows the pMERT (NEST) device 88 from FIG. 7 in which a subject 6 is lying with his/her head against the concave surface of the device 88 . At least one moving magnet is unseen inside the pMERT (NEST) device 88 in order to deliver therapy to the subject 6 . Moving magnets such as those in configurations described herein may be used in the device 88 shown in FIGS.
  • FIG. 9 shows an alternate angle of the subject 6 receiving therapy from the pMERT (NEST) device 88 as described in FIG. 7 and/or FIG. 8 .
  • the pMERT as shown in FIGS. 7-9 contains a single EEG lead (i.e. electrode) which is to be placed at the top of the subject's head.
  • EEG leads i.e. electrode
  • multiple EEG electrodes may be used in recording and/or monitoring the subject's brain waves at least one of before, during, and after the therapy is applied to the subject.
  • the subject or nurse can prepare the EEG leads (and/or electrodes) with an electrolytic gel beforehand to lower the impedance.
  • the reference electrode can be placed on the subject's ear.
  • the reading from a reference EEG electrode is subtracted and/or otherwise removed from the reading from the second EEG electrode.
  • the subject or nurse can follow the instructions on the display, which will provide a walkthrough of the EEG electrode preparation.
  • the EEG is checked by the pMERT to ensure that the electrode is placed correctly. If not, an audible tone or instruction is given to allow the patient to resituate himself/herself until proper contact is made.
  • the patient lies still with eyes closed while the pMERT (NEST) acquires a representative EEG sample.
  • the EEG data is analyzed and, depending on the therapy to be delivered, the magnet or magnets are rotated at the appropriate speed. The patient does not feel anything during the procedure, except for a diminution of the symptoms of the disorder, and perhaps a feeling of calm.
  • the device may sample the EEG data either by subtracting out the influence of the magnet or by temporarily halting the magnet while the EEG data is sampled.
  • the display is used to show time remaining and any other necessary status information for the device.
  • the methods and devices described are intended to be used by psychiatrists/therapists to treat patients with mental disorders. Psychiatrists who take advantage of this therapy can register accounts with a vendor of the devices described and be given a username and password. When a psychiatrist sees a patient with a disorder and the psychiatrist feels that the patient could benefit from the methods or devices described herein, the psychiatrist either orders a device or selects one that has been pre-purchased.
  • the psychiatrist can plug a pMERT (NEST) device into a USB port on a PC connected to an internet. Using web access and their username/password, the psychiatrist can login to the NeoSync website. The pMERT (NEST) will be automatically detected by the NeoSync website, and any necessary software upgrades will be downloaded.
  • pMERT pMERT
  • the psychiatrist can then order a number of dosage quotas for a particular disorder from the website, such as 15 20-minute therapy treatment, one per day, to treat depression.
  • An encrypted key will be downloaded to the pMERT (NEST), which will be set to allow the dosage quotas requested by the psychiatrist. Once this occurs, the psychiatrist will automatically be billed based on the number and type of dosage quotas.
  • the psychiatrist will then bill the patient (or eventually the patient's insurance) for the procedure.
  • the patient can take the pMERT (NEST) device to his/her home to use the device in accordance with the therapy prescribed by the psychiatrist or the patient can be treated in the psychiatrist's office.
  • the psychiatrist Once the patient has used up all the dosage quotas the psychiatrist has loaded onto the device, the patient returns to the psychiatrist with the pMERT (NEST) device.
  • the psychiatrist will connect the pMERT (NEST) device to the PC via a USB cable and will login to the NeoSync website as before.
  • the website will detect the pMERT (NEST) and will upload all treatment information.
  • a report can be generated with this information, giving the psychiatrist a quantitative indication of progress.
  • the report can include for each treatment the date, start time, end time, initial EEG alpha parameters (i.e., power and Q-factor), and the final EEG alpha parameters.
  • the psychiatrist can print the report or save it to a file to be placed in the patient's record. At this point, the psychiatrist can clear the memory of the device and use it for another patient or he/she can order more dosage quotas for the current patient.
  • the psychiatrist decides that the patient should use the pMERT (NEST) for a longer period, the psychiatrist can set up an account for the patient with NeoSync, Inc. This way, the patient is able to order more dosage quotas without returning to the psychiatrist. Only the dosage quotas approved by the psychiatrist will be allowed for the patient to order.
  • the patient can pay NeoSync directly with a credit card or (eventually) insurance. For each session, the psychiatrist may also be paid.
  • the psychiatrist would have access to all reports uploaded from the pMERT (NEST) via the website.
  • Each patient admitted to the study is randomly assigned into one of the two study groups based on treatment using a plugged pMERT (NEST) device and sham, where a pMERT (NEST) device rotates a non-magnetic metal block instead of a magnet.
  • NEST plugged pMERT
  • sham a pMERT (NEST) device rotates a non-magnetic metal block instead of a magnet.
  • Patients are kept blind to the treatment condition.
  • Each treatment consists of 22 daily sessions during a 30-day period (and/or at least 10 sessions during a 2 week period or more).
  • Patients' current antipsychotic treatments are kept unchanged during the study.
  • EEG data during treatments are recorded and individualized according to the alpha EEG intrinsic frequency (8-13 Hz).
  • the precision of the stimulus rate can be refined to the level of 10% of a hertz. It is determined on each patient's average alpha frequency, obtained from 3 central EEG leads (C3, C4, and Cz).
  • EEG data during treatments are recorded from each subject in a supine position with their eyes closed throughout the testing period.
  • Nineteen EEG electrodes (Ag—Ag Cl) are used according to the International 10-20 system and referenced to linked mastoids.
  • Electrooculograms (EOGs) from the outer canthus of both eyes are recorded simultaneously to monitor eye movements.
  • At least two minutes of EEG epochs are collected and digitized by a 12-bit A/D (analog/digital) converter at the rate of 200 Hz by a Cadwell EZ II acquisition system.
  • Sixty seconds of artifact free epochs are utilized for fast Fourier transformations (FFT).
  • FFT window is set at 512 data points with 80% overlap.
  • HAMA Hamilton Anxiety Scale
  • HAMD Hamilton Depression Scale
  • MADRS Montgomery-Asberg Depression Rating Scale
  • BARS Barnes Akathisia Rating Scale
  • SAS Simpson-Angus Scale
  • Patients with a baseline and at least 1 additional set of completed assessments (at least 5 treatment sessions) are included in the analysis of mean treatment effect. Efficacy in clinical ratings is evaluated by using analyses of variance (ANOVA) with repeated measure over time.
  • the models include 2 between-subject factors of treatment and location, and 1 within-subject factors of time. Effect of concomitant antipsychotic treatment can be tested based on the categorization of typical and atypical neuroleptic medications. Grouping differences of all other measures are tested individually using the same statistical model. Using a predefined response criterion, a contingent table analysis can be used to test the group difference in responding rate.
  • Raw EEG data are edited offline by an experienced technician who is blind to the treatment conditions to eliminate any significant (>3_arc) eye movements or any other type of apparent artifact.
  • Ten to twenty-four artifact-free epochs (1,024 data points per epoch) in each recording channel are calculated by a fast Fourier transform (FFT) routine to produce a power spectrum with 0.2 Hz frequency resolution.
  • the intrinsic frequency of alpha EEG is defined as the mean peak frequency (Fp) of 3 central leads (C3, C4, and Cz).
  • EEG variables used in the analysis included power density (Pwr), peak frequency (Fp), Fp longitudinal coherence, and frequency selectivity (Q). See Jin Y et al. Alpha EEG predicts visual reaction time. Int J. Neurosci. 116: 1035-44 (2006), which is incorporated by reference in its entirety.
  • Coherence analysis is carried out between Fz and Pz in the peak alpha frequency. Recording from Cz is chosen to calculate the Q-factor (peak freq/half-power bandwidth), a measure of the alpha frequency selectivity. It is measured in the frequency domain by using a 60 sec artifact free EEG epoch and a 2,048 data point FFT with a 10-point smooth procedure. Multivariate analysis of variance (MANOVA) across all channels for each variable is performed to test the treatment and stimulus location effects. Change score for each variable before and after pMERT (NEST) treatment is used to correlate with the change score of each clinical measure from the same time points.
  • MANOVA Multivariate analysis of variance
  • FIG. 12 shows an example of the Q-factor as used in this invention.
  • the figure shows a sample graph of the frequency distribution of the energy of an EEG signal. It can be seen that a frequency range, ⁇ f can be defined as the frequency bandwidth for which the energy is above one-half the peak energy.
  • the frequency f 0 is defined as the intrinsic frequency in the specified band.
  • the Q-factor is defined as the ratio of f 0 / ⁇ f. As can be seen, when AF decreases for a given f 0 , the Q-factor will increase. This can occur when the peak energy E max of the signal increases or when the bandwidth of the EEG signal decreases.
  • NEST i.e. pMERT
  • pMERT pMERT
  • a NEST device was set at a fixed specified frequency equal to an intrinsic frequency within her alpha EEG band and the magnetic field emanating from the device was applied to the patient's head (cerebral cortex).
  • three consecutive blood pressure measurements were taken at ten minute intervals, showing 110/85 mmHg, 100/82 mmHg, and 100/70 mmHg, respectively.
  • the magnet can be placed anywhere around the patient's head, and locations can be chosen based on the desire for a more focal therapy at a particular location.
  • Alternative embodiments can include stringing two or more cylindrical magnets together on the same shaft, or along different shafts, to spin the magnets in unison to create a particular magnetic field in treating the patient. A non-limiting examples of this are found in FIGS. 13 through 15 .
  • FIG. 13 shows an example embodiment of a diametrically magnetized cylindrical magnet 2 for use in a NEST device.
  • FIG. 14 shows an example embodiment of a NEST device applied to a subject 1406 , the device having a diametrically magnetized cylindrical magnet 1402 and a drive shaft 1404 that rotates the magnet 1402 about its cylinder axis, wherein the cylinder axis coincides with rotation axis 1438 .
  • FIG. 14 shows an example embodiment of a NEST device applied to a subject 1406 , the device having a diametrically magnetized cylindrical magnet 1402 and a drive shaft 1404 that rotates the magnet 1402 about its cylinder axis, wherein the cylinder axis coincides with rotation axis 1438 .
  • FIG. 15 shows an example embodiment of a NEST device applied to a subject 1506 , the device having two diametrically magnetized cylindrical magnets 1502 a , 1502 b and a drive shaft 1404 that simultaneously rotates the magnets 1502 a , 1502 b about their cylinder axes, wherein the cylinder axes are coincident with each other and with rotation axis.
  • the north pole of magnet 1502 a and the north pole of magnet 1502 b are aligned to provide a more uniform magnetic field to the subject 1506 .
  • multiple cylindrical magnets can be arrayed above a patient's head so they spin in unison. These may be connected to each other by belts or gears so that they are driven by at least one motor. Non-limiting examples of these embodiments are shown in FIGS. 16 through 21 .
  • FIG. 16 shows an example embodiment of a NEST device having three diametrically magnetized cylindrical magnets 1602 a , 1602 b , 1602 c rotating about their cylinder axes and applied to a subject 1606 .
  • the poles of each the magnets 1602 a , 1602 b , 1602 c of the shown device are aligned generally to provide a peak magnetic field to the subject 1606 that is coincident with the peak magnetic fields delivered to the subject 1606 from each of the other magnets 1602 a , 1602 b , 1602 c .
  • each of the magnets 1602 a , 1602 b , 1602 c has a neutral plane indicated by the dotted line on each of magnets 1602 a , 1602 b , and 1602 c , and each the neutral planes is aligned to be generally parallel to the scalp of the subject 1606 .
  • This configuration provides a more uniform field to the subject 1606 than if the magnets 1602 a , 1602 b , 1602 c are not aligned in such a manner.
  • FIG. 17 shows an example embodiment of a NEST device 1788 having three diametrically magnetized cylindrical magnets 1702 a , 1702 b , 1702 c configured to rotate about their cylinder axes (not shown).
  • Each of the magnets 1702 a , 1702 b , 1702 c of this example embodiment is coupled to at least one magnet drive pulley 1716 a , 1716 b , 1716 c , 1716 d .
  • Each of the magnet drive pulleys 1716 a , 1716 b , 1716 c , 1716 d has at least one drive belt 1718 a , 1718 b , 1718 c , 1718 d wrapped at least partially about it.
  • the device 1788 also comprises two tensioner assemblies 1708 a , 1708 b , each comprising a tensioner block 1710 a , 1710 b , a tensioner arm 1712 a , 1712 b , and at least one tensioner drive pulley 1714 a , 1714 b , 1714 c each rotating about an axis going through the tensioner arm 1712 a , 1712 b , respectively, the axis generally being parallel to the rotation axis of the magnets and to the drive shaft 1704 of the device 1788 .
  • two tensioner assemblies 1708 a , 1708 b each comprising a tensioner block 1710 a , 1710 b , a tensioner arm 1712 a , 1712 b , and at least one tensioner drive pulley 1714 a , 1714 b , 1714 c each rotating about an axis going through the tensioner arm 1712 a , 1712 b , respectively, the axis generally
  • each of the tensioner assemblies has two tensioner drive pulleys 1714 a , 1714 b , 1714 c , (one tensioner drive pulley of tensioner assembly 1708 is not shown in FIG. 17 —obscured by the side support 1722 , but can be seen, for example, in FIG. 18 ).
  • the drive belts 1718 a , 1718 b , 1718 c , 1718 d are each also wrapped at least partially about at least one tensioner drive pulley 1714 a , 1714 b , 1714 c , (one tensioner drive pulley of tensioner assembly 1708 is not shown in FIG.
  • each the drive belts 1718 a , 1718 b , 1718 c , 1718 d is wrapped at least partially around at least one of the magnet drive pulleys 1716 a , 1716 b , 1716 c , 1716 d and is also wrapped at least partially around at least one of the tensioner drive pulleys 1714 a , 1714 b , 1714 c , (one tensioner drive pulley of tensioner assembly 1708 is not shown in FIG. 17 —obscured by the side support 1722 , but can be seen, for example, in FIG. 18 ) of the tensioner subassemblys 1708 a , 1708 b.
  • the device 1788 shown in FIG. 17 is held together by two side supports 1722 , 1720 connected by a support column 1724 a .
  • a second support column 1724 b may also connect the side supports 1722 , 1720 .
  • Each of the tensioner assemblies 1708 a , 1708 b and each of the magnets 1702 a , 1702 b , 1702 c are mounted to (coupled to) at least one of these supports, if not both the side supports 1722 , 1720 .
  • Each of the magnets 1702 a , 1702 b , 1702 c are rotatably mounted to at least one of the side supports 1722 , 1720 , such that each of the magnets 1702 a , 1702 b , 1702 c can rotate about their rotation axes (cylinder axes) without motion of either of the side supports 1722 , 1720 .
  • at least the tensioner drive pulleys 1714 a , 1714 b , 1714 c (and one tensioner drive pulley unshown in FIG.
  • drive belt 1718 a wraps at least partially around the magnet drive pulley 1716 a of magnet 1702 a , and also wraps at least partially around the tensioner drive pulley 1714 a of the first tensioner assembly 1708 a .
  • the drive shaft 1704 coupled to a motor (not shown), drives the rotation of all of the magnets 1702 a , 1702 b , 1702 c of the shown device 1788 .
  • the drive shaft 1704 is coupled to a first magnet 1702 a which, through its magnet drive pulley 1716 a and associated belt 1718 a turns the first tensioner drive pulley 1714 a of the first tensioner assembly 1708 a .
  • the first tensioner drive pulley 1714 a of the first tensioner assembly 1708 a is coupled to the second tensioner pulley (not shown—obscured by side support 1722 ) of the first tensioner assembly 1708 a , and, thus, when the first tensioner pulley 1714 a is turned by the first drive belt 1718 a , the second tensioner pulley (not shown) is also turned. Since the second drive belt 1718 b is wrapped at least partially around the second tensioner pulley (not shown) as well as the second magnet drive pulley 1716 b of the second magnet 1702 b , the motion of the second tensioner pulley (not shown) moves the second drive belt 1718 b and likewise drives the rotation of the second magnet 1702 b .
  • the second magnet 1702 has a third magnet drive pulley 1716 c which is coupled to the second drive pulley 1716 b , and the third drive belt 1718 c wraps at least partially around the third magnet drive pulley 1716 c , thus, motion of the second drive belt 1718 b also causes motion of the third drive belt 1718 c wrapped at least partially around the third magnet drive pulley 1716 c .
  • the motion of the third drive belt 1718 c also wrapped at least partially around the third tensioner pulley 1714 b of the second tensioner assembly 1708 b thus drives the rotation of the fourth tensioner pulley 1714 c of the second tensioner assembly 1708 b which is coupled to the third tensioner pulley 1714 b of the second tensioner assembly 1708 b .
  • the motion of the fourth drive belt 1718 d drives the rotation of the third magnet 1702 c simultaneously with the rotation of the other two magnets 1702 a , 1702 b.
  • the tensioner assemblies are not present, and the drive shaft drives the magnets connected only to each other using drive belts.
  • only one tensioner assembly is present and is coupled to at least two magnets.
  • only one tensioner assembly is present and is coupled to each of the magnets.
  • the magnets are coupled to each other by gears.
  • the magnets are coupled to each other by a combination of at least one gear and at least one belt.
  • the magnets are coupled to each other by a combination of at least one gear and at least two belts, wherein each belt is coupled to a tensioner assembly as generally described herein.
  • the magnets are coupled to each other by a rotation means, wherein the rotation means is configured to drive the rotation of the magnets simultaneously.
  • the tensioner assemblies in the embodiments shown in FIG. 17 , FIG. 18 , and FIG. 19 are configured to keep the drive belts taut during use and, therefore, ensure that the rotation of the magnets is simultaneous and generally in-phase as applied to the subject where the magnets are aligned such that each of the neutral planes of each of the three magnets are generally aligned to be parallel to the scalp of the subject.
  • FIG. 18 depicts an exploded view of the example embodiment of the NEST device 1888 of FIG. 17 having three diametrically magnetized cylindrical magnets configured to rotate about their cylinder axes. Shown in FIG. 18 is a NEST device 1888 having two tensioner assemblies 1808 a , 1808 b .
  • Tensioner assembly 1808 a comprises a tensioner block 1810 a that couples to the side support 1822 by at least one tensioner dowel pin 1832 a .
  • the tensioner block 1810 a also couples to the side support 1820 by at least one tensioner dowel pin 1832 b .
  • the tensioner block 1810 a floats freely along at least a portion of the dowel pins 1832 a , 1832 b .
  • the tensioner block 1810 a is attached to a tensioner arm 1812 a which has two tensioner drive pulleys 1814 a , 1814 d , which couple to drive belts 1818 a , 1818 b (respectively) which themselves are coupled to magnets 1802 a , 1802 b (respectively) of the device 1888 through magnet drive pulleys 1816 a , 1816 b .
  • the tensioner block 1810 a exerts a force on the belts 1818 a , 1818 b to keep the belts taut during use, since the tensioner block 1810 a is also coupled to tensioner springs 1830 a , 1830 b which push the tensioner block 1810 a away from the side supports 1822 , 1820 , and thus, away from the magnet drive pulleys 1816 a , 1816 b coupled to the side supports 1822 , 1820 by center pins (not shown) that run through each of the drive pulleys 1816 a , 1816 b and the magnets 1802 a , 1802 b .
  • the center pin When the center pin is also attached to a motor, it may also rotate the magnet and its associated magnet drive pulley(s), and it may be called a drive shaft. Nevertheless, the magnet drive pulleys 1816 a , 1816 b can rotate, and with their rotational movement the magnet drive pulleys 1816 a , 1816 b can rotate, or be rotated by, the magnets 1802 a , 1802 b.
  • tensioner assembly 1808 b comprises a tensioner block 1810 b that couples to the side support 1822 by at least one tensioner dowel pin 1832 c .
  • the tensioner block 1810 b also couples to the side support 1820 by at least one tensioner dowel pin 1832 c .
  • the tensioner block 1810 b floats freely along at least a portion of the dowel pins 1832 c , 1832 d .
  • the tensioner block 1810 b is attached to a tensioner arm 1812 b which has two tensioner drive pulleys 1814 b , 1814 c , which couple to drive belts 1818 d , 1818 c (not shown) (respectively) which themselves are coupled to magnets 1802 b , 1802 c (respectively) of the device 1888 through the magnet drive pulleys 1816 c , 1816 d .
  • the tensioner block 1810 b exerts a force on the belts 1818 d , 1818 c (not shown) to keep the belts taut during use, since the tensioner block 1810 b is also coupled to tensioner springs 1830 c , 1830 d which push the tensioner block 1810 b away from the side supports 1822 , 1820 , and thus, away from the magnet drive pulleys 1816 c , 1816 d coupled to the side supports 1822 , 1820 by center pins (not shown) that run through each of the drive pulleys 1816 c , 1816 d and the magnets 1802 b , 1802 c .
  • the center pin When the center pin is also attached to a motor, it may also rotate the magnet(s) and its associated magnet drive pulley(s), and it may be called a drive shaft. Nevertheless, the magnet drive pulleys 1816 c , 1816 d can rotate, and with their rotational movement the magnet drive pulleys 1816 c , 1816 d can rotate, or be rotated by, the magnets 1802 b , 1802 c.
  • FIG. 18 Also shown in FIG. 18 are support screws 1826 a , 1826 b which attach the support columns 1824 b (other support columns are either not called-out or not shown in FIG. 18 ) to the side support 1822 and/or to the side support 1820 .
  • FIG. 19 shows the example NEST device embodiment of FIG. 17 and/or of FIG. 18 having three diametrically magnetized cylindrical magnets 1902 a , 1902 b , 1902 c configured to rotate about their cylinder axes and including a frame 1934 and base 1936 for mounting the NEST device.
  • the embodiment shown in FIG. 19 shows the example NEST device embodiment of FIG. 17 and/or of FIG. 18 having three diametrically magnetized cylindrical magnets 1902 a , 1902 b , 1902 c configured to rotate about their cylinder axes and including a frame 1934 and base 1936 for mounting the NEST device.
  • 19 includes a NEST device having three magnets 1902 a , 1902 b , 1902 c , each having magnet drive pulleys 1916 a , 1916 b , 1916 c , 1916 d at least partially about which is wrapped a drive belt 1918 a , 1918 b , 1918 c , 1918 d each of which is also at least partially wrapped around a tensioner drive pulley 1914 a , 1914 b (not shown) 1914 c (not shown) 1914 d (not shown) coupled to a tensioner arm 1912 a , 1912 b (not shown) of a tensioner assembly.
  • Each tensioner assembly may include a tensioner block 1910 a (not shown) 1910 b , and a tensioner spring 1930 a (not shown), 1930 c which cooperate with at least one of the side supports 1922 , 1920 to pull the drive belts 1918 a , 1918 b , 1918 c , 1918 d taut.
  • the magnets 1902 a , 1902 b , 1902 c are rotatably coupled to side supports 1922 , 1920 , and at least one magnet 1902 a in the embodiment shown is coupled to a drive shaft 1904 which rotates the magnet 1902 a to which it is directly coupled, and through the cooperation of the magnet drive pulleys 1916 a , 1916 b , 1916 c , 1916 d , drive belts 1918 a , 1918 b , 1918 c , 1918 d , and tensioner drive pulleys 914 a , 1914 b (not shown) 1914 c (not shown) 1914 d (not shown), also rotates the other magnets 1902 b , 1902 c of the NEST device such that all of the magnets 1902 a , 1902 b , 1902 c rotate simultaneously.
  • FIG. 20 shows an example embodiment of a NEST device having eight diametrically magnetized cylindrical magnets 2002 a - 2002 h , configured to rotate about their cylinder axes.
  • Each of the magnets 2002 a - 2002 h has at least one magnet drive pulley 2016 a - 2016 n coupled to it which rotates the magnet 2002 a - 2002 h when the magnet drive pulley 2016 a - 2016 n is rotated by a belt 2018 a - 2018 h that is at least partially wrapped around at least one of the magnet drive pulleys 2016 a - 2016 n .
  • a drive shaft 2004 has two drive belts 2018 d , 2018 e wrapped at least partially around the drive shaft 2004 . The drive shaft 2004 thus rotates all of the magnets 2002 a - 2002 h simultaneously through a series of drive belts 2018 a - 2018 h and magnet drive pulleys 2016 a - 2016 n all coupled to the drive shaft 2004 .
  • the first drive belt 2018 e is wrapped at least partially around the drive shaft 2004 , and is also wrapped at least partially around a first magnet drive pulley 2016 h of a first magnet 2002 e .
  • a second drive belt 2018 f is wrapped at least partially around a second magnet drive pulley 2016 i of the first magnet 2002 e .
  • the second drive belt 2018 f is also wrapped at least partially around a third magnet drive pulley 2016 j of the second magnet 2002 f .
  • a third drive belt 2018 g is wrapped at least partially around a fourth magnet drive pulley 2016 k of the second magnet 2002 f .
  • the third drive belt 2018 g is also wrapped at least partially around a fifth magnet drive pulley 20161 of a third magnet 2002 g .
  • a fourth drive belt 2018 h is wrapped at least partially around a sixth magnet drive pulley 2016 m of the third magnet 2002 g .
  • the fourth drive belt 2018 h is also wrapped at least partially around a seventh magnet drive pulley 2016 n of a fourth magnet 2002 h .
  • the motion of the first drive belt 2018 e coupled to the drive shaft 2004 rotates the first magnet 2002 e , the second magnet 2002 f , the third magnet 2002 g , and the fourth magnet 2002 h simultaneously.
  • the fifth drive belt 2018 d is wrapped at least partially around the drive shaft 2004 , and is also wrapped at least partially around an eighth magnet drive pulley 2016 g of a fifth magnet 2002 d .
  • a sixth drive belt 2018 c is wrapped at least partially around a ninth magnet drive pulley 2016 f of the fifth magnet 2002 d .
  • the sixth drive belt 2018 c is also wrapped at least partially around a tenth magnet drive pulley 2016 e of the sixth magnet 2002 c .
  • a seventh drive belt 2018 b is wrapped at least partially around an eleventh magnet drive pulley 2016 d of the sixth magnet 2002 c .
  • the seventh drive belt 2018 b is also wrapped at least partially around a twelfth magnet drive pulley 2016 c of a seventh magnet 2002 b .
  • An eighth drive belt 2018 a is wrapped at least partially around a thirteenth magnet drive pulley 2016 b of the seventh magnet 2002 b .
  • the eighth drive belt 2018 a is also wrapped at least partially around a fourteenth magnet drive pulley 2016 a of an eighth magnet 2002 a .
  • the motion of the fifth drive belt 2018 d coupled to the drive shaft 2004 rotates the fifth magnet 2002 d , the sixth magnet 2002 c , the seventh magnet 2002 b , and the eighth magnet 2002 a simultaneously.
  • the drive shaft has only one drive belt that drives all of the rotation of all of the magnets.
  • the side supports 2022 , 2020 connected by at least two support columns 2024 a , 2024 b .
  • the supports 2020 , 2022 hold each of the magnets 2002 a - 2002 h in place relative to the supports 2020 , 2022 while allowing rotational motion of the magnets 2002 a - 2002 h and of the drive shaft 2004 which may me driven, for non-limiting example, by a motor (not shown).
  • FIG. 21 shows the magnet rotation of the example NEST device embodiment of FIG. 20 having eight diametrically magnetized cylindrical magnets 2102 a - 2102 h configured to rotate about their cylinder axes.
  • FIG. 21 shows a side view of an embodiment of a NEST device (not showing, for example, side supports), which is similar to the embodiment shown in FIG. 20 .
  • each of the magnets 2102 a - 2102 h has at least two drive belts (for example, drive belts 2118 a - 2118 h ) coupled to it which rotate the magnet 2102 a - 2102 h , or which are rotated by the magnet 2102 a - 2102 h , when the drive shaft 2104 is rotated.
  • two drive belts 2118 d , 2118 e are wrapped at least partially around the drive shaft 2104 .
  • the drive shaft 2104 thus rotates all of the magnets 2102 a - 2102 h simultaneously through a series of drive belts 2118 a - 2118 h all coupled to the drive shaft 2104 .
  • Shown in this embodiment is an example of the direction of rotation of the magnets 2102 a - 2102 h (indicated by arrows) resulting from a clockwise rotation of the drive shaft 2104 .
  • An opposite direction of movement is achieved when the drive shaft is rotated in a counter-clockwise direction.
  • the clockwise rotation of the drive shaft 2104 rotates all of the magnets 2102 a - 2102 h in a clockwise direction due to the belt 2118 a - 2118 h arrangement shown.
  • Each of the belts 2118 a - 2118 h shown is wrapped either around two magnets or around a magnet and the drive shaft.
  • a disc shaped magnet that is axially magnetized (the poles are on the top and bottom faces) can be cut in half, one half turned over (aligning N of one half with S of the other half) and placed together.
  • This disc can be spun about the center of the disc to get a magnetic field that is uniform over a large area.
  • two rectangular magnets having poles aligned and positioned similarly to the disc as previously described can be spun about the center of the rectangular magnets to create a similarly uniform field.
  • An example of the disc magnet is shown in FIG. 22
  • an example of the rectangular magnet similar to the disc magnet is shown in FIG. 23 .
  • FIG. 22 shows an example embodiment of a NEST device having two disc magnets 2202 a , 2202 b that rotate about a common rotation axis 2236 .
  • the device comprises two disc shaped magnets 2202 a , 2202 b that are axially magnetized (the poles are on the top and bottom faces).
  • the north pole of the first magnet 2202 a aligns with the south pole of the second magnet 2202 b (aligning their neutral planes).
  • the device further comprises a drive shaft 2204 that aligns with the center of the disc magnets 2202 a , 2202 b and with, therefore, the rotation axis 2236 of the magnets 2202 a , 2202 b.
  • FIG. 23 shows an exploded view of an alternate embodiment of an example NEST device embodiment similar to that of FIG. 22 having two rectangular magnets 2302 a , 2302 b that rotate around a common rotation axis 2336 .
  • the device comprises two rectangular magnets 2302 a , 2302 b that are magnetized such that the north pole of the first magnet 2302 a faces away from the drive shaft 2304 , and the south pole of the first magnet 2302 a faces the drive shaft 2304 , and the north pole of the second magnet 2302 b faces the drive shaft 2304 while the south pole of the second magnet 2302 b faces away from the drive shaft 2304 .
  • each of the magnets 2302 a , 2302 b thus, face the top cover 2352 and the bottom cover 2350 of the device, but the magnets 2302 a , 2302 b , have opposite polarity.
  • the first magnet 2302 a is held in place in the device by a first magnet holder 2344 a having two pieces that are connected by a magnet holder cap screw 2342 and a magnet holder dowel pin 2340 .
  • the first magnet 2302 a is placed between and at least partially within the pieces of the first holder 2344 a .
  • the second magnet 2302 b is held in place in the device by a second magnet holder 2344 b having two pieces that are connected by a magnet holder cap screw (not shown) and a magnet holder dowel pin (not shown).
  • the second magnet 2302 b is placed between and at least partially within the pieces of the second holder 2344 b .
  • the two holders 2344 a , 2344 b are coupled together, and may have a center beam 2348 that holds the first and second holders 2344 a , 2344 b together.
  • the holders 2344 a , 2344 b may also be held together additionally or alternatively by adhesive 2346 .
  • the drive shaft 2304 is coupled to the holders 2344 a , 2344 b , in the embodiment shown, by attaching to the center beam 2348 , which thus couples the magnets 2302 a , 2302 b to the drive shaft 2304 such that rotation of the drive shaft 2304 likewise spins the magnets 2302 a , 2302 b within the holders 2344 a , 2344 b about the rotation axis 2336 .
  • the drive shaft 2304 may alternatively and/or additionally be coupled to the holders 2344 a , 2344 b and to the center beam 2348 by adhesive 2346 .
  • the magnets 2302 a , 2302 b encased in the holders 2344 a , 2344 b are additionally housed within a top cover 2352 and a bottom cover 2350 .
  • the covers 2350 , 2352 are connected to one another by at least one cover cap screw 2354 .
  • the drive shaft 2304 fits through at a hole 2356 in at least one of the covers, for example, the bottom cover 2350 . Where the cover 2350 is disc-shaped, as shown in FIG.
  • the hole 2356 is located the center of the disc cover 2350 , and the hole 2356 is configured such that the drive shaft 2304 may rotate freely within the hole 2304 , for example, with aid of a bearing which allows drive shaft rotation (and, thus, magnet rotation) relative to the covers 2350 , 2352 .
  • FIG. 24 shows an example embodiment of a NEST device similar to the embodiments depicted in FIGS. 22 and/or 23 having two magnets 2402 a , 2402 b rotating about a common rotation axis applied to a subject 2406 and showing the controller subunit 2458 coupled to a drive shaft 2404 that rotates the magnets 2402 a , 2402 b .
  • the controller subunit 2458 may contain a motor (not shown) that cooperates with the drive shaft 2404 to rotate the magnets 2402 a , 2402 b.
  • FIG. 25 shows block diagram of an example embodiment of a NEST device showing example elements of the NEST device and of its controller subunit.
  • the embodiment shown depicts a magnet 2502 that is mounted by a frame 2534 to a base 2536 . This allows the magnet 2502 to be held stationary as the device treats a subject whose head may be positioned near to the magnet 2502 (within the magnetic field produced by the magnet 2502 ).
  • the magnet 2502 is coupled to the controller subunit 2558 by a drive shaft 2504 .
  • the drive shaft 2504 may couple to a motor 2572 of the controller subunit 2558 by a coupling 2578 .
  • the coupling may allow for various magnet arrangements to be interchanged by merely decoupling the drive shaft from the controller subunit and coupling a device having another arrangement of magnets (such as, for example, those described herein).
  • the magnet 2502 may be controlled by the controller subunit 2558 through the motor 2572 that may be driven by a motor driver 2574 .
  • the motor driver 2574 may be coupled (directly or indirectly) to a power supply 2576 .
  • the motor driver 2574 which can control, for non-limiting example, the speed, direction, acceleration, etc, of the magnet 2502 through the drive shaft 2504 , can be directed and/or monitored by controls such as, for example, a device speed control 2560 , an on/off control 2562 , a display 2564 , a random/continuous control 2566 , and a high/low control 2568 .
  • controls such as, for example, a device speed control 2560 , an on/off control 2562 , a display 2564 , a random/continuous control 2566 , and a high/low control 2568 .
  • a user can adjust each of these controls, which are coupled to a processor circuit board 2570 and thus coupled to the motor driver 2574 .
  • the drive shaft 2504 and/or the magnet(s) may be controlled automatically based on a prescribed treatment (time of treatment, frequency of magnet rotation, etc) that is downloaded and/or programmed into the processor circuit board 2570 from a source external or internal to the controller subunit, as previously described herein. Treatments received may be stored by the controller subunit. Additionally and/or alternatively, where EEG electrodes are also present in the device and are capable of measuring the subject's brain waves, the device may adjust the treatment automatically by a biofeedback system. Additionally and/or alternatively, where EEG electrodes are present in the device and are capable of measuring the subject's brain waves, the treatment may be chosen based on the readings of the subject's brain waves prior to the treatment.
  • a prescribed treatment time of treatment, frequency of magnet rotation, etc
  • the treatment may be chosen automatically by the device based on the readings of the subject's brain waves prior to the treatment and based on a set of rules stored in the controller subunit.
  • the controller subunit is capable of storing the output of the EEG electrodes prior to, during, and/or after treatment with the NEST device.
  • the controller subunit is capable of transmitting the output of the EEG electrodes prior to, during, and/or after treatment with the NEST device. This transmitting may be real-time (during measurement), or after storage of the EEG electrode outputs and during an upload or download from the NEST device.
  • FIG. 26 shows an example embodiment of a NEST device having a single bar magnet 2602 that moves linearly along its north-south axis 2639 once each time the supporting ring (or annulus) 2619 is rotated (rotation shown by arrows in FIG. 26 ), providing a pulse-type alternating magnetic field at the frequency of rotation.
  • a magnet 2602 is secured against a rotating ring (or annulus) 2619 with a spring 2628 , where the ring 2619 has one or more detents 2629 .
  • the subject 2606 is shown below the ring 2619 in FIG. 26 .
  • the magnet 2602 will be thrust into each detent 2629 once per rotation.
  • the magnet 2602 will move back to its original position.
  • This periodic thrust may generate a more unipolar pulsatile magnetic field than that generated by a rotating magnet.
  • the width and amplitude of the magnetic pulse depends on the mass and strength of the magnet, as well as the strength of the spring, and the depth of the detent.
  • the ring could be non-circular.
  • the magnet could rotate around the ring, while the ring is stationary.
  • the magnet or magnets could encounter a ridge, or multiple ridges.
  • the magnet or magnets could encounter slopes, rather than sharp detents or ridges.
  • the magnet could be positioned such that the north pole is closer to the treatment area than the south pole, or such that the south pole is closer to the treatment area than the north pole (such as is shown in FIG. 26 ).
  • the number of detents is the same as the number of magnets of the device. In some embodiments, the number of detents is not the same as the number of magnets of the device. In some embodiments, the number of detents is a multiple of the number of magnets of the device. In some embodiments, the number of detents is not a multiple of the number of magnets of the device.
  • the magnet may flip (or rotate) about an axis between the north pole and south pole as a ring similar to that shown in FIG. 26 rotates.
  • the magnet may be freely rotatable about the axis between the north pole and south pole, and the magnet may be rotatable about a shaft.
  • the shaft in this embodiment, is not coupled to a drive source. Rather, the ring itself may drive the flipping (rotating) of the magnet by capturing a first portion of the magnet in a first detent and moving that first portion as the ring moves until a second portion of the magnet is captured by second detent of the ring which likewise moves the second portion of the magnet.
  • the first portion is associated with a first pole of the magnet
  • the second portion is associated with a second pole of the magnet.
  • the first pole may be the north pole of the magnet and the second pole may be the south pole of the magnet.
  • the first pole may be the south pole of the magnet and the second pole may be the north pole of the magnet.
  • a drive source may drive the movement of the ring which, in turn, drives the rotation of the magnet.
  • the drive source may be motor, for non-limiting example.
  • FIGS. 31 and 32 show the results of a clinical trial utilizing the NEST device and methods for the treatment of depression as provided herein.
  • a device was used such as shown in FIG. 19 , with permanent magnets arranged as shown in FIG. 16 .
  • a magnetic field was adjusted to influence the Q-factor of an intrinsic frequency of each subject within the alpha-band. The magnetic field was applied close to the head of the subject. EEG readings were taken before treatment began.
  • a Cadwell Easy 2.1 EEG system was used to take a 19-lead EEG reading.
  • the intrinsic frequency in the alpha band (7-11 Hz) was determined using the initial EEG reading. Patients were placed in one of three groups: constant frequency, random frequency, or sham, with equal probability for each group.
  • FIG. 31 shows the percentage change in HAMD score in subjects being treated with the NEST device over the course of four (4) weeks. It is divided between subjects who responded to treatment (i.e. Responders) and subjects who did not respond to treatment (i.e. Non-Responders). Responders were classified as such when their HAMD scores decreased by 50% at least over the course of the four (4) weeks of treatment.
  • the first bar is the average baseline HAMD score. Each subsequent bar represents the average HAMD score at the end of a week, weeks 1 , 2 , 3 , and 4 , left to right, respectively.
  • FIG. 32 shows the percentage change in HAMD score in subjects being treated with the NEST device versus the SHAM device over the course of four (4) weeks, as described in reference to FIG. 31 above.
  • Baseline is not represented on the graph—it should be assumed to be 0.00.
  • the first data point represents the average change after one (1) week of treatment.
  • the second data point is the average change after two (2) weeks of treatment.
  • the third data point is the average change after three (3) weeks of treatment.
  • the fourth data point is the average change after four (4) weeks of treatment.
  • the top line represents the average HAMD score for subjects treated with the NEST device
  • the bottom line represents the average HAMD score for subjects treated with the SHAM device.
  • FIG. 33 shows the results of a clinical trial utilizing the NEST device for the treatment of anxiety.
  • This trial involved two (2) patients (subjects). Both patients received treatment with the NEST device as shown in FIG. 19 , with permanent magnets arranged as shown in FIG. 16 .
  • a magnetic field was adjusted to influence the Q-factor of an intrinsic frequency of each subject within the alpha-band. The magnetic field was applied close to the head of the subject. EEG readings were taken before treatment began.
  • a Cadwell Easy 2.1 EEG system was used to take a 19-lead EEG reading. The intrinsic frequency in the alpha band (7-11 Hz) was determined using the initial EEG reading.
  • Both patients were treated with a constant frequency, wherein for each patient the NEST was set to rotate the magnets at the intrinsic frequency detected for that patient.
  • Patients received treatment every weekday for 30 days. EEG readings were taken after treatment at least on a weekly basis.
  • the first data point is the baseline HAMA score.
  • the second data point for each line represents the HAMA score after one (1) week of treatment for each patient.
  • the third data point for each line represents the HAMA score after two (2) weeks of treatment for each patient.
  • the fourth data point for each line represents the HAMA score after four (4) weeks of treatment for each patient.
  • the various functions or processes disclosed herein may be described as data and/or instructions embodied in various computer-readable media, in terms of their behavioral, register transfer, logic component, transistor, layout geometries, and/or other characteristics.
  • the logic described herein may comprise, according to various embodiments of the invention, software, hardware, or a combination of software and hardware.
  • Computer-readable media in which such formatted data and/or instructions may be embodied include, but are not limited to, non-volatile storage media in various forms (e.g., optical, magnetic or semiconductor storage media) and carrier waves that may be used to transfer such formatted data and/or instructions through wireless, optical, or wired signaling media or any combination thereof.
  • Examples of transfers of such formatted data and/or instructions by carrier waves include, but are not limited to, transfers (uploads, downloads, e-mail, etc.) over the Internet and/or other computer networks via one or more data transfer protocols (e.g., HTTP, FTP, SMTP, etc.).
  • Such data and/or instruction-based expressions of components and/or processes under the ICS may be processed by a processing entity (e.g., one or more processors) within the computer system in conjunction with execution of one or more other computer programs.
  • a processing entity e.g., one or more processors
  • the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in a sense of “including, but not limited to.” Words using the singular or plural number also include the plural or singular number respectively. Additionally, the words “herein,” “hereunder,” “above,” “below,” and words of similar import refer to this application as a whole and not to any particular portions of this application. When the word “or” is used in reference to a list of two or more items, that word covers all of the following interpretations of the word: any of the items in the list, all of the items in the list and any combination of the items in the list.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Business, Economics & Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Tourism & Hospitality (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Economics (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Primary Health Care (AREA)
  • Strategic Management (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Magnetic Treatment Devices (AREA)
US12/237,304 2007-09-25 2008-09-24 Systems and Methods for Anxiety Treatment Using Neuro-EEG Synchronization Therapy Abandoned US20090198144A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/237,304 US20090198144A1 (en) 2007-09-25 2008-09-24 Systems and Methods for Anxiety Treatment Using Neuro-EEG Synchronization Therapy
US15/891,721 US11311741B2 (en) 2007-09-25 2018-02-08 Systems and methods for anxiety treatment using neuro-EEG synchronization therapy
US17/014,663 US11938336B2 (en) 2007-09-25 2020-09-08 Methods for treating anxiety using neuro-EEG synchronization therapy
US17/650,207 US20220161044A1 (en) 2007-09-25 2022-02-07 Systems and methods for providing treatment to the brain using magnetic field therapy
US17/650,203 US20220161043A1 (en) 2007-09-25 2022-02-07 Systems and methods for providing treatment to the brain using magnetic field therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97509607P 2007-09-25 2007-09-25
US9659608P 2008-09-12 2008-09-12
US12/237,304 US20090198144A1 (en) 2007-09-25 2008-09-24 Systems and Methods for Anxiety Treatment Using Neuro-EEG Synchronization Therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/891,721 Continuation US11311741B2 (en) 2007-09-25 2018-02-08 Systems and methods for anxiety treatment using neuro-EEG synchronization therapy

Publications (1)

Publication Number Publication Date
US20090198144A1 true US20090198144A1 (en) 2009-08-06

Family

ID=40472478

Family Applications (13)

Application Number Title Priority Date Filing Date
US12/237,319 Active 2031-05-04 US8475354B2 (en) 2007-09-25 2008-09-24 Systems and methods for neuro-EEG synchronization therapy
US12/237,295 Active 2030-06-24 US9015057B2 (en) 2007-09-25 2008-09-24 Systems and methods for controlling and billing neuro-EEG synchronization therapy
US12/237,328 Active 2031-02-18 US8480554B2 (en) 2007-09-25 2008-09-24 Systems and methods for depression treatment using neuro-EEG synchronization therapy
US12/237,304 Abandoned US20090198144A1 (en) 2007-09-25 2008-09-24 Systems and Methods for Anxiety Treatment Using Neuro-EEG Synchronization Therapy
US13/682,057 Active US9272159B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US13/682,098 Active US9308387B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US13/681,964 Active US8888672B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US13/682,147 Active US8888673B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US13/682,181 Active US8961386B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US15/891,721 Active 2030-11-14 US11311741B2 (en) 2007-09-25 2018-02-08 Systems and methods for anxiety treatment using neuro-EEG synchronization therapy
US17/014,663 Active 2029-11-29 US11938336B2 (en) 2007-09-25 2020-09-08 Methods for treating anxiety using neuro-EEG synchronization therapy
US17/650,203 Pending US20220161043A1 (en) 2007-09-25 2022-02-07 Systems and methods for providing treatment to the brain using magnetic field therapy
US17/650,207 Pending US20220161044A1 (en) 2007-09-25 2022-02-07 Systems and methods for providing treatment to the brain using magnetic field therapy

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US12/237,319 Active 2031-05-04 US8475354B2 (en) 2007-09-25 2008-09-24 Systems and methods for neuro-EEG synchronization therapy
US12/237,295 Active 2030-06-24 US9015057B2 (en) 2007-09-25 2008-09-24 Systems and methods for controlling and billing neuro-EEG synchronization therapy
US12/237,328 Active 2031-02-18 US8480554B2 (en) 2007-09-25 2008-09-24 Systems and methods for depression treatment using neuro-EEG synchronization therapy

Family Applications After (9)

Application Number Title Priority Date Filing Date
US13/682,057 Active US9272159B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US13/682,098 Active US9308387B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US13/681,964 Active US8888672B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US13/682,147 Active US8888673B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US13/682,181 Active US8961386B2 (en) 2007-09-25 2012-11-20 Systems and methods for neuro-EEG synchronization therapy
US15/891,721 Active 2030-11-14 US11311741B2 (en) 2007-09-25 2018-02-08 Systems and methods for anxiety treatment using neuro-EEG synchronization therapy
US17/014,663 Active 2029-11-29 US11938336B2 (en) 2007-09-25 2020-09-08 Methods for treating anxiety using neuro-EEG synchronization therapy
US17/650,203 Pending US20220161043A1 (en) 2007-09-25 2022-02-07 Systems and methods for providing treatment to the brain using magnetic field therapy
US17/650,207 Pending US20220161044A1 (en) 2007-09-25 2022-02-07 Systems and methods for providing treatment to the brain using magnetic field therapy

Country Status (8)

Country Link
US (13) US8475354B2 (zh)
EP (2) EP2197534B1 (zh)
DK (1) DK2197534T3 (zh)
ES (1) ES2672107T3 (zh)
LT (1) LT2197534T (zh)
NO (1) NO2197534T3 (zh)
SI (1) SI2197534T1 (zh)
WO (4) WO2009042718A1 (zh)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090083071A1 (en) * 2007-09-25 2009-03-26 Neosync, Inc. Systems and Methods for Controlling and Billing Neuro-EEG Synchronization Therapy
US20110034822A1 (en) * 2009-08-06 2011-02-10 Neosync, Inc. Systems and methods for modulating the electrical activity of a brain using neuro-eeg synchronization therapy
US20110112427A1 (en) * 2009-11-12 2011-05-12 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US8926490B2 (en) 2008-09-24 2015-01-06 Neosync, Inc. Systems and methods for depression treatment using neuro-EEG synchronization therapy
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9649502B2 (en) 2011-11-14 2017-05-16 Neosync, Inc. Devices and methods of low frequency magnetic stimulation therapy
US9962555B1 (en) 2017-01-17 2018-05-08 Neosync, Inc. Head-mountable adjustable devices for generating magnetic fields
US10349982B2 (en) 2011-11-01 2019-07-16 Nuvasive Specialized Orthopedics, Inc. Adjustable magnetic devices and methods of using same
US10478232B2 (en) 2009-04-29 2019-11-19 Nuvasive Specialized Orthopedics, Inc. Interspinous process device and method
US10588576B2 (en) 2014-08-15 2020-03-17 Neosync, Inc. Methods and device for determining a valid intrinsic frequency
US10617453B2 (en) 2015-10-16 2020-04-14 Nuvasive Specialized Orthopedics, Inc. Adjustable devices for treating arthritis of the knee
US10646262B2 (en) 2011-02-14 2020-05-12 Nuvasive Specialized Orthopedics, Inc. System and method for altering rotational alignment of bone sections
US10660675B2 (en) 2010-06-30 2020-05-26 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US10729470B2 (en) 2008-11-10 2020-08-04 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US10743794B2 (en) 2011-10-04 2020-08-18 Nuvasive Specialized Orthopedics, Inc. Devices and methods for non-invasive implant length sensing
US10751094B2 (en) 2013-10-10 2020-08-25 Nuvasive Specialized Orthopedics, Inc. Adjustable spinal implant
US10835290B2 (en) 2015-12-10 2020-11-17 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US10918425B2 (en) 2016-01-28 2021-02-16 Nuvasive Specialized Orthopedics, Inc. System and methods for bone transport
CN113412090A (zh) * 2019-02-08 2021-09-17 诺威适骨科专科公司 外部调节装置
US11191579B2 (en) 2012-10-29 2021-12-07 Nuvasive Specialized Orthopedics, Inc. Adjustable devices for treating arthritis of the knee
US11202707B2 (en) 2008-03-25 2021-12-21 Nuvasive Specialized Orthopedics, Inc. Adjustable implant system
US11207110B2 (en) 2009-09-04 2021-12-28 Nuvasive Specialized Orthopedics, Inc. Bone growth device and method
US11234849B2 (en) 2006-10-20 2022-02-01 Nuvasive Specialized Orthopedics, Inc. Adjustable implant and method of use
US11246694B2 (en) 2014-04-28 2022-02-15 Nuvasive Specialized Orthopedics, Inc. System for informational magnetic feedback in adjustable implants
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11304729B2 (en) 2009-02-23 2022-04-19 Nuvasive Specialized Orthhopedics, Inc. Non-invasive adjustable distraction system
USRE49061E1 (en) 2012-10-18 2022-05-10 Nuvasive Specialized Orthopedics, Inc. Intramedullary implants for replacing lost bone
US11357549B2 (en) 2004-07-02 2022-06-14 Nuvasive Specialized Orthopedics, Inc. Expandable rod system to treat scoliosis and method of using the same
US11357547B2 (en) 2014-10-23 2022-06-14 Nuvasive Specialized Orthopedics Inc. Remotely adjustable interactive bone reshaping implant
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11439449B2 (en) 2014-12-26 2022-09-13 Nuvasive Specialized Orthopedics, Inc. Systems and methods for distraction
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11497924B2 (en) 2019-08-08 2022-11-15 Realize MedTech LLC Systems and methods for enabling point of care magnetic stimulation therapy
US11577097B2 (en) 2019-02-07 2023-02-14 Nuvasive Specialized Orthopedics, Inc. Ultrasonic communication in medical devices
US11612416B2 (en) 2015-02-19 2023-03-28 Nuvasive Specialized Orthopedics, Inc. Systems and methods for vertebral adjustment
US11696836B2 (en) 2013-08-09 2023-07-11 Nuvasive, Inc. Lordotic expandable interbody implant
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11737787B1 (en) 2021-05-27 2023-08-29 Nuvasive, Inc. Bone elongating devices and methods of use
US11766252B2 (en) 2013-07-31 2023-09-26 Nuvasive Specialized Orthopedics, Inc. Noninvasively adjustable suture anchors
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US11794029B2 (en) 2016-07-01 2023-10-24 Btl Medical Solutions A.S. Aesthetic method of biological structure treatment by magnetic field
US11801187B2 (en) 2016-02-10 2023-10-31 Nuvasive Specialized Orthopedics, Inc. Systems and methods for controlling multiple surgical variables
US11806528B2 (en) 2020-05-04 2023-11-07 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
US11806054B2 (en) 2021-02-23 2023-11-07 Nuvasive Specialized Orthopedics, Inc. Adjustable implant, system and methods
US11826565B2 (en) 2020-05-04 2023-11-28 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
US11839410B2 (en) 2012-06-15 2023-12-12 Nuvasive Inc. Magnetic implants with improved anatomical compatibility
US11857226B2 (en) 2013-03-08 2024-01-02 Nuvasive Specialized Orthopedics Systems and methods for ultrasonic detection of device distraction
US11871974B2 (en) 2007-10-30 2024-01-16 Nuvasive Specialized Orthopedics, Inc. Skeletal manipulation method
US11878162B2 (en) 2016-05-23 2024-01-23 Btl Healthcare Technologies A.S. Systems and methods for tissue treatment
US11883643B2 (en) 2016-05-03 2024-01-30 Btl Healthcare Technologies A.S. Systems and methods for treatment of a patient including RF and electrical energy
US11896816B2 (en) 2021-11-03 2024-02-13 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
US11925389B2 (en) 2008-10-13 2024-03-12 Nuvasive Specialized Orthopedics, Inc. Spinal distraction system

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089719B2 (en) * 2009-03-20 2015-07-28 ElectroCore, LLC Non-invasive methods and devices for inducing euphoria in a patient and their therapeutic application
US20090264785A1 (en) * 2008-04-18 2009-10-22 Brainscope Company, Inc. Method and Apparatus For Assessing Brain Function Using Diffusion Geometric Analysis
US8364254B2 (en) * 2009-01-28 2013-01-29 Brainscope Company, Inc. Method and device for probabilistic objective assessment of brain function
DE102009026897A1 (de) * 2009-06-10 2010-12-16 Sirona Dental Systems Gmbh Sensor sowie Magnetfeldeinheit zur Verwendung innerhalb eines Magnetresonanztomographie-Systems oder eines Magnetresonanzspektroskopie-Systems
US9375585B2 (en) 2009-06-17 2016-06-28 Nexstim Oy Magnetic stimulation device and method
US20110015538A1 (en) * 2009-07-17 2011-01-20 Matthews Jr Thomas Virgil System and method for analyzing electroencephalography data
US10321840B2 (en) 2009-08-14 2019-06-18 Brainscope Company, Inc. Development of fully-automated classifier builders for neurodiagnostic applications
US20110144520A1 (en) * 2009-12-16 2011-06-16 Elvir Causevic Method and device for point-of-care neuro-assessment and treatment guidance
US9095266B1 (en) * 2010-08-02 2015-08-04 Chi Yung Fu Method for treating a patient
US9037224B1 (en) * 2010-08-02 2015-05-19 Chi Yung Fu Apparatus for treating a patient
US8734488B2 (en) 2010-08-09 2014-05-27 Ellipse Technologies, Inc. Maintenance feature in magnetic implant
ITTO20100146U1 (it) * 2010-08-24 2012-02-25 Bruno Santanera Dispositivo cilindrico per l'applicazione controllata di campi magnetici al corpo umano.
ES1073912Y (es) * 2010-10-14 2011-10-04 Pellicer Carlos F Equipo medico
RU2462182C2 (ru) * 2010-10-25 2012-09-27 Ирина Николаевна Долгова Способ ранней диагностики хронических нарушений мозгового кровообращения, обусловленных артериальной гипотензией
CN103619408B (zh) * 2011-03-18 2016-05-25 悉尼科技大学 一种用于活化神经和/或肌肉的装置
FI20116085L (fi) * 2011-11-03 2013-05-04 Nexstim Oy Menetelmä ja laite aivojen transkraniaalisen stimulaation vaikutusten määrittämiseksi
CA2851551A1 (en) * 2011-10-14 2013-04-18 Nexstim Oy Method and apparatus for approximating effects of transcranial magnetic stimulation to a brain
RU2473303C1 (ru) * 2011-12-13 2013-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт нейрохирургии имени академика Н.Н. Бурденко РАМН Способ определения риска развития осложнений в раннем послеоперационном периоде у больных после удаления опухолей базально-диэнцефальной локализации
US10849563B2 (en) * 2012-03-19 2020-12-01 University Of Florida Research Foundation, Inc. Methods and systems for brain function analysis
WO2013152354A2 (en) 2012-04-06 2013-10-10 Newport Brain Research Laboratory Inc. rTMS AT HARMONICS OF BIOLOGICAL SIGNALS
JP2015519096A (ja) 2012-04-06 2015-07-09 ニューポート ブレイン リサーチ ラボラトリー インコーポレイテッド 周波数特異的感覚刺激
MX344672B (es) 2012-04-06 2017-01-04 Kosivana Holdings Ltd Dispositivo de estimulacion magnetica transcraneal repetitiva.
EP2848183A4 (en) * 2012-05-07 2016-05-25 Olympus Corp MANAGEMENT DEVICE
US9814426B2 (en) 2012-06-14 2017-11-14 Medibotics Llc Mobile wearable electromagnetic brain activity monitor
DE102012013534B3 (de) 2012-07-05 2013-09-19 Tobias Sokolowski Vorrichtung für repetitive Nervenstimulation zum Abbau von Fettgewebe mittels induktiver Magnetfelder
ES2776178T3 (es) * 2012-10-24 2020-07-29 Dreamscape Medical Llc Sistemas para detectar bio-señales basadas en el cerebro
US9251713B1 (en) 2012-11-20 2016-02-02 Anthony J. Giovanniello System and process for assessing a user and for assisting a user in rehabilitation
US20140194668A1 (en) * 2013-01-10 2014-07-10 Device Therapeutics, Inc. Portable Therapeutic Device Using Rotating Static Magnetic Fields
US20140235925A1 (en) * 2013-02-20 2014-08-21 HIRAM Abi PAZ Systems and methods for portative magneto therapy
US11730970B2 (en) 2013-03-14 2023-08-22 The Methodist Hospital Method and apparatus for providing transcranial magnetic stimulation (TMS) to an individual
US9456784B2 (en) * 2013-03-14 2016-10-04 The Methodist Hospital Method and apparatus for providing transcranial magnetic stimulation (TMS) to a patient
PL3033007T3 (pl) 2013-08-15 2020-04-30 The Methodist Hospital Urządzenie do przezczaszkowej stymulacji magnetycznej (TMS) pacjenta
DE102013219541B4 (de) 2013-09-27 2019-05-09 Evonik Degussa Gmbh Verbessertes Verfahren zur pulvermetallurgischen Herstellung thermoelektrischer Bauelemente
CA2929874C (en) 2013-11-22 2023-06-13 Saluda Medical Pty Ltd Method and device for detecting a neural response in a neural measurement
US9795801B2 (en) * 2014-06-17 2017-10-24 Talal Zoabi Combination aroma and magnetotherapy device and methods of use
WO2016053375A1 (en) 2014-10-01 2016-04-07 James Phillips System and method for transcranial current loop brain stimulation
EP3011996B1 (de) * 2014-10-24 2020-08-26 Grander GmbH Magnetvorrichtung
CN104799918A (zh) * 2015-04-14 2015-07-29 苏州瑞华医院有限公司 一种医用吸铁器
US11491342B2 (en) 2015-07-01 2022-11-08 Btl Medical Solutions A.S. Magnetic stimulation methods and devices for therapeutic treatments
US20180001107A1 (en) 2016-07-01 2018-01-04 Btl Holdings Limited Aesthetic method of biological structure treatment by magnetic field
US10695575B1 (en) 2016-05-10 2020-06-30 Btl Medical Technologies S.R.O. Aesthetic method of biological structure treatment by magnetic field
WO2017076320A1 (zh) * 2015-11-04 2017-05-11 纽沃凯生物科技（深圳）有限公司 用电磁场调制脑睡眠兴奋区的方法和仪器
US20170151442A1 (en) * 2015-11-05 2017-06-01 Warren Winslow Walborn Hair loss regrowth and hair treatment device
EP3196951B1 (de) 2016-01-21 2018-11-14 Evonik Degussa GmbH Rationelles verfahren zur pulvermetallurgischen herstellung thermoelektrischer bauelemente
EP3589356B1 (en) * 2016-04-11 2023-07-26 Monash University Transcranial stimulation with real-time monitoring
US10406368B2 (en) * 2016-04-19 2019-09-10 Boston Scientific Neuromodulation Corporation Pulse generator system for promoting desynchronized firing of recruited neural populations
US11464993B2 (en) 2016-05-03 2022-10-11 Btl Healthcare Technologies A.S. Device including RF source of energy and vacuum system
WO2017193078A1 (en) 2016-05-05 2017-11-09 The Methodist Hospital Method and apparatus for providing transcranial magnetic stimulation (tms) to an individual
US11534619B2 (en) 2016-05-10 2022-12-27 Btl Medical Solutions A.S. Aesthetic method of biological structure treatment by magnetic field
KR102236614B1 (ko) * 2016-05-11 2021-04-09 주식회사 칼라세븐 스마트통신기기 기반의 저출력 광선치료 서비스 제공 시스템 및 방법
CN105943048B (zh) * 2016-06-27 2018-11-13 首都医科大学附属北京胸科医院 一种基于核磁共振技术区分结核性脑膜炎和病毒性脑膜炎的方法及其应用
US10420953B2 (en) * 2016-08-27 2019-09-24 Wave Neuroscience, Inc. RTMS pulse frequency optimization
CN106730370A (zh) * 2017-01-25 2017-05-31 浙江和也健康科技有限公司 一种旋磁驱动静磁磁力线模拟针灸治疗的方法
US11420071B2 (en) 2017-04-11 2022-08-23 Peaklogic, Inc. Minimum neuronal activation threshold transcranial magnetic stimulation at personalized resonant frequency
CA3063384C (en) 2017-05-18 2022-05-17 Multi Radiance Medical Restructuring neural pathways in the brain with a combination of transcranial therapies
JP2020523172A (ja) 2017-06-08 2020-08-06 ワインバーグ・メディカル・フィジックス・インコーポレイテッドＷｅｉｎｂｅｒｇ Ｍｅｄｉｃａｌ Ｐｈｙｓｉｃｓ， Ｉｎｃ． 介入のための開口を備える片側磁気共鳴画像システムおよび当該システムを動作させるための手法
CN107688725A (zh) * 2017-07-26 2018-02-13 西北工业大学 一种基于混合Lie算子辛算法的不变流形计算方法
RU2682991C1 (ru) * 2017-12-21 2019-03-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ диагностики ранних признаков недостаточности мозгового кровообращения у больных хронической обструктивной болезнью легких
CN110192858A (zh) * 2018-02-27 2019-09-03 鸿海精密工业股份有限公司 核磁共振成像仪以及失智症预检系统
US11406841B2 (en) 2018-04-08 2022-08-09 Conway Ho Magnetic stimulation with variable pulsed intervals
US11464397B2 (en) 2018-09-27 2022-10-11 University Of Utah Research Foundation Soft robot to navigate the natural lumens of a living organism using undulatory locomotion generated by a rotating magnetic dipole field
JP7131267B2 (ja) * 2018-10-01 2022-09-06 スミダコーポレーション株式会社 生体刺激用磁場発生装置
EP3880299A1 (en) * 2018-11-13 2021-09-22 The Methodist Hospital Method and apparatus for oncomagnetic treatment
JP7460155B2 (ja) * 2018-11-15 2024-04-02 公立大学法人広島市立大学 脳機能計測装置及び脳機能計測方法
CN109893143B (zh) * 2019-03-22 2022-05-24 焦作大学 一种心理综合测试仪
EP4066887B1 (en) 2019-04-11 2023-11-01 BTL Medical Solutions a.s. Devices for aesthetic treatment of biological structures by radiofrequency and magnetic energy
EP4146061A1 (en) * 2020-05-07 2023-03-15 Wave Neuroscience, Inc. Eeg based variable stimulation
WO2021237179A1 (en) * 2020-05-21 2021-11-25 Duke University Neurofeedback devices, systems, and methods for pain management
WO2021257967A1 (en) 2020-06-19 2021-12-23 The Methodist Hospital Dba Houston Methodist Hospital Method and apparatus for oncomagnetic treatment
US20230256250A1 (en) * 2020-07-13 2023-08-17 EPIC Neuro, Inc. Brain stimulation using subcranial electrode and subcutaneous electrode
US11793456B2 (en) 2021-01-07 2023-10-24 WellBrain LLC Treatment using individualized transcranial magnetic stimulation
US11786747B2 (en) 2021-01-07 2023-10-17 WellBrain LLC Treatment using individualized transcranial magnetic stimulation
US11610731B2 (en) 2021-03-09 2023-03-21 Hirofusa Otsubo Apparatus for assembling a non-directional free electron generating repelling magnet combination
US20240050763A1 (en) * 2021-03-26 2024-02-15 Wave Neuroscience, Inc. Electroencephalogram (eeg) based transcranial magnetic stimulation (tms) networks
TWI826150B (zh) 2022-01-12 2023-12-11 塞席爾商凡尼塔斯研究中心股份有限公司 可編程rTMS裝置、rTMS裝置和可編程系統、電刺激裝置
CN117838425A (zh) * 2024-03-07 2024-04-09 杭州英哲家禾信息科技有限公司 拼接式医用冰帽

Citations (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727857A (en) * 1984-04-19 1988-03-01 Dieter Rau Device for producing pulsating magnetic fields for therapeutic purposes
US5036858A (en) * 1990-03-22 1991-08-06 Carter John L Method and apparatus for changing brain wave frequency
US5409445A (en) * 1992-05-05 1995-04-25 Rubins; Tye Brain wave synchronizer
US5453072A (en) * 1989-10-31 1995-09-26 Anninos; Photios Electronic apparatus for treating epileptic individuals
US5496258A (en) * 1990-08-24 1996-03-05 Anninos; Photios Electronic device for treating epileptic individuals
US5632720A (en) * 1995-03-27 1997-05-27 Kleitz; Chelton R. Magnetic massage wand
US5667469A (en) * 1993-10-08 1997-09-16 Zhang; Xiaoyun Strong magnetism therapeutic apparatus with permanent-magnets rotating at low frequency
US5707334A (en) * 1995-08-21 1998-01-13 Young; Robert B. Method of treating amygdala related transitory disorders
US5788624A (en) * 1993-08-05 1998-08-04 Hangcheng Lu Magnetic therapy and a magnetic-field scanning physiotherapeutic device
US5935054A (en) * 1995-06-07 1999-08-10 Loos; Hendricus G. Magnetic excitation of sensory resonances
US5954629A (en) * 1996-02-21 1999-09-21 Pioneer Electronic Corporation Brain wave inducing system
US6001055A (en) * 1996-05-07 1999-12-14 Souder; James Magnetic therapy device
US6234953B1 (en) * 1996-06-06 2001-05-22 Lawson Research Institute Electrotherapy device using low frequency magnetic pulses
US6238333B1 (en) * 1995-06-07 2001-05-29 Hendricus G. Loos Remote magnetic manipulation of nervous systems
US6266556B1 (en) * 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6290638B1 (en) * 1995-04-27 2001-09-18 Luis E. Canedo Electromagnetic method of treatment of epilepsy and apparatus therefor
US6402678B1 (en) * 2000-07-31 2002-06-11 Neuralieve, Inc. Means and method for the treatment of migraine headaches
US6463328B1 (en) * 1996-02-02 2002-10-08 Michael Sasha John Adaptive brain stimulation method and system
US20020147380A1 (en) * 2001-02-28 2002-10-10 Vincent Ardizzone Bi-axial rotating magnetic therapeutic device
US20020153015A1 (en) * 2000-02-16 2002-10-24 Garibaldi Jeffrey M. Magnetic medical devices with changeable magnetic moments and method of navigating magnetic medical devices with changeable magnetic moments
US6488617B1 (en) * 2000-10-13 2002-12-03 Universal Hedonics Method and device for producing a desired brain state
US20020183587A1 (en) * 1999-12-28 2002-12-05 Dormer Kenneth J. Direct drive movement of body constituent
US20030093028A1 (en) * 2001-11-09 2003-05-15 Michael Spiegel Appararus and method for magnetic induction of therapeutic electric fields
US6663557B2 (en) * 2001-02-13 2003-12-16 Scott H. Werny Dynamic magnetic device and method, and components thereof
US6679825B2 (en) * 2002-02-05 2004-01-20 Pedro J. Alicea Pain eliminator
US20040138578A1 (en) * 2002-07-25 2004-07-15 Pineda Jaime A. Method and system for a real time adaptive system for effecting changes in cognitive-emotive profiles
US20040143296A1 (en) * 2002-12-17 2004-07-22 Xiaoming Wang Method and apparatus for inducing alpha rhythm to the human body
US20050043774A1 (en) * 2003-05-06 2005-02-24 Aspect Medical Systems, Inc System and method of assessment of the efficacy of treatment of neurological disorders using the electroencephalogram
US20050107655A1 (en) * 2002-04-05 2005-05-19 Oliver Holzner Method and apparatus for the prevention of epileptic seizures
US20050107654A1 (en) * 2003-11-17 2005-05-19 Riehl Mark E. Determining stimulation levels for transcranial magnetic stimulation
US20050118266A1 (en) * 2002-02-11 2005-06-02 M.Z.I. Khan Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
US20050124848A1 (en) * 2002-04-05 2005-06-09 Oliver Holzner Method and apparatus for electromagnetic modification of brain activity
US20050154426A1 (en) * 2002-05-09 2005-07-14 Boveja Birinder R. Method and system for providing therapy for neuropsychiatric and neurological disorders utilizing transcranical magnetic stimulation and pulsed electrical vagus nerve(s) stimulation
US20050187423A1 (en) * 2002-12-13 2005-08-25 Vincent Ardizzone Magnetic therapeutic device
US20050228209A1 (en) * 2004-04-09 2005-10-13 The Board Of Trustees Of The Leland Stanford Junior University Robotic apparatus for targeting and producing deep, focused transcranial magnetic stimulation
US20050256539A1 (en) * 2002-03-25 2005-11-17 George Mark S Methods and systems for using transcranial magnetic stimulation to enhance cognitive performance
US6978179B1 (en) * 2002-02-27 2005-12-20 Flagg Rodger H Method and apparatus for magnetic brain wave stimulation
US20060015153A1 (en) * 2004-07-15 2006-01-19 Gliner Bradford E Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
US20060058572A1 (en) * 2002-07-25 2006-03-16 Nicolia Anninou Electronic device for strengthening the immune system
US7033312B2 (en) * 2001-04-20 2006-04-25 Mclean Hospital Corporation Magnetic field stimulation techniques
US20060094924A1 (en) * 2004-10-29 2006-05-04 Riehl Mark E System and method to reduce discomfort using nerve stimulation
US20060149119A1 (en) * 2005-01-03 2006-07-06 Wei-Cheng Wang Method for moderation of sleep disorder
US20060161039A1 (en) * 2005-01-20 2006-07-20 Neuronetics, Inc. Articulating arm
US20060189866A1 (en) * 2003-06-27 2006-08-24 Fralex Therapeutics, Inc. System for image-guided pulsed magnetic field diagnosis and treatment
US20060212090A1 (en) * 2005-03-01 2006-09-21 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation
US20060217781A1 (en) * 2005-03-24 2006-09-28 John Michael S Systems and Methods for Treating Disorders of the Central Nervous System by Modulation of Brain Networks
US20060258950A1 (en) * 2002-02-04 2006-11-16 Synergistic Neurotherapy Adjustment Process, Inc. (Trade At Synaps) Method and apparatus for utilizing amplitude-modulated pulse-width modulation signals for neurostimulation and treatment of neurological disorders using electrical stimulation
US20070004957A1 (en) * 2003-01-31 2007-01-04 Andreas Hilburg Assembly and method for carrying out magnetotherapy
US20070106170A1 (en) * 2005-11-10 2007-05-10 Conopco, Inc., D/B/A Unilever Apparatus and method for acquiring a signal
US20070142874A1 (en) * 2005-01-21 2007-06-21 John Michael S Multiple-symptom medical treatment with roving-based neurostimulation.
US20070179558A1 (en) * 2006-01-30 2007-08-02 Gliner Bradford E Systems and methods for varying electromagnetic and adjunctive neural therapies
US20070203390A1 (en) * 2001-04-20 2007-08-30 Rohan Michael L Magnetic field treatment techniques
US20070208209A1 (en) * 1996-09-10 2007-09-06 Holcomb Robert R Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity
US7297100B2 (en) * 2000-06-09 2007-11-20 Fralex Therapeutics, Inc. Device for magnetic and electric field shielding
US20070282156A1 (en) * 2004-06-16 2007-12-06 Maurits Konings Apparatus For Generating Electric Current Field In The Human Body And Method For The Use Thereof
US20080046013A1 (en) * 2006-08-15 2008-02-21 Lozano Andres M Method for treating eating disorders
US20080081941A1 (en) * 2006-09-28 2008-04-03 Giulio Tononi Method and apparatus for promoting restorative sleep
US20080125669A1 (en) * 2001-07-11 2008-05-29 Cns Response, Inc. Electroencephalography based systems and methods for selecting therapies and predicting outcomes
US20090083071A1 (en) * 2007-09-25 2009-03-26 Neosync, Inc. Systems and Methods for Controlling and Billing Neuro-EEG Synchronization Therapy
US20110034822A1 (en) * 2009-08-06 2011-02-10 Neosync, Inc. Systems and methods for modulating the electrical activity of a brain using neuro-eeg synchronization therapy
US20110112427A1 (en) * 2009-11-12 2011-05-12 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US20110137104A1 (en) * 2008-09-24 2011-06-09 Neosync, Inc. Systems and methods for depression treatment using neuro-eeg synchronization therapy
US20130137918A1 (en) * 2011-11-14 2013-05-30 Neosync, Inc. Devices and methods of low frequency magnetic stimulation therapy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US788624A (en) * 1904-02-16 1905-05-02 John Bildson Railway-signal.
US3821949A (en) 1972-04-10 1974-07-02 Menninger Foundation Bio-feedback apparatus
DE3417773A1 (de) * 1984-05-14 1985-02-14 Alois 8000 München Hörl Vorrichtung zur herstellung pulsierender magnetfelder fuer therapeutische zwecke
US5092835A (en) * 1990-07-06 1992-03-03 Schurig Janet L S Brain and nerve healing power apparatus and method
US5691324A (en) 1994-01-14 1997-11-25 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US5769778A (en) 1994-04-22 1998-06-23 Somatics, Inc. Medical magnetic non-convulsive stimulation therapy
WO1996015829A2 (en) 1994-11-18 1996-05-30 Advatech Corporation Apparatus for inducing dc electric fields in biological material and method of using it
IT1280812B1 (it) 1995-03-21 1998-02-11 Bruno Pirone Apparecchio per magnetoterapia.
US5817000A (en) 1995-09-13 1998-10-06 Souder; James Magnetic therapy device
US5925070A (en) 1996-04-04 1999-07-20 Medtronic, Inc. Techniques for adjusting the locus of excitation of electrically excitable tissue
AUPO478297A0 (en) 1997-01-24 1997-02-20 Commonwealth Scientific And Industrial Research Organisation Improvements in high speed electric motors
US6157278A (en) * 1997-07-23 2000-12-05 Odin Technologies Ltd. Hybrid magnetic apparatus for use in medical applications
FI105163B (fi) 1998-07-10 2000-06-30 Juha Virtanen Menetelmä ja laite lumemagneettistimulaation tuottamiseksi
DE29821635U1 (de) 1998-12-03 1999-07-29 Schmeiser Gerät zur Erzeugung eines Magnetfeldes zur Behandlung von an Tinitus erkrankten Patienten
AUPR711701A0 (en) 2001-08-17 2001-09-06 Advanced Diagnostic Development Pty Ltd Magnetic field therapy
AU2003201032A1 (en) 2002-01-07 2003-07-24 Stephen James Crampton Method and apparatus for an avatar user interface system
US7819794B2 (en) * 2002-10-21 2010-10-26 Becker Paul F Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields
EP1736205B1 (en) 2003-05-13 2008-10-22 Hitachi, Ltd. Particle beam irradiation apparatus and treatment planning unit
JP4506102B2 (ja) * 2003-05-26 2010-07-21 日産自動車株式会社 燃料電池システム
EP1677674A4 (en) 2003-08-20 2009-03-25 Philometron Inc HYDRATION CONTROL
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20080009772A1 (en) * 2003-11-26 2008-01-10 Wicab, Inc. Systems and methods for altering brain and body functions and for treating conditions and diseases of the same
JP4833202B2 (ja) * 2004-06-18 2011-12-07 ニューロントリックス インコーポレイテッド 神経学的疾患のための誘発反応試験システム
US7976451B2 (en) * 2005-06-16 2011-07-12 The United States Of America As Represented By The Department Of Health And Human Services Transcranial magnetic stimulation system and methods
US7684867B2 (en) * 2005-11-01 2010-03-23 Boston Scientific Neuromodulation Corporation Treatment of aphasia by electrical stimulation and/or drug infusion
US20070135859A1 (en) 2005-12-09 2007-06-14 Peter Eriksson Use of transcranial magnetic stimulation to improve memory and stress related syndromes in humans
ITRE20060158A1 (it) 2006-12-20 2008-06-21 Genesis Elettronica S R L Apparecchio medicale per applicazioni magnetiche
WO2008130533A2 (en) 2007-04-14 2008-10-30 Etis Investments, Inc. System for delivery of magnetic stimulation
WO2009036040A1 (en) 2007-09-10 2009-03-19 Neostim, Inc. Automated movement of electromagnets tracking eccentricity of the head
US20100185042A1 (en) 2007-08-05 2010-07-22 Schneider M Bret Control and coordination of transcranial magnetic stimulation electromagnets for modulation of deep brain targets
CN103619408B (zh) 2011-03-18 2016-05-25 悉尼科技大学 一种用于活化神经和/或肌肉的装置
US9456784B2 (en) 2013-03-14 2016-10-04 The Methodist Hospital Method and apparatus for providing transcranial magnetic stimulation (TMS) to a patient
US10588576B2 (en) 2014-08-15 2020-03-17 Neosync, Inc. Methods and device for determining a valid intrinsic frequency
JP1602547S (zh) 2017-01-17 2018-04-23

Patent Citations (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727857A (en) * 1984-04-19 1988-03-01 Dieter Rau Device for producing pulsating magnetic fields for therapeutic purposes
US5453072A (en) * 1989-10-31 1995-09-26 Anninos; Photios Electronic apparatus for treating epileptic individuals
US5697883A (en) * 1989-10-31 1997-12-16 Anninos; Photios Method of inhibiting seizure activity in epileptic individuals
US5036858A (en) * 1990-03-22 1991-08-06 Carter John L Method and apparatus for changing brain wave frequency
US5496258A (en) * 1990-08-24 1996-03-05 Anninos; Photios Electronic device for treating epileptic individuals
US5409445A (en) * 1992-05-05 1995-04-25 Rubins; Tye Brain wave synchronizer
US5788624A (en) * 1993-08-05 1998-08-04 Hangcheng Lu Magnetic therapy and a magnetic-field scanning physiotherapeutic device
US5667469A (en) * 1993-10-08 1997-09-16 Zhang; Xiaoyun Strong magnetism therapeutic apparatus with permanent-magnets rotating at low frequency
US5632720A (en) * 1995-03-27 1997-05-27 Kleitz; Chelton R. Magnetic massage wand
US6290638B1 (en) * 1995-04-27 2001-09-18 Luis E. Canedo Electromagnetic method of treatment of epilepsy and apparatus therefor
US5935054A (en) * 1995-06-07 1999-08-10 Loos; Hendricus G. Magnetic excitation of sensory resonances
US6238333B1 (en) * 1995-06-07 2001-05-29 Hendricus G. Loos Remote magnetic manipulation of nervous systems
US5707334A (en) * 1995-08-21 1998-01-13 Young; Robert B. Method of treating amygdala related transitory disorders
US6463328B1 (en) * 1996-02-02 2002-10-08 Michael Sasha John Adaptive brain stimulation method and system
US5954629A (en) * 1996-02-21 1999-09-21 Pioneer Electronic Corporation Brain wave inducing system
US6231497B1 (en) * 1996-05-07 2001-05-15 James Souder Magnetic therapy device
US6001055A (en) * 1996-05-07 1999-12-14 Souder; James Magnetic therapy device
US6234953B1 (en) * 1996-06-06 2001-05-22 Lawson Research Institute Electrotherapy device using low frequency magnetic pulses
US20070208209A1 (en) * 1996-09-10 2007-09-06 Holcomb Robert R Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity
US20020007128A1 (en) * 1998-04-27 2002-01-17 Ives John R. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6266556B1 (en) * 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US20020183587A1 (en) * 1999-12-28 2002-12-05 Dormer Kenneth J. Direct drive movement of body constituent
US20020153015A1 (en) * 2000-02-16 2002-10-24 Garibaldi Jeffrey M. Magnetic medical devices with changeable magnetic moments and method of navigating magnetic medical devices with changeable magnetic moments
US7297100B2 (en) * 2000-06-09 2007-11-20 Fralex Therapeutics, Inc. Device for magnetic and electric field shielding
US6402678B1 (en) * 2000-07-31 2002-06-11 Neuralieve, Inc. Means and method for the treatment of migraine headaches
US6488617B1 (en) * 2000-10-13 2002-12-03 Universal Hedonics Method and device for producing a desired brain state
US6663557B2 (en) * 2001-02-13 2003-12-16 Scott H. Werny Dynamic magnetic device and method, and components thereof
US20020147380A1 (en) * 2001-02-28 2002-10-10 Vincent Ardizzone Bi-axial rotating magnetic therapeutic device
US6648812B2 (en) * 2001-02-28 2003-11-18 Nu-Magnetics, Inc. Bi-axial rotating magnetic therapeutic device
US20050124847A1 (en) * 2001-02-28 2005-06-09 Vincent Ardizzone Bi-axial rotating magnetic therapeutic device
US7282021B2 (en) * 2001-04-20 2007-10-16 Mclean Hospital Corporation Magnetic field stimulation techniques
US7033312B2 (en) * 2001-04-20 2006-04-25 Mclean Hospital Corporation Magnetic field stimulation techniques
US20070203390A1 (en) * 2001-04-20 2007-08-30 Rohan Michael L Magnetic field treatment techniques
US20080125669A1 (en) * 2001-07-11 2008-05-29 Cns Response, Inc. Electroencephalography based systems and methods for selecting therapies and predicting outcomes
US20030093028A1 (en) * 2001-11-09 2003-05-15 Michael Spiegel Appararus and method for magnetic induction of therapeutic electric fields
US20060258950A1 (en) * 2002-02-04 2006-11-16 Synergistic Neurotherapy Adjustment Process, Inc. (Trade At Synaps) Method and apparatus for utilizing amplitude-modulated pulse-width modulation signals for neurostimulation and treatment of neurological disorders using electrical stimulation
US6679825B2 (en) * 2002-02-05 2004-01-20 Pedro J. Alicea Pain eliminator
US20050118266A1 (en) * 2002-02-11 2005-06-02 M.Z.I. Khan Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
US6978179B1 (en) * 2002-02-27 2005-12-20 Flagg Rodger H Method and apparatus for magnetic brain wave stimulation
US20050256539A1 (en) * 2002-03-25 2005-11-17 George Mark S Methods and systems for using transcranial magnetic stimulation to enhance cognitive performance
US20050107655A1 (en) * 2002-04-05 2005-05-19 Oliver Holzner Method and apparatus for the prevention of epileptic seizures
US20050124848A1 (en) * 2002-04-05 2005-06-09 Oliver Holzner Method and apparatus for electromagnetic modification of brain activity
US20050154426A1 (en) * 2002-05-09 2005-07-14 Boveja Birinder R. Method and system for providing therapy for neuropsychiatric and neurological disorders utilizing transcranical magnetic stimulation and pulsed electrical vagus nerve(s) stimulation
US7258659B2 (en) * 2002-07-25 2007-08-21 Nicolia Anninou Electronic device for strengthening the immune system
US20060058572A1 (en) * 2002-07-25 2006-03-16 Nicolia Anninou Electronic device for strengthening the immune system
US20040138578A1 (en) * 2002-07-25 2004-07-15 Pineda Jaime A. Method and system for a real time adaptive system for effecting changes in cognitive-emotive profiles
US20050187423A1 (en) * 2002-12-13 2005-08-25 Vincent Ardizzone Magnetic therapeutic device
US20040143296A1 (en) * 2002-12-17 2004-07-22 Xiaoming Wang Method and apparatus for inducing alpha rhythm to the human body
US20070004957A1 (en) * 2003-01-31 2007-01-04 Andreas Hilburg Assembly and method for carrying out magnetotherapy
US20050043774A1 (en) * 2003-05-06 2005-02-24 Aspect Medical Systems, Inc System and method of assessment of the efficacy of treatment of neurological disorders using the electroencephalogram
US20060189866A1 (en) * 2003-06-27 2006-08-24 Fralex Therapeutics, Inc. System for image-guided pulsed magnetic field diagnosis and treatment
US20050107654A1 (en) * 2003-11-17 2005-05-19 Riehl Mark E. Determining stimulation levels for transcranial magnetic stimulation
US20050228209A1 (en) * 2004-04-09 2005-10-13 The Board Of Trustees Of The Leland Stanford Junior University Robotic apparatus for targeting and producing deep, focused transcranial magnetic stimulation
US20070282156A1 (en) * 2004-06-16 2007-12-06 Maurits Konings Apparatus For Generating Electric Current Field In The Human Body And Method For The Use Thereof
US20060015153A1 (en) * 2004-07-15 2006-01-19 Gliner Bradford E Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
US20060094924A1 (en) * 2004-10-29 2006-05-04 Riehl Mark E System and method to reduce discomfort using nerve stimulation
US20060149119A1 (en) * 2005-01-03 2006-07-06 Wei-Cheng Wang Method for moderation of sleep disorder
US20060161039A1 (en) * 2005-01-20 2006-07-20 Neuronetics, Inc. Articulating arm
US20070142874A1 (en) * 2005-01-21 2007-06-21 John Michael S Multiple-symptom medical treatment with roving-based neurostimulation.
US20060212090A1 (en) * 2005-03-01 2006-09-21 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation
US20060217781A1 (en) * 2005-03-24 2006-09-28 John Michael S Systems and Methods for Treating Disorders of the Central Nervous System by Modulation of Brain Networks
US20070106170A1 (en) * 2005-11-10 2007-05-10 Conopco, Inc., D/B/A Unilever Apparatus and method for acquiring a signal
US20070179558A1 (en) * 2006-01-30 2007-08-02 Gliner Bradford E Systems and methods for varying electromagnetic and adjunctive neural therapies
US20080046013A1 (en) * 2006-08-15 2008-02-21 Lozano Andres M Method for treating eating disorders
US20080081941A1 (en) * 2006-09-28 2008-04-03 Giulio Tononi Method and apparatus for promoting restorative sleep
US20130144106A1 (en) * 2007-09-25 2013-06-06 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US20130150651A1 (en) * 2007-09-25 2013-06-13 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US8480554B2 (en) * 2007-09-25 2013-07-09 Neosync, Inc. Systems and methods for depression treatment using neuro-EEG synchronization therapy
US8475354B2 (en) * 2007-09-25 2013-07-02 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US20130150650A1 (en) * 2007-09-25 2013-06-13 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US20090082690A1 (en) * 2007-09-25 2009-03-26 Neosync, Inc. Systems and Methods for Neuro-EEG Synchronization Therapy
US20090083071A1 (en) * 2007-09-25 2009-03-26 Neosync, Inc. Systems and Methods for Controlling and Billing Neuro-EEG Synchronization Therapy
US20130144107A1 (en) * 2007-09-25 2013-06-06 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US20130144108A1 (en) * 2007-09-25 2013-06-06 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US20110137104A1 (en) * 2008-09-24 2011-06-09 Neosync, Inc. Systems and methods for depression treatment using neuro-eeg synchronization therapy
US20110118536A1 (en) * 2008-09-24 2011-05-19 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US8465408B2 (en) * 2009-08-06 2013-06-18 Neosync, Inc. Systems and methods for modulating the electrical activity of a brain using neuro-EEG synchronization therapy
US20110034822A1 (en) * 2009-08-06 2011-02-10 Neosync, Inc. Systems and methods for modulating the electrical activity of a brain using neuro-eeg synchronization therapy
US20110112427A1 (en) * 2009-11-12 2011-05-12 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US8585568B2 (en) * 2009-11-12 2013-11-19 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US20130137918A1 (en) * 2011-11-14 2013-05-30 Neosync, Inc. Devices and methods of low frequency magnetic stimulation therapy

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11712268B2 (en) 2004-07-02 2023-08-01 Nuvasive Specialized Orthopedics, Inc. Expandable rod system to treat scoliosis and method of using the same
US11357549B2 (en) 2004-07-02 2022-06-14 Nuvasive Specialized Orthopedics, Inc. Expandable rod system to treat scoliosis and method of using the same
US11234849B2 (en) 2006-10-20 2022-02-01 Nuvasive Specialized Orthopedics, Inc. Adjustable implant and method of use
US11672684B2 (en) 2006-10-20 2023-06-13 Nuvasive Specialized Orthopedics, Inc. Adjustable implant and method of use
US8888673B2 (en) 2007-09-25 2014-11-18 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US8475354B2 (en) 2007-09-25 2013-07-02 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US8480554B2 (en) 2007-09-25 2013-07-09 Neosync, Inc. Systems and methods for depression treatment using neuro-EEG synchronization therapy
US9308387B2 (en) 2007-09-25 2016-04-12 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US20090083071A1 (en) * 2007-09-25 2009-03-26 Neosync, Inc. Systems and Methods for Controlling and Billing Neuro-EEG Synchronization Therapy
US11311741B2 (en) 2007-09-25 2022-04-26 Wave Neuroscience, Inc. Systems and methods for anxiety treatment using neuro-EEG synchronization therapy
US8888672B2 (en) 2007-09-25 2014-11-18 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US20090204015A1 (en) * 2007-09-25 2009-08-13 Neosync, Inc. Systems and Methods for Depression Treatment Using Neuro-EEG Synchronization Therapy
US8961386B2 (en) 2007-09-25 2015-02-24 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US9015057B2 (en) 2007-09-25 2015-04-21 Neosync, Inc. Systems and methods for controlling and billing neuro-EEG synchronization therapy
US11938336B2 (en) 2007-09-25 2024-03-26 Wave Neuroscience, Inc. Methods for treating anxiety using neuro-EEG synchronization therapy
US9272159B2 (en) 2007-09-25 2016-03-01 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US11871974B2 (en) 2007-10-30 2024-01-16 Nuvasive Specialized Orthopedics, Inc. Skeletal manipulation method
US11202707B2 (en) 2008-03-25 2021-12-21 Nuvasive Specialized Orthopedics, Inc. Adjustable implant system
US8926490B2 (en) 2008-09-24 2015-01-06 Neosync, Inc. Systems and methods for depression treatment using neuro-EEG synchronization therapy
US8870737B2 (en) 2008-09-24 2014-10-28 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US11925389B2 (en) 2008-10-13 2024-03-12 Nuvasive Specialized Orthopedics, Inc. Spinal distraction system
US11974782B2 (en) 2008-11-10 2024-05-07 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US10729470B2 (en) 2008-11-10 2020-08-04 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US11918254B2 (en) 2009-02-23 2024-03-05 Nuvasive Specialized Orthopedics Inc. Adjustable implant system
US11304729B2 (en) 2009-02-23 2022-04-19 Nuvasive Specialized Orthhopedics, Inc. Non-invasive adjustable distraction system
US11602380B2 (en) 2009-04-29 2023-03-14 Nuvasive Specialized Orthopedics, Inc. Interspinous process device and method
US10478232B2 (en) 2009-04-29 2019-11-19 Nuvasive Specialized Orthopedics, Inc. Interspinous process device and method
US10357660B2 (en) 2009-08-06 2019-07-23 Neosync, Inc. Systems and methods for modulating the electrical activity of a brain using neuro-EEG synchronization therapy
US8465408B2 (en) 2009-08-06 2013-06-18 Neosync, Inc. Systems and methods for modulating the electrical activity of a brain using neuro-EEG synchronization therapy
US9713729B2 (en) 2009-08-06 2017-07-25 Neosync, Inc. Systems and methods for modulating the electrical activity of a brain using neuro-EEG synchronization therapy
US20110034822A1 (en) * 2009-08-06 2011-02-10 Neosync, Inc. Systems and methods for modulating the electrical activity of a brain using neuro-eeg synchronization therapy
US11207110B2 (en) 2009-09-04 2021-12-28 Nuvasive Specialized Orthopedics, Inc. Bone growth device and method
US11944358B2 (en) 2009-09-04 2024-04-02 Nuvasive Specialized Orthopedics, Inc. Bone growth device and method
US8585568B2 (en) * 2009-11-12 2013-11-19 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US10821293B2 (en) 2009-11-12 2020-11-03 Wave Neuroscience, Inc. Systems and methods for neuro-EEG synchronization therapy
US9446259B2 (en) 2009-11-12 2016-09-20 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US20110112427A1 (en) * 2009-11-12 2011-05-12 Neosync, Inc. Systems and methods for neuro-eeg synchronization therapy
US10065048B2 (en) 2009-11-12 2018-09-04 Neosync, Inc. Systems and methods for neuro-EEG synchronization therapy
US11975213B2 (en) 2009-11-12 2024-05-07 Wave Neuroscience, Inc. Systems for neuro-EEG synchronization therapy
US11497530B2 (en) 2010-06-30 2022-11-15 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US10660675B2 (en) 2010-06-30 2020-05-26 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US10646262B2 (en) 2011-02-14 2020-05-12 Nuvasive Specialized Orthopedics, Inc. System and method for altering rotational alignment of bone sections
US11406432B2 (en) 2011-02-14 2022-08-09 Nuvasive Specialized Orthopedics, Inc. System and method for altering rotational alignment of bone sections
US10743794B2 (en) 2011-10-04 2020-08-18 Nuvasive Specialized Orthopedics, Inc. Devices and methods for non-invasive implant length sensing
US11445939B2 (en) 2011-10-04 2022-09-20 Nuvasive Specialized Orthopedics, Inc. Devices and methods for non-invasive implant length sensing
US11123107B2 (en) 2011-11-01 2021-09-21 Nuvasive Specialized Orthopedics, Inc. Adjustable magnetic devices and methods of using same
US10349982B2 (en) 2011-11-01 2019-07-16 Nuvasive Specialized Orthopedics, Inc. Adjustable magnetic devices and methods of using same
US11918255B2 (en) 2011-11-01 2024-03-05 Nuvasive Specialized Orthopedics Inc. Adjustable magnetic devices and methods of using same
US9649502B2 (en) 2011-11-14 2017-05-16 Neosync, Inc. Devices and methods of low frequency magnetic stimulation therapy
US11839410B2 (en) 2012-06-15 2023-12-12 Nuvasive Inc. Magnetic implants with improved anatomical compatibility
USRE49061E1 (en) 2012-10-18 2022-05-10 Nuvasive Specialized Orthopedics, Inc. Intramedullary implants for replacing lost bone
USRE49720E1 (en) 2012-10-18 2023-11-07 Nuvasive Specialized Orthopedics, Inc. Intramedullary implants for replacing lost bone
US11213330B2 (en) 2012-10-29 2022-01-04 Nuvasive Specialized Orthopedics, Inc. Adjustable devices for treating arthritis of the knee
US11871971B2 (en) 2012-10-29 2024-01-16 Nuvasive Specialized Orthopedics, Inc. Adjustable devices for treating arthritis of the knee
US11191579B2 (en) 2012-10-29 2021-12-07 Nuvasive Specialized Orthopedics, Inc. Adjustable devices for treating arthritis of the knee
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US11857226B2 (en) 2013-03-08 2024-01-02 Nuvasive Specialized Orthopedics Systems and methods for ultrasonic detection of device distraction
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US11766252B2 (en) 2013-07-31 2023-09-26 Nuvasive Specialized Orthopedics, Inc. Noninvasively adjustable suture anchors
US11696836B2 (en) 2013-08-09 2023-07-11 Nuvasive, Inc. Lordotic expandable interbody implant
US11576702B2 (en) 2013-10-10 2023-02-14 Nuvasive Specialized Orthopedics, Inc. Adjustable spinal implant
US10751094B2 (en) 2013-10-10 2020-08-25 Nuvasive Specialized Orthopedics, Inc. Adjustable spinal implant
US11246694B2 (en) 2014-04-28 2022-02-15 Nuvasive Specialized Orthopedics, Inc. System for informational magnetic feedback in adjustable implants
US10588576B2 (en) 2014-08-15 2020-03-17 Neosync, Inc. Methods and device for determining a valid intrinsic frequency
US11357547B2 (en) 2014-10-23 2022-06-14 Nuvasive Specialized Orthopedics Inc. Remotely adjustable interactive bone reshaping implant
US11963705B2 (en) 2014-12-26 2024-04-23 Nuvasive Specialized Orthopedics, Inc. Systems and methods for distraction
US11890043B2 (en) 2014-12-26 2024-02-06 Nuvasive Specialized Orthopedics, Inc. Systems and methods for distraction
US11439449B2 (en) 2014-12-26 2022-09-13 Nuvasive Specialized Orthopedics, Inc. Systems and methods for distraction
US11612416B2 (en) 2015-02-19 2023-03-28 Nuvasive Specialized Orthopedics, Inc. Systems and methods for vertebral adjustment
US10617453B2 (en) 2015-10-16 2020-04-14 Nuvasive Specialized Orthopedics, Inc. Adjustable devices for treating arthritis of the knee
US11596456B2 (en) 2015-10-16 2023-03-07 Nuvasive Specialized Orthopedics, Inc. Adjustable devices for treating arthritis of the knee
US10835290B2 (en) 2015-12-10 2020-11-17 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US11504162B2 (en) 2015-12-10 2022-11-22 Nuvasive Specialized Orthopedics, Inc. External adjustment device for distraction device
US10918425B2 (en) 2016-01-28 2021-02-16 Nuvasive Specialized Orthopedics, Inc. System and methods for bone transport
US11801187B2 (en) 2016-02-10 2023-10-31 Nuvasive Specialized Orthopedics, Inc. Systems and methods for controlling multiple surgical variables
US11883643B2 (en) 2016-05-03 2024-01-30 Btl Healthcare Technologies A.S. Systems and methods for treatment of a patient including RF and electrical energy
US11878162B2 (en) 2016-05-23 2024-01-23 Btl Healthcare Technologies A.S. Systems and methods for tissue treatment
US11896821B2 (en) 2016-05-23 2024-02-13 Btl Healthcare Technologies A.S. Systems and methods for tissue treatment
US11794029B2 (en) 2016-07-01 2023-10-24 Btl Medical Solutions A.S. Aesthetic method of biological structure treatment by magnetic field
US9962555B1 (en) 2017-01-17 2018-05-08 Neosync, Inc. Head-mountable adjustable devices for generating magnetic fields
US10835754B2 (en) 2017-01-17 2020-11-17 Wave Neuroscience, Inc. Head-mountable adjustable devices for generating magnetic fields
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11577097B2 (en) 2019-02-07 2023-02-14 Nuvasive Specialized Orthopedics, Inc. Ultrasonic communication in medical devices
US11589901B2 (en) * 2019-02-08 2023-02-28 Nuvasive Specialized Orthopedics, Inc. External adjustment device
CN113412090A (zh) * 2019-02-08 2021-09-17 诺威适骨科专科公司 外部调节装置
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US11497924B2 (en) 2019-08-08 2022-11-15 Realize MedTech LLC Systems and methods for enabling point of care magnetic stimulation therapy
US11878167B2 (en) 2020-05-04 2024-01-23 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
US11806528B2 (en) 2020-05-04 2023-11-07 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
US11826565B2 (en) 2020-05-04 2023-11-28 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
US11813451B2 (en) 2020-05-04 2023-11-14 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient
US11806054B2 (en) 2021-02-23 2023-11-07 Nuvasive Specialized Orthopedics, Inc. Adjustable implant, system and methods
US11944359B2 (en) 2021-02-23 2024-04-02 Nuvasive Specialized Orthopedics, Inc. Adjustable implant, system and methods
US11737787B1 (en) 2021-05-27 2023-08-29 Nuvasive, Inc. Bone elongating devices and methods of use
US11896816B2 (en) 2021-11-03 2024-02-13 Btl Healthcare Technologies A.S. Device and method for unattended treatment of a patient

Also Published As

Publication number Publication date
US8480554B2 (en) 2013-07-09
US9308387B2 (en) 2016-04-12
WO2009042721A1 (en) 2009-04-02
US11938336B2 (en) 2024-03-26
US9015057B2 (en) 2015-04-21
US20220161044A1 (en) 2022-05-26
US8475354B2 (en) 2013-07-02
US8961386B2 (en) 2015-02-24
US20090082690A1 (en) 2009-03-26
US8888673B2 (en) 2014-11-18
EP2197534B1 (en) 2018-03-07
US9272159B2 (en) 2016-03-01
SI2197534T1 (en) 2018-08-31
LT2197534T (lt) 2018-06-25
WO2009042722A1 (en) 2009-04-02
US20090204015A1 (en) 2009-08-13
EP2197534A1 (en) 2010-06-23
US8888672B2 (en) 2014-11-18
US20130150650A1 (en) 2013-06-13
US20130144106A1 (en) 2013-06-06
US20220161043A1 (en) 2022-05-26
NO2197534T3 (zh) 2018-08-04
EP2197534A4 (en) 2011-02-02
WO2009042720A1 (en) 2009-04-02
DK2197534T3 (en) 2018-06-14
ES2672107T3 (es) 2018-06-12
EP3403570A1 (en) 2018-11-21
US20130144108A1 (en) 2013-06-06
US11311741B2 (en) 2022-04-26
US20090083071A1 (en) 2009-03-26
WO2009042718A1 (en) 2009-04-02
US20130150651A1 (en) 2013-06-13
US20200398070A1 (en) 2020-12-24
US20180229049A1 (en) 2018-08-16
US20130144107A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
US11938336B2 (en) Methods for treating anxiety using neuro-EEG synchronization therapy
US11975213B2 (en) Systems for neuro-EEG synchronization therapy
US10357660B2 (en) Systems and methods for modulating the electrical activity of a brain using neuro-EEG synchronization therapy
US8926490B2 (en) Systems and methods for depression treatment using neuro-EEG synchronization therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEOSYNC, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PHILLIPS, JAMES WILLIAM;JIN, YI;REEL/FRAME:029488/0939

Effective date: 20081027

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION